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PREAMBLE
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the management and prevention of disease
states. Rigorous and expert analysis of the available data
documenting relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve
the effectiveness of care, optimize patient outcomes, and
have a favorable effect on the overall cost of care by focusing
resources on the most effective strategies.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged
in the production of such guidelines in the area of cardio-
vascular disease since 1980. This effort is directed by the
ACC/AHA Task Force on Practice Guidelines. Its charge
is to develop and revise practice guidelines for important
cardiovascular diseases and procedures. Experts in the sub-
ject under consideration are selected from both organiza-
tions to examine subject-specific data and write guidelines.
The process includes additional representatives from other
medical practitioner and specialty groups where appropriate.
Writing groups are specifically charged to perform a formal
literature review, weigh the strength of evidence for or
against a particular treatment or procedure, and include
estimates of expected health outcomes. Patient-specific
modifiers, comorbidities, and issues of patient preference
that might influence the choice of particular tests or
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therapies are considered as well as frequency of follow-up
and cost-effectiveness.
The ACC/AHA Task Force on Practice Guidelines
makes every effort to avoid any actual or potential conflicts
of interest that might arise as a result of an outside
relationship or personal interest of a member of the writing
panel. Specifically, all members of the writing panel are
asked to provide disclosure statements of all such relation-
ships that might be perceived as real or potential conflicts of
interest. These statements are reviewed by the parent task
force, reported orally to all members of the writing panel at
the first meeting, and updated yearly and as changes occur.
These practice guidelines are intended to assist physicians
in clinical decision making by describing a range of accept-
able approaches for the diagnosis, management, or preven-
tion of specific diseases or conditions. These guidelines
attempt to define practices that meet the needs of most
patients in most circumstances. The ultimate judgment
regarding care of a particular patient must be made by the
physician and patient in light of all of the circumstances
presented by the patient.
The executive summary and recommendations are pub-
lished in the May 4, 1999, issue of Circulation. The full text is
published in the Journal of the American College of Cardiology.
Reprints of both the full text and the executive summary and
recommendations are available from both organizations.
These guidelines have been officially endorsed by the
Society for Cardiac Angiography and Interventions.
James L. Ritchie, MD, FACC
Chair, ACC/AHA Task Force on Practice Guidelines
I. INTRODUCTION
The ACC/AHA Task Force on Practice Guidelines herein
revises and updates the original “Guidelines for Coronary
Angiography,” published in 1987 (1). The frequent and
still-growing use of coronary angiography, its relatively high
costs, its inherent risks and the ongoing evolution of its
indications have given this revision urgency and priority.
The expert committee appointed included private practitio-
ners and academicians. Committee members were selected
to represent both experts in coronary angiography and
senior clinician consultants. Representatives from the family
practice and internal medicine professions were also in-
cluded on the committee.
The English-language medical literature was searched for
the 10 years preceding development of the guidelines. The
searches yielded .1,600 references that the committee
reviewed for relevance. Evidence relative to the use of
coronary angiography was compiled and evaluated by the
committee. Whereas randomized trials are often available
for reference in the development of treatment guidelines,
randomized trials regarding the use of diagnostic procedures
such as coronary angiography are rarely available (2). For
development of these guidelines, when coronary angiogra-
phy was a necessary procedure in describing a clinical subset
or in choosing a course of treatment and that therapy was
shown to have an advantage for the patient, especially in the
context of a randomized trial, then the indication for
angiography was given greater consideration than indica-
tions cited in less-rigorous evaluations of data.
This document uses the ACC/AHA classifications of
Class I, II, or III. These classes summarize the indications
for coronary angiography as follows:
Class I: Conditions for which there is evidence for
and/or general agreement that the procedure
is useful and effective.
Class II: Conditions for which there is conflicting ev-
idence and/or a divergence of opinion about
the usefulness/efficacy of performing the pro-
cedure.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well es-
tablished by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that the procedure is not
useful/effective and in some cases may be
harmful.
The weight of evidence in support of the recommenda-
tion for each listed indication is presented as follows:
Level of Evidence A: The presence of multiple random-
ized clinical trials.
Level of Evidence B: The presence of a single ran-
domized trial or nonrandomized
studies.
Level of Evidence C: Expert consensus.
This document was reviewed by 6 outside reviewers, 3
nominated by the ACC and 3 by the AHA, as well as by
reviewers nominated by the Society for Cardiac Angiogra-
phy and Interventions (SCAI), the American College of
Physicians (ACP), and the American Academy of Family
Physicians (AAFP). The document will be reevaluated two
years after the date of publication and yearly thereafter and
considered current unless the task force publishes a further
revision or withdrawal.
Recommendations concerning the staffing and equip-
ment of cardiac catheterization laboratories are beyond the
scope of this report and can be found elsewhere (3).
Statements concerning the use and safety of ambulatory and
outpatient cardiac catheterization procedures and the per-
formance of cardiac catheterization in laboratories without
on-site cardiac surgical backup are available (3).
This report is not intended to provide strict indications or
contraindications for coronary angiography because, in the
individual patient, multiple other considerations may be
relevant, including the family setting, occupational needs,
and individual lifestyle preferences. Rather, the report is
intended to provide general guidelines that may be helpful
to the practitioner.
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For these guidelines, coronary angiography is defined as
the radiographic visualization of the coronary arteries after
direct opacification with contrast media. After a discussion
of general considerations regarding coronary angiography,
the applications of coronary angiography in specific disease
states are presented and discussed in the body of this report.
Recommendations are made for appropriate use of coronary
angiography in these conditions. After the body of the
guidelines, appendices are presented that include a discus-
sion of special considerations regarding coronary angiog-
raphy; a discussion of alternative imaging modalities, in-
cluding intravascular coronary ultrasound, intracoronary
Doppler ultrasound, and coronary angioscopy; definitions of
angiographic coronary anatomy and the Canadian Cardio-
vascular Society (CCS) classification of angina; and the
desired elements of a coronary angiographic report.
II. GENERAL CONSIDERATIONS
REGARDING CORONARY ANGIOGRAPHY
A. Definitions
Coronary angiography is defined as the radiographic visualiza-
tion of the coronary vessels after the injection of radiopaque
contrast media (4,5). The radiographic images are permanently
recorded for future review with either 35-mm cine film or
digital recording. Percutaneous or cutdown techniques, usually
from the femoral or brachial artery, are used for insertion of
special intravascular catheters. Coronary angiography further
requires selective cannulation of the ostium of the left and right
coronary arteries and, if present, each saphenous vein graft or
internal mammary artery graft to obtain optimal selective
contrast injection and imaging. Numerous specialized catheters
have been designed for this purpose. Physicians performing
these procedures must be technically proficient in all aspects of
the procedure and have a complete understanding of the
clinical indications and risks of the procedure and of coronary
anatomy, physiology and pathology. It is also important that
these physicians understand the fundamentals of optimal
radiographic imaging and radiation safety. Coronary angiog-
raphy is usually performed as part of cardiac catheterization,
which may also involve angiography of other vessels or cardiac
chambers, and hemodynamic assessment as needed for a
complete invasive diagnostic evaluation of the individual pa-
tient’s cardiovascular condition.
Coronary anatomy varies, and several nomenclatures have
been used to describe the anatomy and extent of disease.
Currently, the most commonly used is that described in the
Coronary Artery Surgery Study (CASS), recently modified
by the Bypass Angioplasty Revascularization Investigation
(BARI) Study Group (6,7). These schemes acknowledge
three major coronary arteries: the left anterior descending
(LAD), the circumflex, and the right coronary artery, with
right-dominant, balanced, or left-dominant circulations. A
diagram and description of the coronary anatomy are shown
in Appendix A. In this nomenclature, the coronary tree is
divided into 29 segments with the ability to account for
anatomic variations, such as a large branching obtuse
marginal of the circumflex. The extent of disease is usually
defined as one-vessel, two-vessel, three-vessel, or left main
disease, with significant disease taken to mean the presence
of a stenosis of $50% diameter reduction, although many
angiographers define a significant stenosis as being nar-
rowed by $70% diameter reduction. Other methods to
quantify the extent of disease, such as an obstructive
coronary artery score or myocardial jeopardy score, have also
been used and have been shown to be predictive of long-
term outcome (8–10). Although coronary lesions that
reduce luminal diameter ,50% are considered hemodynam-
ically insignificant, they are not clinically benign. These
lesions may progress either acutely or chronically, and
patients with nonsignificant obstructions have significantly
more cardiovascular events during follow-up than those
with truly normal coronary angiograms (11).
B. Purpose
The purpose of coronary angiography is to define coro-
nary anatomy and the degree of luminal obstruction of the
coronary arteries (4,5). Information obtained from the
procedure includes identification of the location, length,
diameter, and contour of the coronary arteries; the presence
and severity of coronary luminal obstruction(s); character-
ization of the nature of the obstruction (including the
presence of atheroma, thrombus, dissection, spasm, or
myocardial bridging), and an assessment of blood flow. In
addition, the presence and extent of coronary collateral
vessels can be assessed.
Coronary angiography remains the standard for assess-
ment of anatomic coronary disease, because no other cur-
rently available test can accurately define the extent of
coronary luminal obstruction. Because the technique can
only provide information about abnormalities that narrow
the lumen, it is limited in its ability to accurately define the
etiology of the obstruction or detect the presence of non-
obstructive atherosclerotic disease. A more detailed descrip-
tion of the limitations of coronary angiography and the use
of alternative imaging modalities is contained in Appendices
B and C. Despite these and other limitations, coronary
angiography is the only method currently available for
defining the details of the entire coronary endoluminal
vascular anatomy, and it provides the reference standard
against which other tests are compared. The procedure is
associated with a small but definable risk (Table 1) and is
relatively expensive. As such, the physician must make
reasoned decisions on its use based on the anticipated
clinical benefit versus the risks and costs of the procedure.
Coronary angiography is principally used in three clinical
situations (12): first, to determine the presence and extent of
obstructive coronary artery disease (CAD) in a setting in
which the diagnosis is uncertain and CAD cannot be
reasonably excluded by noninvasive testing; second, to assess
the feasibility and appropriateness of various forms of
therapy, such as revascularization by percutaneous or surgi-
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cal interventions; and finally, as a research tool for the
assessment of treatment results and the progression or
regression of coronary atherosclerosis.
C. Morbidity and Mortality
Although the incidences of significant morbidity and
mortality are low, coronary angiography may cause serious
complications and, thus, the benefits must justify the risks.
A 1990 survey by the SCAI indicated that the total risk of
all major complications from coronary angiography is ,2%
(Table 1) (13). Although serious complications are rare,
certain groups of patients are at higher risk. The stability of
the patient before the procedure significantly influences
outcome, with the highest risk associated with patients who
undergo the procedure in an emergency setting. Patients
with critical left main coronary stenosis have a .2-fold
higher risk of complications from coronary angiography,
and care is required when procedures are performed on
patients in whom left main lesions are suspected (14).
Another study from the SCAI registry database identified
12 predictors of major complications after cardiac catheter-
ization (Table 2) (15). Patients in a moribund condition
before the procedure had the highest risk (10-fold), and
shock, acute myocardial infarction (MI), renal insufficiency,
and cardiomyopathy increased the risk of complications.
Despite the higher risk of complications in these patients,
the risk-benefit ratio may still favor performance of coronary
angiography, because the information obtained may be
invaluable in making appropriate decisions about therapeu-
tic interventions. Although age is not shown in Table 2, it
is generally considered to be a significant factor related to
cardiovascular mortality after coronary angiography. The
skill and experience of the operator, the catheterization
laboratory staff, and the preprocedure and postprocedure
staff are also important factors in reducing complications.
Operator experience is clearly related to lower complication
rates. This fact has led one national organization to recom-
mend a minimum operator volume of 150 diagnostic cath-
eterizations per year (16). This is also true for coronary
angioplasty facilities. Recent studies have suggested that
laboratory volumes of .200 angioplasty cases per year and
75 cases per operator are necessary to minimize complica-
tions and maximize success (17–19). A recent ACC expert
consensus document discusses the issue in more detail (19).
Many catheterization laboratories are located in hospitals
without on-site cardiac surgery facilities. Although there is
no evidence that outcomes are worse in these laboratories, if
ad hoc angioplasty is anticipated, or the patient is likely to
need urgent or emergency surgery after angiography, trans-
fer to a hospital that can provide both diagnostic and
therapeutic procedures should be strongly considered.
D. Relative Contraindications
There are no absolute contraindications for coronary
angiography. Commonly accepted relative contraindications
are shown in Table 3. Although these contraindications are
widely used, few data exist as to the inherent risks of
performing the procedure when these problems are present.
Of the known relative contraindications to coronary
angiography, renal insufficiency has been the most exten-
sively studied (20–29). The reported incidence of significant
worsening of renal function after angiography ranges from
10% to 40% in these patients. The risk increases with the
severity of preexisting renal insufficiency (24). In patients
without preexisting renal insufficiency, the risk of develop-
ing a significant reduction in renal function is 0% to 0.5%.
More than 75% of patients who develop renal insufficiency
recover completely, but permanent impairment of renal
function that requires dialysis can occur in up to 10% of
patients who develop this complication. Baseline creatinine,
male sex, diabetes, and volume of contrast are independent
predictors of the development of renal insufficiency after
Table 1. Risk of Cardiac Catheterization and Coronary
Angiography (No. of Patients 5 59,792)
%
Mortality 0.11
Myocardial infarction 0.05
Cerebrovascular accident 0.07
Arrhythmia 0.38
Vascular complications 0.43
Contrast reaction 0.37
Hemodynamic complications 0.26
Perforation of heart chamber 0.03
Other complications 0.28
Total of major complications 1.70
Modified with permission from Noto et al. (13).
Table 2. Multivariate Predictors of Major Complications of
Coronary Angiography (No. of procedures 5 58,332)
Variable Coefficient
Odds Ratio
(95% CI)
Moribund 21.90 10.22 (3.77, 27.76)
Shock 21.09 6.52 (4.18, 10.18)
Acute MI ,24 h 20.98 4.03 (2.61, 6.21)
Renal insufficiency 20.43 3.30 (2.39, 4.55)
Cardiomyopathy 20.79 3.29 (2.23, 4.86)
Aortic valve disease 20.36 2.72 (2.02, 3.66)
Mitral valve disease 20.30 2.33 (1.76, 3.08)
Congestive heart failure 20.32 2.22 (1.71, 2.90)
New York Heart Association
Functional
Class I 1.00
Class II 1.15 (0.94, 1.41)
Class III 1.32 (0.92, 1.51)
Class IV 1.52 (1.16, 1.74)
Hypertension 20.38 1.45 (1.22, 1.73)
Unstable angina 20.24 1.42 (1.16, 1.74)
Outpatient/inpatient 0.34 0.63 (0.52, 0.76)
Moribund indicates a patient who responds poorly due to a life-threatening condition;
MI, myocardial infarction; major complication, any adverse event listed in Table 1.
Modified with permission from Laskey et al. (15).
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contrast injection. Diabetic patients with preexisting renal
insufficiency are particularly prone to develop renal failure
(22). In patients at risk for renal failure, pretreatment with
intravenous fluids or mannitol or with intravenous furo-
semide after angiography, as well as the use of nonionic
contrast media, has been beneficial in some studies
(20,23,28). However, in a recent randomized study, intra-
venous hydration with 0.45% saline was the most effective
means of preventing worsening renal failure in high-risk
patients, reducing the risk of worsening renal failure from
40% with furosemide and 28% with mannitol to 11% with
intravenous hydration (20). It is also critical that the volume
of contrast be minimized to reduce the chance of contrast-
induced renal failure.
Major reactions to angiographic contrast medium are
rare, but in patients with a known anaphylactoid reaction to
contrast media, the risk of subsequent reaction may be as
high as 50% (30,31). Patients with a known cardiovascular
disorder who are taking a beta-blocker are at increased risk
for contrast reactions (31). Observational studies suggest
that pretreatment of a reaction-prone patient with a corti-
costeroid and/or a H1 and H2 histamine blocker can reduce
this risk to an acceptable level when the indications for the
procedure justify its need (30–33). However, only one
randomized trial of corticosteroids has been conducted. In
that study, a two-dose corticosteroid regimen (before and
after angiography) significantly reduced the incidence of
anaphylactoid reactions (34). In addition, the use of non-
ionic contrast may reduce the incidence of subsequent
anaphylactic reactions (32,34).
The presence of uncompensated congestive heart failure
increases the chance of major complications after coronary
angiography. Although limited data are available to accu-
rately define its risk, treatment of the heart failure before
coronary angiography is advised. In addition, it is advisable
to limit contrast volume and use nonionic contrast media in
patients with poor left ventricular function to reduce the
adverse hemodynamic effects of contrast media.
It should be recognized that most of the relative contra-
indications may be temporary or reversible, and therefore if
the procedure can be safely delayed, risks may be lowered. In
high-risk patients and patients with relative contraindica-
tions, the procedure should not be performed in an outpa-
tient setting. The guidelines for outpatient cardiac catheter-
izations are described in more detail in the “ACC/AHA
Guidelines for Cardiac Catheterization and Cardiac Cath-
eterization Laboratories” (3).
E. Utilization
In 1993, cardiac catheterization was the second most
frequently performed in-hospital operative procedure in the
U.S. and the most frequently performed procedure in
patients older than 65 years of age (35). In that year,
'1,078,000 inpatient cardiac catheterization procedures
were performed (36). It is estimated that an additional
668,000 patients received cardiac catheterization as outpa-
tients (John Goodman and Associates, 1996, personal oral
communication). There are no similar data specific for use
of coronary angiography, but in adult patients, cardiac
catheterization includes coronary angiography in most cases.
Approximately 48% of cardiac catheterizations are now
performed in the elderly, who are defined as $65 years of
age (35). Men are more likely to have cardiac catheterization
than women. There are also racial differences in use of
coronary angiography in the U.S. In 1993, cardiac cathe-
terization was performed in 349 of 100,000 patients in the
white population, 235 of 100,000 in the black population,
and 316 of 100,000 in other races.
The use of cardiac catheterization continues to grow.
According to data from Medicare (37), the combined
number of inpatient left-heart catheterizations and right-
and left-heart catheterizations, ie, those procedures that
most often include coronary angiography, increased from
575,000 in 1991 to 793,000 in 1995, an increase of 38% over
4 years. The number of outpatient cardiac catheterizations is
more difficult to determine. It is estimated that in 1986,
'5% of the total volume of catheterizations in Medicare
patients were performed in outpatients, whereas in 1993,
that figure had risen to 23%.
Although it has been suggested by many that managed
care will curtail further growth in the frequency of cardiac
catheterization, that has yet to occur. Given a prediction of
40% growth in the population aged .45 years from 1995 to
2010, and the present trend of increased utilization, it is
possible that by 2010, '3,000,000 cardiac catheterizations
will be performed annually in the U.S.
Table 3. Relative Contraindications to Coronary Angiography
Acute renal failure
Chronic renal failure secondary to diabetes
Active gastrointestinal bleeding
Unexplained fever, which may be due to infection
Untreated active infection
Acute stroke
Severe anemia
Severe uncontrolled hypertension
Severe symptomatic electrolyte imbalance
Severe lack of cooperation by patient due to psychological or
severe systemic illness
Severe concomitant illness that drastically shortens life
expectancy or increases risk of therapeutic interventions
Refusal of patient to consider definitive therapy such as PTCA,
CABG, or valve replacement
Digitalis intoxication
Documented anaphylactoid reaction to angiographic contrast
media
Severe peripheral vascular disease limiting vascular access
Decompensated congestive heart failure or acute pulmonary
edema
Severe coagulopathy
Aortic valve endocarditis
PTCA indicates percutaneous transluminal coronary angioplasty; CABG, coronary
artery bypass graft.
1761JACC Vol. 33, No. 6, 1999 Scanlon and Faxon
May 1999:1756–824 ACC/AHA Coronary Angiography Guidelines
In 1994, '10% of cardiac catheterizations were per-
formed in patients with a Diagnosis Related Group (DRG)
diagnosis of acute MI (38,39). Although this is only a small
percentage of those patients studied by coronary angiogra-
phy, the infarction subgroup has been well characterized.
The frequency of its use is growing in this group of patients:
from 1987 to 1990, the proportion of Medicare patients
with infarction who had cardiac catheterization increased
from 24% to 33% (40). Infarction patients admitted to
hospitals with cardiac catheterization laboratories are '3
times more likely to undergo angiography than are patients
admitted to hospitals without such facilities (41,42). Pa-
tients treated for MI by invasive cardiologists have a similar
likelihood of undergoing angiography as patients treated by
noninvasive cardiologists (68% vs. 59% at Massachusetts
General Hospital), but the likelihood of having angioplasty
or surgery is higher for patients treated by invasive cardiol-
ogists (43).
In the U.S., there are substantial regional differences in
the use of coronary angiography (35). In the GUSTO-1
(Global Utilization of Streptokinase and Tissue Plasmino-
gen Activator for Occluded Coronary Arteries) study of
patients with acute MI, the proportion undergoing angiog-
raphy varied substantially between 7 regions evaluated (44).
In New England, 52% of patients with acute MI underwent
coronary angiography, whereas in the other 7 regions, the
frequency of use was much higher at between 66% and 81%.
The regional use of angiography was closely related to its
availability in all regions, except for New England. Despite
these regional variations in utilization, there was no appar-
ent relationship between procedure rate and certain patient
outcomes. The incidence of recurrent infarction or death at
30-day and one-year follow-up did not vary from region to
region. In another study that evaluated Medicare patients
with MI, the frequency of catheterization was 45% in
patients in Texas but only 30% in patients in New York
(45). In Texas, use was higher for all clinical subgroups
analyzed except for those at greatest risk for reinfarction,
that is, non–Q-wave infarction or patients with postinfarc-
tion angina, for whom the rates were similar to those in
New York. Despite the increased use of coronary angiog-
raphy in Texas, the adjusted mortality at two-year follow-up
was significantly lower in New York, and patients in New
York had fewer symptoms. Conversely, in an analysis of use
of coronary angiography within three months of an acute
MI among 6,851 patients hospitalized at 16 Kaiser Perma-
nente hospitals from 1990 to 1992, the rates of angiography
(ranging from 30% to 77%) were inversely related to the risk
of death from heart disease (p 5 0.03) and the risk of heart
disease events (p , 0.001) over one to four years of
follow-up (46). This association was strongest among pa-
tients for whom published criteria indicated that angiogra-
phy was necessary.
For postinfarction patients, there is also an international
difference in use of angiography. In both the GUSTO (47)
and the SAVE (Survival and Ventricular Enlargement)
trials (48), angiography was used more frequently after
infarction in patients in the United States than in Canada.
Despite this difference in utilization, there were no differ-
ences in mortality or reinfarction rates between the two
countries, although for both studies there was a higher
incidence of symptoms in Canadian patients at follow-up.
Similar conclusions were formed in a recent study compar-
ing elderly patients with MI in the U.S. and Canada (49).
This variation in use has led many to question the
appropriateness of angiography (50,51), particularly for
patients with MI. Appropriateness was evaluated for pa-
tients treated in the Myocardial Infarction Triage and
Intervention Project (MITI), a study of acute MI performed
in Seattle and King County, Washington (38). It was found
that except for recurrent angina, clinical risk factors that
predict higher mortality were associated with a lower rather
than a higher use of angiography, which suggests that many
patients who needed angiography did not receive it. Al-
though these data do not determine with certainty whether
angiographic procedures are overused in patients at low
mortality risk or underused in patients at greater mortality
risk, they suggest that the current balance between patient
survival risk and procedure utilization may not be the most
efficient use of this expensive resource (38).
Other studies examining the appropriateness of angiog-
raphy have yielded widely varied results (Table 4). These
studies generally rely on criteria established by an expert
panel to determine if angiography was necessary and appro-
priate. How well the opinion of such expert panels actually
agreed with practicing physicians had not been examined
until recently, but the level of agreement was found to be
quite good (58). Areas of patient management in which
variation in the appropriateness of coronary angiography
was greater were in older individuals and in those with
uncomplicated MI. Estimates for the rate of inappropriate
angiography have varied from as high as 58% in a two-
hospital study in Israel (53) to as low as 2% in a Swedish
report (56). The U.S. studies have included several reports
from the Rand Corporation investigators (52,55,59). Using
criteria for appropriateness developed through a consensus
panel of both specialists and generalists, Rand investigators
categorize angiography as appropriate, of “uncertain” value,
or inappropriate. By their criteria, angiography in New York
State was judged as appropriate in 76% of cases, of uncertain
value in 20%, and inappropriate in only 4% (52). Other
studies, particularly those that compare U.S. care with that
in Canada, have suggested that inappropriate indications
may be as high as 15% to 18% in some centers (57).
Unfortunately, current studies do not allow a final estimate
as to how frequently coronary angiography is performed
inappropriately.
Although most analyses have examined how often un-
necessary or inappropriate angiography is performed, few
have focused on how frequently patients fail to undergo
angiography despite firm indications for its use. A recent
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study from southern California examined how frequently
patients with a “necessary” indication for angiography,
defined as a very positive stress test, were not referred for
further evaluation by angiography (60). Among .160
patients with a “necessary” indication, only 47% underwent
angiography within three months of the stress test and 61%
within 12 months. After adjustment for demographics and
clinical presentation, patients cared for by a cardiologist
were more likely to undergo necessary angiography than
those cared for by nonspecialists (74% vs. 44% by one year).
These data, although preliminary, raise concern that widely
accepted and effective diagnostic tests and therapies are not
being used in substantial numbers of patients. They also
confirm findings from other studies that specialists in
cardiovascular disease are more likely to provide appropriate
or “necessary” procedures than generalists (61,62).
There are no data available regarding how often coronary
angiography can appropriately be performed in any one
patient. It seems reasonable that a significant clinical change
could warrant a repeat angiogram in a patient with known
CAD, if the indication for angiography was in agreement
with these guidelines. The committee considers it unrea-
sonable to perform a repeat angiogram in a patient with
recurrent chest pain who has had a previously normal
coronary angiogram within the preceding five years, unless
there is an intervening documented MI or significantly
worsening findings on noninvasive testing. However, in
patients with angiographically significant CAD, who were
initially treated medically but in whom coronary revascular-
ization later becomes clinically necessary, it is common
practice to allow such a patient to proceed with revascular-
ization without a repeat angiogram if ,6 months have
elapsed since the prior coronary angiogram, but to repeat
angiography if .6 months have passed.
On occasion, angiographic image quality or lesion visu-
alization is inadequate to make a judgment regarding the
best route of care for a patient, especially in deciding on a
revascularization procedure. In this case, a repeat angiogram
may be necessary. However, if repetitive angiography be-
comes an ongoing problem in any laboratory, the laboratory
director should critically review the equipment and staff
performance and especially the practice of those physicians
who undertake repetitive angiographic procedures. In the
absence of clinical indications, repeat angiography is both
costly and potentially dangerous.
F. Costs
The total cost of coronary angiography includes labora-
tory fee, professional fee and costs related to preprocedure
and postprocedure observation and laboratory testing (63).
Additional costs may accrue if inadequate studies must be
repeated or if complications develop (64). Charges generally
are different from costs and are usually higher. Charge
information is more readily available than cost information
(65). There is disagreement regarding the effect that labo-
ratory volume has on costs. Some recommend that a
laboratory should perform $300 to 400 procedures per year
to maximize economic efficiency, primarily to make up for
capital outlay and its amortization (66,67), whereas others
have found no relation between volume and costs (68,69).
The 1992 mean charge for cardiac catheterization for
inpatients younger than 65 years without a diagnosis of
acute MI was $10,880, varying by state from a low of $6,400
in Maryland to $17,600 in California (70). Eighty-two
percent of the total charge was for hospital care. Of this
amount, 62% was related to catheterization laboratory and
ancillary charges and 38% for room and board. The physi-
cian charge made up 18% of the total, averaging $2,000 and
varying from $1,300 in South Carolina to $2,550 in Cali-
fornia. Costs related to physician fees are falling. Medicare
payment for physician services for a typical procedure, e.g.,
a left-heart catheterization with a left ventriculogram or
angiography of the native coronaries as well as one addi-
tional angiographic component, with supervision and inter-
pretation, was $725 in 1994 and $700 in 1996, and further
reductions are anticipated (37).
Outpatient catheterization may be lower in cost, but how
much lower is unclear. A prospective study of patients who,
on the basis of published guidelines, were candidates for
outpatient procedures found that charges for outpatient
procedures were $580 less than for inpatient procedures, but
Table 4. Appropriateness of Angiography: Range of Findings in Literature
Author Study Cohort Methods Results
Bernstein et al. (52) 1,335 patients Rand method Inappropriate, 4%
15 hospitals in New York
Mozes and Shabtai (53) 499 patients Consensus panel Inappropriate, 58%
2 hospitals in Israel
Hampton et al. (54) 3 centers in England Expert panel Inappropriate, 10%–28%
McGlynn et al. (55) 1,336 patients Rand method in United States Inappropriate, 4%–10%
15 hospitals in New York; 15 in Canada Consensus panel in Canada
Bengston et al. (56) 831 patients in Sweden Expert panel Inappropriate, 2%
Roos et al. (57) 351 patients in Canada Expert panel In Canada, inappropriate, 9%
1,677 patients in United States In United States, inappropriate,
15%–18%
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actual cost savings were only $218 per patient (71). Previous
reports suggested that the nonprofessional component of
charges could be reduced by 31% to 55% for an outpatient
procedure (72,73).
G. Cost-Effectiveness
There has been relatively little study of the cost-
effectiveness of coronary angiography compared with non-
invasive techniques for the diagnosis and subsequent man-
agement of CAD (74). In part, this lack of evidence exists
because coronary angiography frequently leads to a revascu-
larization procedure, and thus it is difficult to separate the
cost-benefit aspects of the diagnostic test from those of the
procedure that subsequently follows. However, several re-
ports regarding the cost-effectiveness of coronary angiogra-
phy have recently been published.
Patterson et al. (74) compared the cost-effectiveness of
coronary angiography with that of ECG stress testing,
single photon emission-computed tomography (SPECT)
imaging, and stress positron emission tomography (PET)
scanning as a first technique to diagnose CAD. In this
Bayesian analysis, effectiveness was defined as the number of
patients with diagnosed CAD and utility as the clinical
outcome, i.e., the number of quality-adjusted life years
(QALY) extended by therapy after the diagnosis of CAD.
The authors used published values for costs, accuracy, and
complication rates of the various tests. At a clinically derived
pretest probability of significant CAD of ,70%, noninva-
sive testing was more cost-effective than coronary angiog-
raphy as an initial procedure. Above a threshold probability
of 70% (for example, middle-aged men with typical angina),
proceeding directly to angiography as the first test had the
lowest cost per effect or utility.
Other studies have examined the cost-effectiveness of
combined diagnostic coronary angiography and angioplasty
as a single procedure rather than having patients undergo
two procedures. Rozenman and colleagues (75) studied
.2,000 patients over a three-year period and found no
difference in success or complication rates for patients who
had diagnostic angiography and angioplasty performed at
the same time, compared with having them done as separate
procedures. They found no difference in length of stay after
angioplasty between combined and staged treatment strat-
egies and concluded that same-setting angioplasty was likely
to be more cost-effective. However, a formal analysis of true
costs was not performed. In a similar manner, O’Keefe et al.
(76) compared 219 patients undergoing combined proce-
dures with a matched population of 191 patients who had
separate procedures. The success and complication rates
were similar, and the average total charge for a combined
procedure was $11,128 compared with $13,160 in those
undergoing separate procedures. The authors also estimated
that significant savings would occur with respect to total
contrast, fluoroscopic time and total procedure time.
Kuntz et al. (77) recently estimated the cost-effectiveness
of routine coronary angiography after acute MI. Decision-
tree chance node probabilities were estimated with the use
of pooled data from randomized clinical trials and other
relevant literature, costs were estimated with the use of the
Medicare Part A database, and quality-of-life adjustments
were derived from a survey of 1,051 patients with a recent
MI. Routine coronary angiography increased quality-
adjusted life expectancy in almost all post-MI subgroups
compared with patients given initial medical therapy with-
out angiography; however, the cost per QALY gained
ranged widely, from $17,000 to .$1 million. When a
threshold of ,$50,000 was considered cost-effective, which
compares favorably with the cost of using various medical
strategies after MI, routine angiography was cost-effective
for patient subgroups with severe postinfarction angina or a
strongly positive exercise tolerance test, and for most sub-
groups with a prior MI, even with a negative stress test.
Clearly, more research on the cost-effectiveness of coronary
angiography is needed before the optimal use of this
procedure in a wide range of clinical circumstances can be
determined.
III. CORONARY
ANGIOGRAPHY FOR SPECIFIC CONDITIONS
A. Known or Suspected CAD*
1. General Considerations. Coronary atherosclerosis is a
slowly progressive process that can be clinically inapparent
for long periods of time (78–80). Coronary disease often
becomes clinically evident because of the occurrence of
symptoms, such as angina or those associated with MI.
Patients with known CAD are those in whom the disease
has been documented by either angiography or MI (i.e.,
using WHO criteria). “Suspected coronary disease” means
that a patient’s symptoms or other clinical characteristics
suggest a high likelihood for significant CAD and its related
adverse outcomes but that evidence of CAD has not yet
been documented as defined above.
Patients may develop symptoms at one point in time but
may become asymptomatic thereafter as the result of a
change in the disease or as the result of therapy. For
instance, many patients are asymptomatic after an uncom-
plicated MI, as are patients with mild angina, who can be
rendered asymptomatic by medications. The severity of
clinical presentations and the degree of provokable ischemia
on noninvasive testing are the principal factors used in
determining the appropriateness of coronary angiography.
Although the extent of coronary disease defined by coronary
angiography does predict outcome, use of coronary angiog-
raphy as a “screening tool” in unselected populations is
neither prudent nor cost-effective (74). The same can be
stated regarding the routine use of exercise testing (81),
*As used in this document, the term “coronary artery disease” is broadly inclusive,
encompassing atherosclerotic coronary disease with or without clinical manifestations
as well as rarer forms of coronary disease that can produce obstruction and/or flow
limitation, eg, embolus, spasm, arteritis, congenital abnormality and trauma.
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radionuclide imaging (82) and stress echocardiography (83)
in unselected patients. With only a few exceptions, coronary
angiography is not clearly indicated in asymptomatic pa-
tients with either known or suspected CAD, unless nonin-
vasive testing (performed as recommended in the ACC/
AHA noninvasive guidelines), reveals findings that suggest
a high risk for adverse outcome (81,82). Coronary angiog-
raphy is also frequently done during evaluation for other
cardiac conditions, such as valvular heart disease, congestive
heart failure, or assessment of congenital heart disease. In
this setting, angiography may be performed in asymptom-
atic patients. The details of indications for coronary angiog-
raphy in specific conditions are described below.
2. Stable Angina
a. Definitions
Patients with CAD may become symptomatic in many
different ways but most commonly develop angina pectoris.
In this document, angina pectoris (or simply angina) means
a chest discomfort due to myocardial ischemia, often de-
scribed as a transient squeezing, pressure-like precordial
discomfort. Angina is generally provoked by physical effort
(particularly during the postprandial state), with exposure to
cold environment or by emotional stress. The discomfort on
effort is relieved by rest, its duration being a matter of
minutes. The ease of provocation, frequency and duration of
episodes may remain relatively unchanged in individuals for
extended time periods, leading to the term “stable angina
pectoris.”
Not all stable chest pain syndromes are truly anginal.
Various authors have subdivided stable chest pain syn-
dromes in an attempt to link the quality of symptoms with
the prevalence of significant CAD. Diamond and Forrester
(84) found significant CAD at angiography in 89% of
patients with typical angina but in only 50% with atypical
angina and merely 16% of patients with nonanginal chest
pain.
In CASS, 8,157 patients with chronic stable chest pain
who underwent coronary angiography were characterized by
type of symptoms reported. The CASS definitions of
anginal type have become standards for much subsequent
literature (85). “Definite angina” was defined as substernal
discomfort precipitated by exertion and relieved by rest or
nitroglycerin in ,10 min. Most patients reported typical
radiation to the shoulders, jaw or inner aspect of the arm.
Patients with probable angina had most of the features of
definite angina, but the features were atypical in some
respects (e.g., radiation, unpredictable relief with nitroglyc-
erin or duration up to 15 to 20 min). The third group had
“nonspecific chest pain” that did not fit either of the above
two groups. The prevalence of significant CAD in patients
with definite angina, probable angina and nonspecific chest
pain was 93%, 66% and 14% in men, and 72%, 36% and 6%
in women (p , 0.001). The age and sex of the patients as
well as the character of chest pain were important determi-
nants of disease prevalence and severity. Coronary disease
associated with high risk for adverse outcomes, that is, left
main or three-vessel disease, occurred in .50% of middle-
aged men and older women with definite angina and most
men who had probable angina who were .60 years. In
contrast, high-risk coronary disease was uncommon in both
men and women with nonspecific chest pain, especially in
patients ,60 years.
The definition and diagnosis of angina is sometimes made
more difficult by the predominance of other symptoms such as
exertional dyspnea or fatigue, which may be “anginal equiva-
lents.” Women frequently present with symptoms that do not
have the features classically described in studies of large
populations of middle-aged men. Furthermore, women have a
higher frequency of asymptomatic ischemia (86).
Angina is further defined according to a gradient of severity
as outlined by the CCS classification (87) (Appendix D). In
addition, asymptomatic patients with CAD are those with no
symptoms to suggest myocardial ischemia in the previous six
weeks (88). It is recognized that when tested, a subgroup of
these patients will have transient abnormalities consistent with
myocardial ischemia in the absence of symptoms. This is
termed silent ischemia, and the abnormalities detected may
consist of reversible ECG ST-segment shifts on exercise
testing or ambulatory monitoring, perfusion abnormalities on
radionuclide scans (i.e., stress 201Tl, sestamibi, and PET) or
regional wall motion abnormalities during left ventricular
imaging (i.e., stress echocardiography or radionuclide ventricu-
lography). It is appropriate to use the term ischemia in this
context and to reserve the term angina to describe the subjec-
tive symptom felt by patients during episodes of myocardial
ischemia. In general, these ischemic test results relate to the
functional severity of CAD and are predictors of risk for future
adverse outcome, independent of the perception of, or severity
of symptoms. Thus, the absence of current symptoms does not
necessarily mean either the absence of ischemia or the absence
of an impaired prognosis. Diabetes, older age, female gender,
hypertension, polyneuropathy, and cardiac transplantation,
when accompanied by significant CAD, are all associated with
a high frequency of ischemia or even MI without symptoms
(89–92).
Patients with known CAD can be divided into two
groups based on whether or not they ever had symptoms.
One group includes those who were never symptomatic but
in whom CAD was documented for other reasons. For
example, abnormalities on a stress test led to an angiogram;
the patient was a cardiac surgical candidate (e.g., valve
replacement) and therefore angiography was done as a
preoperative evaluation; or other clinical findings (e.g.,
asymptomatic MI or abnormal ECG) led to an angiogram.
The other group includes those who were previously symp-
tomatic but are currently asymptomatic (i.e., no symptoms
within six weeks). This group would include, for example,
those who previously had angina but are now asymptomatic;
patients after symptomatic MI with no postinfarction an-
gina; patients after revascularization (either CABG or
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PTCA) who now have no angina; and those who were
effectively treated (i.e., drugs or activity restriction) who
now have no angina. Although this grouping is convenient
because it summarizes how these patients present to the
clinician, there are no data to suggest that such clinical
grouping, based on whether or not patients are currently
symptomatic, has prognostic significance.
b. Management Approach for Symptomatic Patients
Patients with stable chest pain syndromes should undergo
a thorough clinical evaluation, including classification of
chest pain type into definite or probable angina or nonspe-
cific chest pain, and identification of risk factors (age,
tobacco use, dyslipidemia, hypertension, family history of
premature coronary disease, activity profile, obesity, post-
menopausal status and diabetes). The physical examination
will usually detect evidence of other types of heart disease
that can cause angina, e.g., aortic stenosis, hypertrophic
cardiomyopathy or severe pulmonary hypertension. An
assessment of contraindications for coronary angiography
should be part of this clinical assessment. The CCS classi-
fication of angina provides a useful guide for the assessment
of severity of definite or probable angina. Severe symptoms
(CCS class III or IV) suggest severe CAD and are an
indication for cardiac catheterization.
Optimal medical management may include nitrates,
long-acting calcium channel blockers, and beta-adrenergic
blocking agents, as well as attention to associated conditions
such as hypertension, dyslipidemia and diabetes. Therapy is
considered adequate if it includes two of the three antian-
ginal agents used at or near maximum recommended doses
in addition to antiplatelet therapy. For most patients,
medical therapy is considered successful when angina has
been eliminated or no longer adversely influences their
lifestyle, and they are able to exercise beyond the end of
stage II of the Bruce protocol without experiencing angina
and ST-segment depression. Patients with definite or prob-
able angina for whom optimal pharmacologic therapy has
failed and those with an intolerance to these medications are
candidates for coronary angiography. Patients who are
treated medically but who demonstrate subsequent deterio-
ration on noninvasive testing that suggests progression of
disease are often considered for coronary angiography.
Coronary angiography should also be considered for pa-
tients whose angina accelerates or intensifies despite ade-
quate medical care, even if their symptoms do not fulfill the
criteria for a diagnosis of unstable angina. Stable angina
patients who have survived sudden cardiac death or sus-
tained ventricular tachycardia are generally referred for
coronary angiography to identify coronary lesions that, if
treated appropriately, could relieve the ischemic substrate
for lethal arrhythmias (93).
From time to time, CCS class I to II patients, whose
occupation or other circumstance constitutes a risk to
themselves or others, should undergo coronary angiography
even in the absence of high-risk markers for adverse
outcome on noninvasive testing. Such “need-to-know” cir-
cumstances may exist for airplane pilots, train operators,
firefighters, school bus drivers, serious athletes and others.
c. Management Approach for Asymptomatic or Mildly
Symptomatic Patients With Known or Suspected CAD
A scheme for noninvasive evaluation of a mildly symp-
tomatic or asymptomatic patient suspected or known to
have significant CAD is shown in Figure 1. Exercise-
induced ECG changes, abnormalities on radionuclide myo-
cardial perfusion scans, and abnormalities on ventricular
wall motion studies (Table 5) are established markers for
high risk of adverse outcomes. Although these noninvasive
stress test markers are neither 100% sensitive nor 100%
specific, when properly used, they do have very acceptable
predictive value for adverse outcome. Thus, they aid in the
selection of appropriate candidates for coronary angiography
when symptom severity alone does not support such a
recommendation. A minority of patients undergoing non-
invasive testing will have findings that suggest a high risk for
adverse outcome, but in most of these high-risk cases, a
recommendation for coronary angiography is warranted.
The criteria (Fig. 2) cited for identifying patients at high
risk for adverse outcome during exercise ECG testing have
evolved from both the original and the revised joint ACC/
AHA Task Force reports (81,95) and a special report on
exercise standards from the AHA (96). These reports
emphasize the difficulties in interpreting ECG changes in
selected populations, such as premenopausal women with a
low pretest likelihood of coronary disease. Also, it should be
noted that most apparently healthy men who have a positive
(i.e., 1-mm ST depression) exercise ECG test (without
high-risk criteria) but who lack clinical risk factors do not
have significant CAD (97).
Radionuclide perfusion imaging techniques generally
have higher specificity for significant CAD than ECG-
based tests used alone but are much more costly. The
radionuclide techniques are most cost-effective in identify-
ing severe multivessel CAD in patients with uninterpretable
ECGs and in patients who have an abnormal exercise ECG
that does not fulfill high-risk criteria (Table 5). These
findings are summarized in the “ACC/AHA Guidelines for
Clinical Use of Cardiac Radionuclide Imaging” (82,98).
That committee concluded that use of exercise or pharma-
cologic myocardial perfusion imaging with thallium or rest
and exercise radionuclide angiography was usually appropri-
ate and considered useful for assessment of severity of
ischemia and risk stratification of patients with known or
suspected CAD. They thought that the use of gated
sestamibi perfusion imaging was also acceptable for this
purpose but that its usefulness was less well established. The
most consistent predictor of cardiac death or nonfatal MI
was the number of transient perfusion defects provoked by
either exercise or pharmacologic stress. Patients with CAD
and redistribution defects on stress thallium imaging in .1
coronary artery region or who have a combination of
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redistribution abnormalities and increased lung uptake are
at increased risk for adverse outcome (98). Normal stress
201Tl scans are highly predictive of a good outcome, even in
patients with documented CAD. An analysis of 3,595 such
patients, followed up for #29 months in 16 separate studies,
revealed a 0.9% annual rate of cardiac death or MI (99),
nearly as low as that seen in the general population (100).
Assessment of left ventricular function (radionuclide
ventriculography or echocardiography) shows that mortality
rates progressively increase as left ventricular ejection frac-
tion at rest decreases. When ejection fraction decreases
$10% with exercise or fails to exceed 0.50 during exercise,
particularly in association with new or worsening regional
wall motion abnormalities, prognosis is also impaired (98).
Similarly, patients at increased risk for adverse outcome can
be identified by a reduced ejection fraction with rest
echocardiography or by stress echocardiography that shows
multiple new or worsening regional wall motion abnormal-
ities during stress (100–109).
Appropriate treatment of patients with ischemia but not
severe symptoms was addressed in the Asymptomatic Car-
diac Ischemia Pilot (ACIP) study (88,110,111). Clinically
stable patients with CAD (a third were asymptomatic, and
the majority had multivessel disease and normal ventricular
function) and ischemia on both stress testing and ambula-
tory ECG monitoring were randomized to either initial
medical or revascularization treatment strategies. Patients
randomized to a medical strategy could cross over to
revascularization at any time to relieve severe symptoms.
Although there were only a small number of events, the
results suggested that patients randomized to initial revas-
cularization had better outcomes (fewer deaths and nonfatal
Figure 1. Clinical context for noninvasive and invasive diagnostic testing of patients with suspected ischemic heart disease. *ECG
interpretable unless preexcitation, electronically paced rhythm, left bundle-branch block or resting ST-segment depression .1 mm. See
text for discussion of digoxin use, left ventricular hypertrophy, and ST depression ,1 mm. **For example, high risk if Duke treadmill score
predicts average annual mortality .3% (see Fig. 2 for nomogram). Modified from Figure 1 of the “ACC/AHA Guidelines for Exercise
Testing” (81).
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MIs as well as hospitalizations) at one and two years than
did those randomized to initial medical treatment
(110,112). Although these findings require confirmation in
a larger trial with mortality as the outcome, they do support
overviews of nonrandomized (113,114) and randomized
(115) trial data that concluded that asymptomatic or mildly
symptomatic patients with severe ischemia on noninvasive
testing do better with initial revascularization than with
initial medical therapy.
There is varying opinion as to when coronary angiogra-
phy should be performed in asymptomatic patients in whom
noninvasive testing indicates ischemia (i.e., a high proba-
bility of CAD), but in whom test criteria do not indicate
high risk for adverse outcomes. In part, this is attributable to
the observation that the development of ischemia on these
tests may not in itself indicate a poor prognosis (99). In this
group with ischemia, but no test abnormalities to suggest
high risk, the presence of multiple clinical risk factors such
as increased age, diabetes, or occupational or lifestyle risks
become increasingly important considerations when deter-
mining whether coronary angiography should be performed.
However, it should be recognized that there are no con-
trolled studies that show an advantage for angiography or
revascularization over a conservative medical “wait and see”
approach for any of these clinical subsets.
Because transplanted hearts often develop occlusive cor-
onary arteriopathy, and because ischemia in patients with
denervated hearts is generally asymptomatic, it has become
common practice to perform periodic coronary angiography
(and often intravascular coronary ultrasound), usually annu-
ally, after transplantation. The prognostic benefit of this
practice has not been clearly established. It has also become
a common part of the screening process to perform coronary
angiography in candidates for liver, lung or kidney trans-
plantation if they are $40 years of age, even in the absence
of significant clinical risk factors for coronary disease. It
would seem that noninvasive testing could be substituted for
coronary angiography in many of these patients.
d. Management Approach for Patients Resuscitated From
Sudden Cardiac Death
Adult patients successfully resuscitated from cardiac ar-
rest who do not have clinical findings that suggest other
causes of the arrest generally have extensive CAD. In the
absence of recognized precipitating factors, such as acute
MI, these patients are at high risk for recurrent cardiac
arrest, and coronary angiography is of value in determining
the underlying cause and planning the most appropriate
therapeutic approach. Observational data indicate that cor-
onary bypass surgery may be associated with reduced adverse
outcome in that subgroup with significant coronary disease
(93). It has been reported that immediate coronary angiog-
raphy in survivors of out-of-hospital cardiac arrest reveals
acute coronary occlusion in '50% of patients and that
successful emergency angioplasty of an acute occlusion is an
independent predictor of survival (116). A recent AHA
statement further addresses this issue (117).
Recommendations for Coronary Angiography in
Patients With Known or Suspected CAD Who Are
Currently Asymptomatic or Have Stable Angina
Class I
1. CCS class III and IV angina on medical treatment.
(Level of Evidence: B)
2. High-risk criteria on noninvasive testing regardless
of anginal severity (Table 5). (Level of Evidence: A)
3. Patients who have been successfully resuscitated
from sudden cardiac death or have sustained
(>30 s) monomorphic ventricular tachycardia or
nonsustained (<30 s) polymorphic ventricular
tachycardia. (Level of Evidence: B)
Class IIa
1. CCS class III or IV angina, which improves to class
I or II with medical therapy. (Level of Evidence: C)
2. Serial noninvasive testing using identical testing
protocols, at the same level of medical therapy,
showing progressively worsening abnormalities.
(Level of Evidence: C)
3. Patients with angina and suspected coronary dis-
ease who, due to disability, illness, or physical
challenge, cannot be adequately risk stratified by
other means. (Level of Evidence: C)
4. CCS class I or II angina with intolerance to adequate
medical therapy or with failure to respond, or patients
who have recurrence of symptoms during adequate
medical therapy as defined above. (Level of Evidence:
C)
5. Individuals whose occupation involves the safety of
others (e.g., pilots, bus drivers, etc.) who have
Table 5. Noninvasive Test Results Predicting High Risk* for
Adverse Outcomes in Patients With Known or Suspected
Coronary Artery Disease†
Severe resting left ventricular dysfunction (LVEF ,35%)
High-risk treadmill score (score #211)†
Severe exercise left ventricular dysfunction (exercise LVEF
,35%)
Stress-induced large perfusion defect (particularly if anterior)
Stress-induced multiple moderate perfusion defects
Large, fixed perfusion defect with LV dilatation or increased
lung uptake (thallium 201)
Stress-induced moderate perfusion defect with LV dilatation or
increased lung uptake (thallium 201)
Echocardiographic wall motion abnormality (involving .2
segments) developing at low dose of dobutamine (#10 mg/kg
per minute) or low heart rate (,120 beats/min)
Stress echocardiographic evidence of extensive ischemia
LVEF indicates left ventricular ejection fraction.
*Annual mortality rate .3%.
†Treadmill score is calculated using Bruce protocol, duration of exercise in
minutes 2 (5 3 maximal ST-segment deviation during or after exercise in mm) 2
(4 3 treadmill angina index). The numerical treadmill angina index was 0 for no
angina, 1 for nonlimiting angina, and 2 for exercise-limiting angina.
From Mark et al. (94).
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abnormal but not high-risk stress test results, or
multiple clinical features that suggest high risk.
(Level of Evidence: C)
Class IIb
1. CCS class I or II angina with demonstrable isch-
emia but no high-risk criteria on noninvasive test-
ing. (Level of Evidence: C)
2. Asymptomatic man or postmenopausal woman with
>2 major clinical risk factors and abnormal but not
high-risk criteria on noninvasive testing (performed
for indications stated in the ACC/AHA noninva-
sive testing guidelines) without known coronary
heart disease. (Level of Evidence: C)
3. Asymptomatic patients with prior MI with normal
resting left ventricular function and ischemia on
noninvasive testing, but without high-risk criteria.
(Level of Evidence: C)
4. Periodic evaluation after cardiac transplantation.
(Level of Evidence: C)
5. Candidate for liver, lung or renal transplant >40
years old as part of evaluation for transplantation.
(Level of Evidence: C)
Class III
1. Angina in patients who prefer to avoid revascular-
ization even though it might be appropriate. (Level
of Evidence: C)
2. Angina in patients who are not candidates for
coronary revascularization or in whom revascular-
ization is not likely to improve quality or duration
of life. (Level of Evidence: C)
3. As a screening test for CAD in asymptomatic
patients. (Level of Evidence: C)
Figure 2. Nomogram of the prognostic relations in the treadmill score. Determination of prognosis proceeds in five steps:
1. The observed amount of exercise-induced ST-segment deviation (the largest elevation or depression after resting changes have been
subtracted) is marked on the line for ST-segment deviation during exercise.
2. The observed degree of angina during exercise is marked on the line for angina.
3. The marks for ST-segment deviation and degree of angina are connected with a straight edge. The point where this line intersects the
ischemia reading line is noted.
4. The total number of minutes of exercise in treadmill testing according to the Bruce protocol (or the equivalent in multiples of resting
oxygen consumption [METs] from an alternative protocol) is marked on the exercise-duration line.
5. The mark for ischemia is connected with that for exercise duration. The point at which this line intersects the line for prognosis
indicates the five-year survival rate and average annual mortality for patients with these characteristics.
Patients with ,1 mm of exercise-induced ST-segment depression should be counted as having 0 mm. Angina during exercise refers to
typical effort angina or an equivalent exercise-induced symptom that represents the patient’s presenting complaint. This nomogram applies
to patients with known or suspected coronary artery disease, without prior revascularization or recent myocardial infarction, who undergo
exercise testing prior to coronary angiography.
Modified from Mark et al. (94).
Copyright © 1991 Massachusetts Media Society. All rights reserved. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. NEJM
1991;325:849–53. With permission Shaw L, Harrell FE Jr., et al.
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4. After CABG or angioplasty when there is no evi-
dence of ischemia on noninvasive testing, unless
there is informed consent for research purposes.
(Level of Evidence: C)
5. Coronary calcification on fluoroscopy, electron
beam CT, or other screening tests without criteria
listed above. (Level of Evidence: C)
e. Management of Patients With Nonspecific Chest Pain
Chest pain syndromes that are not characteristic of
angina have previously been called noncardiac, atypical, or
angiographically negative chest pain, as well as chest pain of
undetermined origin (37–39). These terms are generally
used to describe chest pain syndromes that are not associ-
ated with myocardial ischemia and are not of a cardiac cause.
However, “atypical angina” generally means that myocardial
ischemia is the cause of the symptoms, but the clinical
presentation is unusual and should not be confused with
nonspecific chest pain. For the purpose of this document and
for consistency with previous documents, chest pain or cardiac
symptoms not thought to be consistent with definite or
probable angina are classified as nonspecific chest pain.
Nonspecific chest pain is very infrequently due to myo-
cardial ischemia secondary to significant CAD, with a
prevalence of 14% in men and 6% in women in one study
(85). Other causes of myocardial ischemia, such as variant
angina due to coronary spasm, or cocaine abuse, or syndrome
X due to microvascular dysfunction, can infrequently present as
nonspecific chest pain as well. Other cardiac causes include
mitral valve prolapse, myocarditis, pericarditis and aortic dis-
section. Mitral valve prolapse is often associated with nonspe-
cific chest pain. Although the cause is poorly understood, one
postulate is that traction of the papillary muscle, induced by
abnormal mitral valve motion, causes ischemia (118).
Noncardiac causes of nonspecific chest pain include
costochondritis and esophageal disorders. Several disorders
of the esophagus cause retrosternal chest pressure that can
mimic myocardial ischemic-type chest pain. These include
gastroesophageal reflux, irritable esophagus with altered
gastroesophageal motility and a hypertensive lower esoph-
ageal sphincter (119). Many patients with both ischemic
cardiac and esophageal pain can distinguish the symptoms,
but some cannot. Exertional symptoms resulting from an
esophageal source may also occur (119–121). Gastroesoph-
ageal reflux is a common, treatable cause of chest discomfort
in patients with CAD who have nonspecific chest pain
symptoms and remain symptomatic despite aggressive an-
tianginal therapy (122). In one study, esophageal manom-
etry, pH, and Holter monitoring were performed in patients
with refractory nonspecific chest pain on optimal medical
therapy for CAD. Of the 88% with chest pain identical to
their anginal syndrome, 23% had acid reflux, 4% had cardiac
ischemia, and 73% had no demonstrable cause. Up to 30%
of patients with nonspecific chest pain will have an esoph-
ageal motility disorder (123). In some cases, antianginal
therapy may exacerbate esophageal reflux symptoms because
many of the drugs used to reduce these symptoms also lower
esophageal sphincter tone (124,125).
A generalized disorder of smooth muscle function involv-
ing the esophagus, airways, musculoskeletal vasculature,
central nervous system, and coronary microvasculature has
been proposed (121). Some data suggest that gastroesoph-
ageal reflux and esophageal motility abnormalities may elicit
myocardial ischemia and chest pain, a phenomenon termed
“linked” angina. Acid stimulation caused typical angina
(associated with a reduction in coronary blood flow velocity)
in about half of syndrome X patients, which suggests that
linked angina may indeed occur (119). However, other
studies refute this concept (125,126).
If noncardiac causes are excluded or unlikely, or if the
patient has significant cardiovascular risk factors that raise
the suspicion of coronary disease, a noninvasive evaluation is
appropriate. A number of guidelines specifically address this
issue in detail (81–83,95–99). If noninvasive testing indi-
cates a high risk for adverse outcome, then referral for
coronary angiography should be made. Patients with non-
specific chest pain and evidence of myocardial ischemia but
without indicators of high risk may be started on medical
therapy with careful follow-up to assess their clinical re-
sponse (127). Those who are intolerant of medical therapy,
who fail to respond adequately to medical therapy, or in
whom chest pain limits their lifestyle significantly despite
taking $2 antianginal medications should be considered for
coronary angiography. Patients who repeatedly present to
the hospital with nonspecific chest pain, but who fail to have
high-risk markers for ischemia, may also benefit from
coronary angiography. The findings of a normal coronary
angiogram in such patients indicate a good long-term
prognosis that is reassuring to both the patient and the
physician. Studies have indicated that a normal angiogram
in this setting significantly reduces symptoms and subse-
quent hospitalizations (128).
Recommendations for Coronary Angiography in
Patients With Nonspecific Chest Pain
Class I
High-risk findings on noninvasive testing. (Level of
Evidence: B)
Class IIa
None.
Class IIb
Patients with recurrent hospitalizations for chest pain
who have abnormal (but not high-risk) or equivocal
findings on noninvasive testing. (Level of Evidence: B)
Class III
All other patients with nonspecific chest pain. (Level of
Evidence: C)
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3. Unstable Angina
a. Definitions
The acute coronary syndromes include unstable angina,
non–Q-wave MI, and acute Q-wave MI. The diagnosis of
unstable angina has been complicated by a broad range of
presentations that can vary between atypical chest pain and
acute MI. An expert panel of clinicians attempted to clarify
the definition of unstable angina in the recently published
“Clinical Practice Guideline for Unstable Angina”
(129,130). Three possible presentations are described:
● Symptoms of angina at rest (usually prolonged .20 min);
● New-onset (,2 months) exertional angina of at least
CCS class III in severity;
● Recent (,2 months) acceleration of angina as reflected by
an increase in severity of at least one CCS class to at least
CCS class III.
Variant angina, non–Q-wave MI and recurrent angina
.24 h after MI are considered part of the spectrum of
unstable angina. However, in this document, non–Q-wave
MI is discussed in the section on acute MI.
Our understanding of stable and unstable coronary syn-
dromes continues to evolve along with our increased under-
standing of their pathophysiology. Locally produced vaso-
active mediators and complex coronary morphologic
characteristics may promote a dynamic process of thrombo-
sis and fibrinolysis via platelet activation that can lead to
acute coronary syndromes. Serum markers, such as creatine
phosphokinase isoforms and cardiac troponin T and I, have
led to an increased appreciation of the close relationship
between unstable angina and MI.
b. Pathophysiology
Unstable ischemic coronary syndromes are characterized
by severe but often transient episodes of myocardial isch-
emia caused by a critical obstruction to coronary blood flow.
These episodes are almost always caused by $1 of several
pathophysiologic mechanisms that interfere with the bal-
ance of myocardial oxygen supply and demand. The spon-
taneous rupture of lipid-laden, macrophage-rich atheroscle-
rotic plaques may initiate unstable angina, acute MI, or
sudden death (131) through platelet aggregation and
thrombus formation over the fissured plaque (132). Plaque
rupture leads to total or subtotal occlusion, resulting in a
silent progression of the occlusive process or an acute
coronary syndrome. Coronary angiography cannot predict
vulnerable plaques, but once thrombosis has occurred, a
filling defect indicating thrombus may be detected by
angiography (133). Patients with unstable angina have more
complex coronary lesions and more intracoronary thrombus
on angiography than patients with stable angina (134,135).
The coronary angiographic findings in unstable angina are
often indistinguishable from those of non–Q-wave MI
(133). Unstable angina with a clinical duration of ,2
months is characterized angiographically by a high inci-
dence of complex lesions. In a blinded retrospective angio-
graphic study of 52 patients with unstable angina ,2
months in duration compared with 32 patients having
“chronic” unstable angina for .6 months, those with
chronic unstable angina had a greater number of diseased
vessels, fewer eccentric lesions and a better collateral circu-
lation (136).
c. Risk Stratification
Within the group of patients with unstable angina,
variable clinical outcomes are seen. The Braunwald classi-
fication (137) was developed as a means to grade patients
with unstable angina according to severity of expected
outcome, on the basis of the clinical manifestations and
circumstances of their presentation (137). In this classifica-
tion, consideration is given to history, associated ECG
changes, and concurrent medical therapy in evaluating
symptomatology. Risk stratification based on the Braunwald
classification system has recently been validated by two
groups, confirming its prognostic utility (138,139). The
Agency for Health Care Policy and Research (AHCPR)
Clinical Practice Guideline for unstable angina is a refinement
of the Braunwald classification. Categories of severity are
different, but as with the original scheme, the AHCPR
guideline uses clinical circumstances, ECG changes, and in-
tensity of therapy to develop an algorithm for the diagnosis and
management of patients with suspected unstable angina (140).
d. Prognosis
Overall, the risk of a major adverse cardiac clinical event
(death or nonfatal MI) in patients with unstable angina is
less than that observed with acute MI but greater than in
stable angina. This risk is highest at the time of presentation
and declines to baseline within two months (141). One-year
follow-up of the 1,473 Thrombolysis in Myocardial Infarc-
tion (TIMI) IIIB patients revealed a 4.3% mortality rate and
an 8.8% incidence of nonfatal infarction at one year, but a
substantial percentage of these cases had a non–Q-wave MI
(142). In another study of 1,897 patients admitted to the
coronary care unit in whom an infarction did not evolve and
some of whom may not have had CAD, the 10-year cardiac
mortality rate was 22% (143). Accordingly, identification of
the high-risk patient is of paramount importance.
Silent ischemia has also been identified as a marker for
unfavorable outcome in patients with unstable angina (144).
In addition to the clinical history and ECG findings, certain
serum markers have recently been shown to identify a
high-risk subgroup (145–147). In these studies, elevations
in creatine kinase (CK) isoforms, cardiac troponin T and I,
and acute phase reactants appear to identify a subgroup of
patients with unstable angina at high risk for adverse
outcome (148–150).
e. Management Approach
A management approach to unstable angina is outlined in
the AHCPR Clinical Practice Guideline that is based on an
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assessment of both the likelihood of CAD and the short-
and long-term prognoses of such patients (129). For those
judged in their initial evaluation and treatment phase to be
at low risk for adverse outcomes (Table 6), the guidelines
recommend outpatient management. Patients thought to be
at intermediate or high risk for death or nonfatal MI should
be admitted to the hospital for intensive medical manage-
ment. For patients who do not respond after an hour of
aggressive therapy or who have recurrence of symptoms
after initial stabilization and are thus considered refractory,
emergency or urgent coronary angiography should be per-
formed and intraaortic counterpulsation considered. Emer-
gency catheterization refers to a diagnostic catheterization
study that is performed immediately or as soon as possible,
i.e., within 6 h. Urgent coronary angiography refers to a
study performed within 24 h of hospitalization.
For patients whose condition stabilizes after initial treat-
ment, the AHCPR Unstable Angina Clinical Practice
Guideline proposes either an “early invasive” or “early
conservative” strategy. With the early invasive strategy, all
hospitalized patients (intermediate and high risk) without
contraindications, receive elective cardiac catheterization
within 48 h. With the early conservative strategy, only
patients with high-risk indicators (prior revascularization,
congestive heart failure, left ventricular ejection fractions
,0.50, malignant ventricular arrhythmia, persistent or re-
current ischemic pain and/or functional study indicating
high risk) are referred for cardiac catheterization. In the
TIMI IIIB trial, a low six-week mortality rate (2.4%) and
occurrence of infarction or reinfarction (6.3%) were
achieved with either an early conservative or early invasive
strategy. However, the early invasive strategy resulted in a
reduced length of stay and reduced number of readmissions
as well as less use of antianginal drugs (151). In a further
analysis of patients treated with PTCA in the TIMI IIIB
study, PTCA within 24 h of admission was an independent
predictor of the occurrence of a subsequent cardiovascular
event, especially if these patients were being treated emer-
gently (152). This committee believes that an early invasive
strategy with early coronary angiography is useful and
effective, although probably better done after 24 h of
aggressive medical management, including aspirin, standard
or low-molecular-weight heparin and a glycoprotein IIb/
IIIa inhibitor, if the clinical situation allows.
As summarized earlier, coronary angiography is indicated
in unstable angina when subsequent revascularization is
likely to alter the natural history or when patients have
continued symptoms. When symptoms are intractable, the
guidelines recommend emergent or urgent coronary angiog-
raphy. The incidence of truly refractory angina was evalu-
ated in a group of 125 patients with unstable angina studied
over a five-year period in the recent era of five-drug therapy
(intravenous heparin, aspirin, nitrates, calcium channel
blockers and beta-blockers). All patients had .20 min of
angina at rest with reversible ECG changes. Of the 52%
who were thought to be medically refractory by the referring
practitioners, 83% could be rendered free of chest pain by a
more aggressive medical regimen. The incidence of truly
medically refractory unstable angina with this five-drug
regimen was found to be infrequent at 8.8% (153) and
would probably be even less frequent with the addition of
low-molecular-weight heparin and/or glycoprotein IIb/IIIa
Table 6. Short-Term Risk of Death or Nonfatal Myocardial Infarction in Patients With Unstable Angina
High Risk Intermediate Risk Low Risk
At least 1 of the following features
must be present:
No high-risk features but must have any of
the following:
No high- or intermediate-risk features but
may have any of the following features:
Prolonged ongoing (.20 min) chest
pain
Prolonged (.20 min) angina at rest, now
resolved, with moderate or high
likelihood of CAD
Increased frequency, severity, or duration
of angina
Pulmonary edema, most likely related
to ischemia
Angina at rest (.20 min or relieved with
rest or sublingual nitroglycerin)
Angina provoked at lower threshold
Angina at rest with dynamic ST
changes $1 mm
Nocturnal angina New-onset angina with 2 wk to 2 mo
before presentation
Angina with new or worsening MR
murmur
Angina with dynamic T-wave changes Normal or unchanged ECG
Angina with S3 or new/worsening rales New-onset CCSC III or IV angina in the
past 2 weeks with moderate or high
likelihood of CAD
Angina with hypotension Pathological Q waves or resting ST
depression #1 mm in multiple lead
groups (anterior, inferior, lateral)
Age .65 y
MR indicates magnetic resonance; CAD, coronary artery disease; and CCSC, Canadian Cardiovascular Society classification.
Note: Estimation of the short-term risks of death and nonfatal myocardial infarction in unstable angina is a complex, multivariable problem that cannot be fully specified in
a table. Therefore, this table is meant to offer general guidance and illustration rather than rigid algorithms. In addition, more recent studies have shown that elevated serum
troponin levels are associated with intermediate or high risk.
From Braunwald et al (129).
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inhibitors, as used today. Coronary angiography may be
deferred for 48 h in these patients who have been thus
stabilized.
Outpatient evaluation of low-risk patients (Table 6)
should begin promptly and should include exercise stress
testing for patients with normal rest ECGs who are not
taking digoxin or exercise or pharmacologic stress testing
with myocardial perfusion scanning or echocardiography for
all others. Evaluation of left ventricular function is also
important. In the low-risk patient with known coronary
disease, the goal is to determine whether revascularization is
indicated. In those not previously known to have CAD, the
goal is to establish a diagnosis and further stratify the
patients according to risk.
Many patients with recurrent chest discomfort not sug-
gestive of angina have had normal coronary angiograms
during the past five years. Even though many of these
patients repeatedly seek cardiovascular care, repeat angiog-
raphy is generally not considered to be indicated unless their
clinical presentations convincingly suggest the presence of
new CAD.
Patients with variant angina may present with chest pain
and acute ECG changes. Cardiac catheterization is often
performed in these patients to establish a diagnosis and to
exclude fixed obstructive disease, which might require re-
vascularization.
Recommendations for Coronary Angiography in
Unstable Coronary Syndromes
Class I
1. High or intermediate risk for adverse outcome in
patients with unstable angina (Table 6) refractory
to initial adequate medical therapy, or recurrent
symptoms after initial stabilization. Emergent cath-
eterization is recommended. (Level of Evidence: B)
2. High risk for adverse outcome in patients with
unstable angina (Table 6). Urgent catheterization is
recommended. (Level of Evidence: B)
3. High- or intermediate-risk unstable angina that sta-
bilizes after initial treatment. (Level of Evidence: A)
4. Initially low short-term-risk unstable angina (Table
6) that is subsequently high risk on noninvasive
testing (Table 5). (Level of Evidence: B)
5. Suspected Prinzmetal variant angina. (Level of Ev-
idence: C)
Class IIa
None.
Class IIb
Low short-term–risk unstable angina, without high-risk
criteria on noninvasive testing. (Level of Evidence: C)
Class III
1. Recurrent chest discomfort suggestive of unstable
angina, but without objective signs of ischemia and
with a normal coronary angiogram during the past
five years. (Level of Evidence: C)
2. Unstable angina in patients who are not candidates
for coronary revascularization or in patients for
whom coronary revascularization will not improve
the quality or duration of life. (Level of Evidence: C)
4. Recurrence of Symptoms After Revascularization
a. Definitions
Evidence of myocardial ischemia in the patient who has
undergone a revascularization procedure (PTCA or CABG)
may represent ischemic myocardium that was not revascular-
ized by intention for either technical or clinical reasons, or was
deferred for later treatment if the patient remained symptom-
atic. Alternatively, it may represent recurrent ischemia due to
restenosis, graft occlusion or progression of atherosclerosis.
Ischemia may present as a recurrence of the preprocedural
symptoms. However, not uncommonly, especially after surgical
revascularization, recurrent ischemia may present with atypical
features. Indeed, there is an increased incidence of silent
ischemia in postoperative patients (154,155).
b. Recurrence of Symptoms After Catheter-Based
Revascularization
(1) Abrupt Closure After Catheter-Based
Revascularization
Acute coronary closure complicates 2% to 11% of percu-
taneous coronary interventions and, if treated by balloon
angioplasty alone, is associated with a high incidence of
death (up to 5%), MI (up to 27%), and the need for
emergency bypass surgery (up to 10%) (156–159). In most
cases, acute closure can be managed by stenting and is
successfully reversed in most of such patients, reducing the
complication rate to ,2%. However, those patients whose
arteries are not successfully reopened are at high risk for
death, MI, or emergency CABG. Furthermore, follow-up
of patients with major clinical ischemic events after abrupt
closure suggests that they continue to be at increased risk
compared with those who are successfully redilated (159). In
contrast, when closure is successfully treated, outcome is
favorable. In a study from the Cleveland Clinic (160), 88 of
4,863 consecutive patients undergoing angioplasty who had
successful treatment of in-laboratory closure were compared
with the 4,775 patients who had a successful uncomplicated
procedure. No difference in one-year outcomes between the
groups was found. On the basis of these observations,
coronary angiography is generally performed emergently on
any patient with suspected abrupt closure with the intent for
repeat intervention, if possible.
Acute closure after balloon angioplasty primarily occurs
within the first 24 h. With intracoronary stent implantation,
closure occurs over a more prolonged (3 to 11 days) time
course and has been termed “subacute thrombosis.” The
incidence of subacute thrombosis is substantially higher
(10.1%) for bailout stenting compared with stents placed
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electively. With current stent-placement methods and an-
tiplatelet therapies, the incidence of subacute closure is ,1%
(161,162). When it occurs, subacute stent thrombosis pre-
sents as an acute coronary syndrome similar to acute closure
and acute MI. Emergent catheterization is indicated.
(2) Periprocedural Enzyme Elevation
Elevations in enzyme markers of myocardial necrosis
occur in 12% to 22% of patients after percutaneous inter-
ventional procedures. In patients with unstable angina and
non–Q-wave MI, elevations in these markers portend an
unfavorable prognosis. Asymptomatic enzyme elevations
after coronary interventions previously had been regarded by
many as clinically inconsequential. However, evaluation of
the CAVEAT population (n 5 1,012) showed a worse
clinical outcome for patients with an elevated CK level after
the procedure (163). Likewise, in a study of new device
angioplasty, elevated enzymes were shown to predict in-
hospital complications (164). In contrast, in a study of 565
patients after directional atherectomy, a correlation between
CK-MB isoform elevations and adverse long-term sequelae
was not confirmed (165). Preliminary evidence suggests that
platelet IIb/IIIa glycoprotein receptor blockade may reduce
the risk of enzyme elevation in patients treated with
angioplasty, directional atherectomy, or stents and in pa-
tients undergoing saphenous vein graft percutaneous inter-
vention (164,166,167).
Although a poorer long-term outcome appears to be
associated with micronecrosis, clear indications for coronary
angiography in this situation are currently lacking. Accord-
ingly, the committee believes that treatment of these pa-
tients should be based on the other clinical guidelines
discussed in this document.
(3) Restenosis
Recurrence of stenosis after percutaneous transluminal
coronary intervention is still the major limitation to long-
term clinical success of the procedure. A distinction should
be made between clinical and angiographic restenosis.
Clinical, i.e., symptomatic, restenosis should be suspected in
patients who present with recurrent angina within nine
months of a catheter-based revascularization procedure.
The incidence of clinical restenosis parallels the number of
target lesions revascularized, as documented in many con-
trolled clinical trials with angiographic follow-up. The
clinical presentation of restenosis tends to mirror the index
presentation; 75% of patients who initially presented with
unstable angina will re-present with unstable angina. Other
patients will demonstrate a steady progression of anginal
symptoms over several weeks. Angiographic restenosis (of-
ten defined as the return of stenosis $50%) is not always
apparent clinically, and its incidence is higher than the rate
of clinical restenosis. Although coronary angiography in
asymptomatic postangioplasty patients who have a positive
stress test may reveal angiographic restenosis, these patients
generally have a good outcome, and asymptomatic angio-
graphic restenosis may regress (168). The development of
clinical symptoms .9 months after PTCA is more likely
due to progression of native coronary disease than restenosis
(169,170).
Coronary angiography is generally performed in symp-
tomatic patients with suspected restenosis to reassess anat-
omy and to repeat revascularization as needed. Conse-
quently, when suspicion of restenosis is high, coronary
angiography is generally performed in a center where repeat
revascularization can be performed immediately after the
angiogram.
In agreement with the noninvasive testing guidelines, the
committee discourages routine noninvasive evaluation of
asymptomatic patients after angioplasty. It does recommend
selective testing of patients considered to be at particularly
high risk, such as those with decreased left ventricular
function, multivessel CAD, proximal LAD disease, previ-
ous cardiac arrest, diabetes mellitus, hazardous occupations
and suboptimal PTCA results. When noninvasive testing
has been done in asymptomatic patients after angioplasty
and reveals markers of high risk for adverse outcome,
coronary angiography is indicated. Asymptomatic patients
with an abnormal but not high-risk noninvasive test result
often can be successfully treated medically, with coronary
angiography performed only when symptoms develop or
high-risk markers present on noninvasive testing.
c. Recurrence of Symptoms After Coronary Artery Bypass
Surgery
Patients with prior bypass surgery who develop postop-
erative angina represent an important subset of patients who
require thoughtful evaluation and therapy. Arterial conduits
often provide long-term patency over at least 15 years.
Saphenous vein grafts are more vulnerable to graft athero-
sclerosis and subsequent closure. Approximately 10% of
patients will have vein graft closure within the first two
months after surgery and another 10% within the first year
(171). Vein graft patency is relatively stable from years 3 to
5, but after 10 years, 40% of vein grafts are occluded (172).
In a study of 977 patients after bypass surgery, 30% had
angina in the first year, 46% at 3 years and 50% at 8 years of
follow-up (173). Postoperative angina occurs more fre-
quently in women than men (174). Furthermore, many
postoperative patients have asymptomatic myocardial isch-
emia (155). Postoperative angina is an increasing problem.
For example, in the BARI registry (175), the percentage of
patients presenting for revascularization who had prior
surgical revascularization increased from 20% to 33% over
the time period of enrollment. It is generally believed that
patients with recurrent ischemia after coronary artery bypass
surgery have an increased risk of adverse outcomes; treat-
ment must balance the risk of reoperation with the risk of
medical management or percutaneous revascularization. Re-
operative risk is dependent on both age and the patient’s
clinical presentation (176). In a study of 2,030 patients
followed up for a mean of 7.8 years after surgery at a single
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site, there was a 5.7% mortality rate for patients undergoing
elective reoperation, compared with a 10.9% mortality rate
in patients having urgent reoperation, and a 16.4% mortality
rate in those undergoing emergent reoperation (177). Five-
and 10-year survival rates were 76% and 55%, respectively,
for patients aged ,50 years at reoperation and 63% and
40%, respectively, for those .70 years of age.
Catheter-based techniques are attractive as an alternative
to the high risk of reoperation but are not without risk,
especially when performed in an older vein graft. In a study
of 89 saphenous vein graft lesions treated percutaneously in
75 patients with medically refractory angina, clinical success
(angiographic success plus hospital discharge without major
complication) was achieved in 70 (178). In this series, there
was a 3% incidence of early mortality, 3% had nonfatal MI,
and 1% required emergency reoperation. During late
follow-up, 23% had a repeat PTCA, 3% needed reopera-
tion, and 25% died. Long-term survival of this cohort was
compared with a similar surgically treated group. At 30
days, survival was better in the graft angioplasty patients
(97% vs. 92%), but there was no difference at six months,
and by five years there was a trend toward better survival in
the reoperative group.
Other percutaneous techniques such as transluminal ex-
traction atherectomy, excimer laser, and directional coro-
nary atherectomy do not appear to offer superior effective-
ness in dealing with vein graft atherosclerosis compared
with standard balloon angioplasty (179–183). The use of
coronary artery stents for disease in saphenous vein grafts is
becoming almost routine (184,185). One randomized con-
trolled study has evaluated the role of stent placement in
saphenous vein graft disease. In the SAVED trial, patients
were randomized to stenting or balloon annuloplasty. In-
hospital outcomes were similar, but there was a significant
reduction in repeat revascularization six months after the
procedure in the stent group (186).
Coronary angiography is reasonable in patients who are
symptomatic within the first 12 months after bypass surgery,
because relatively low-risk revascularization by percutaneous
techniques can often be offered. Angiography should be
avoided in postbypass patients who, by virtue of age or other
comorbidity, are poor candidates for repeat revascularization
by either reoperation or angioplasty. Postbypass patients
who are suitable candidates for further revascularization and
who have noninvasive evidence of high-risk disease are
appropriate subjects for coronary angiography. Those who
are symptomatic but deemed to be low risk by noninvasive
testing, perhaps due to collateralization, can be treated
medically before angiography is considered.
Recommendations for Coronary Angiography in
Patients With Postrevascularization Ischemia
Class I
1. Suspected abrupt closure or subacute stent throm-
bosis after percutaneous revascularization. (Level of
Evidence: B)
2. Recurrent angina or high-risk criteria on noninva-
sive evaluation (Table 5) within nine months of
percutaneous revascularization. (Level of Evidence: C)
Class IIa
1. Recurrent symptomatic ischemia within 12 months
of CABG. (Level of Evidence: B)
2. Noninvasive evidence of high-risk criteria occur-
ring at any time postoperatively. (Level of Evidence:
B)
3. Recurrent angina inadequately controlled by med-
ical means after revascularization. (Level of Evi-
dence: C)
Class IIb
1. Asymptomatic post-PTCA patient suspected of
having restenosis within the first months after
angioplasty because of an abnormal noninvasive
test but without noninvasive high-risk criteria.
(Level of Evidence: B)
2. Recurrent angina without high-risk criteria on non-
invasive testing occurring >1 year postoperatively.
(Level of Evidence: C)
3. Asymptomatic postbypass patient in whom a dete-
rioration in serial noninvasive testing has been
documented but who is not high risk on noninva-
sive testing. (Level of Evidence: C)
Class III
1. Symptoms in a postbypass patient who is not a
candidate for repeat revascularization. (Level of
Evidence: C)
2. Routine angiography in asymptomatic patients af-
ter PTCA or other surgery, unless as part of an
approved research protocol. (Level of Evidence: C)
5. Acute MI
a. Introduction
During the past 15 years, the treatment of Q-wave MI
has shifted from a passive approach emphasizing supportive
care and management of complications to a more active
therapeutic approach. Coronary angiography is rarely per-
formed during or after MI solely for diagnostic purposes.
The vast majority of procedures are done to evaluate the
patient for a percutaneous or surgical revascularization
procedure. Therefore, the appropriateness of performing
coronary angiography after MI is, by necessity, linked to the
efficacy of these revascularization procedures as measured by
an improved outcome for the patient. As discussed in
section II, several recent studies have shown considerable
variation in the use of coronary angiography after MI within
regions of the U.S., between the U.S. and Canada, between
health maintenance organizations and fee-for-service hos-
pitals, between primary care physicians and cardiologists,
and between invasive and noninvasive cardiologists (43–
45,47,48,60,187). These data do not show a consistent
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relationship between the increased use of coronary angiog-
raphy after MI and improvements in outcome.
Guidelines covering PTCA, CABG surgery and the
treatment of patients with acute MI have been published by
the ACC/AHA Task Force on the Assessment of Diag-
nostic and Therapeutic Procedures within the past five years
and contain recommendations relevant to the use of coro-
nary angiography (188–190).
b. Definitions
According to World Health Organization criteria, the
diagnosis of MI is based on the presence of at least two of
the following: 1) a clinical history of ischemic-type chest
discomfort, 2) changes on ECG tracings obtained serially
and 3) a rise and fall in enzyme markers of myocardial cell
necrosis (191,192). A convenient way to categorize patients
who present with ischemic chest discomfort and suspicion
of MI is by the presence or absence of ST-segment
elevation, and this distinction will be used in these guide-
lines. The majority of patients presenting with ischemic
chest pain and ST elevation will subsequently have some
enzyme marker of myocardial necrosis with or without
development of Q waves. Of those who present with
ischemic chest pain and no ST-segment elevation, some will
evolve serum markers of myocardial necrosis with or with-
out Q waves while others, without an elevation in serum
markers, will later be classified as having unstable angina
(Fig. 3).
These guidelines were developed following the general
pattern used to organize the “ACC/AHA Guidelines for
the Management of Patients With Acute Myocardial In-
farction” (190). Accordingly, the use of coronary angiogra-
phy was evaluated in three distinct time periods after
infarction. It must be emphasized, however, that these time
periods are somewhat arbitrary, because patients who
present with MI may not be immediately identified, do not
uniformly present at a common starting point in the event
and may evolve through the infarction at different rates. It is
also clinically useful to stratify patients with suspected MI
by the presence or absence of ST-segment elevation on the
ECG. Because clinical outcomes, especially after thrombol-
ysis, are similar, we have included in the group with ST
elevation patients with typical ischemic chest pain and a new
(or presumed new) bundle-branch block obscuring the
ECG diagnosis of MI. Patients with ongoing ischemic
chest pain but without ST-segment elevation are a distinct
group with different indications for coronary angiography
compared with those who have ST-segment elevation.
The first time period discussed relates to the use of
coronary angiography during the initial recognition and
management of the patient in the emergency department.
For the patient who presents acutely with ST-segment
elevation or bundle-branch block obscuring the diagnosis of
MI, coronary angiography is coupled with the intent to
perform primary PTCA as an alternative to thrombolytic
therapy. Other indications discussed are related to patients
who present with similar ECG findings and are not treated
by primary PTCA (i.e., who receive thrombolytic or no
reperfusion therapy) or who have a strong suggestion of MI,
but do not have ST-segment elevation.
The second general time period relates to the use of
coronary angiography during the hospital-management phase
of the patient with MI. During this phase, the need for
coronary angiography is generally driven by the development of
some complication of the infarction, such as spontaneous
recurrent ischemia, heart failure related to ventricular septal
defect, or papillary muscle dysfunction or persistent malignant
arrhythmias occurring beyond the first 24 h after infarction.
The final general time period after MI during which
coronary angiography may be necessary occurs when the
patient is being prepared for hospital discharge and under-
goes risk stratification. In practical terms, this is defined not
by a specific time but rather by the evaluations performed to
determine the risk of future morbid events and the need for
additional therapies. The process of risk stratification occurs
throughout the clinician’s entire encounter with the patient
as information is gathered about the extent and conse-
quences of the infarction.
c. Coronary Angiography During the Initial Management of
Patients in the Emergency Department
(1) Patients Presenting With Suspected MI and
ST-Segment Elevation or Bundle-Branch Block
Of all patients who ultimately are diagnosed with acute
MI, those presenting with ST-segment elevation have been
Figure 3. Nomenclature of acute coronary syndromes. Patients
with ischemic discomfort may present with or without ST-
segment elevation on the ECG. The majority (large arrow) of
patients with ST-segment elevation ultimately develop a Q-wave
acute MI, whereas a minority (small arrow) develop a non–Q-
wave acute MI. Of the patients who present without ST-segment
elevation, the majority (large arrows) are ultimately diagnosed as
having either unstable angina or non–Q-wave acute MI on the
basis of the presence or absence of a cardiac marker such as
CK-MB detected in the serum; a minority of such patients
ultimately develop a Q-wave acute MI. The spectrum of clinical
conditions ranging from unstable angina to non–Q-wave acute MI
and Q-wave acute MI is referred to as the acute coronary
syndromes. Reprinted with permission from Antman EM, Braun-
wald E. Acute myocardial infarction. In: Heart Disease. A Text-
book of Cardiovascular Medicine. 5th ed. Philadelphia, PA: WB
Saunders, 1996. *Positive serum cardiac marker.
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studied most extensively. Patients with ST-segment eleva-
tion have a high likelihood of thrombus occluding the
infarct-related artery (193,194). Considerable data exist
showing that coronary reperfusion can be accomplished
either by intravenous thrombolytic therapy or direct me-
chanical intervention within the infarct-related artery. Be-
cause the benefit obtained is directly linked to the time
required to reestablish normal (TIMI grade 3) distal blood
flow (195–197), rapid triage decisions are mandatory, and
delays in instituting reperfusion therapy must be minimized.
The “ACC/AHA Guidelines for the Management of Pa-
tients with Acute Myocardial Infarction” provide a compre-
hensive discussion of the indications, contraindications,
advantages, and disadvantages of thrombolytic therapy and
direct coronary angioplasty (190). Although it is not the
purpose of these guidelines to re-examine in detail the
merits of these two reperfusion strategies, this is a rapidly
evolving area, and some new information exists.
(a) Coronary Angiography Immediately After Thrombolytic
Therapy
Once the clinician has made the decision to administer a
systemic thrombolytic drug, there are two circumstances in
which coronary angiography coupled with the intention to
perform PTCA have been evaluated. The first involves the
routine use of coronary angiography and PTCA immedi-
ately after thrombolytic therapy. Throughout many early
trials of intravenous thrombolytic therapy, it was docu-
mented that the infarct-related artery failed to open by 90
minutes in 20% to 40% of patients (198–200). Even with
current regimens, thrombolytic failures occur in 10% to 25%
of patients (197,201). Reocclusion despite successful initial
reperfusion occurs in an additional 12% (202), and in the
majority of patients, a significant stenosis remains after
thrombolysis (198–200). Because of these issues, a few
small studies and three randomized, prospective trials eval-
uated strategies in which coronary angiography followed by
PTCA of a residual stenosis was routinely performed in all
patients immediately after thrombolytic therapy (198–
200,203–207). It was the hypothesis of these trials that
identifying and dilating the residual stenosis might improve
outcome. The TIMI IIA study (200), the Thrombolysis in
Acute Myocardial Infarction (TAMI) study (198), and the
European Cooperative Study Group trial (199) were con-
cordant in their conclusions that immediate coronary an-
giography and PTCA neither preserves myocardium nor
reduces the incidence of reinfarction or death compared
with a more conservative approach in which angiographic
evaluation and intervention is reserved for patients who have
spontaneous or inducible ischemia after infarction. Further-
more, those treated with immediate PTCA within hours of
thrombolytic therapy had a higher 24-h complication rate
and mortality at one year (199,205,207).
Although the routine use of coronary angiography and
PTCA immediately after thrombolytic therapy in all pa-
tients cannot be advised, a separate circumstance exists
when there is serious concern that thrombolysis has failed.
In this clinical situation, recanalization of the infarct-related
artery by so-called “rescue” or “adjuvant” (190) PTCA has
been suggested to establish patency of the affected artery,
salvage any remaining viable myocardium, and improve
survival. Unfortunately, there is no reliable way to identify
patients in whom thrombolytic therapy has failed. Clinical
markers of reperfusion, such as relief of chest pain, resolu-
tion of ST-segment elevation, and occurrence of reperfusion
arrhythmias do not accurately predict the success or failure
of thrombolysis (208), and immediate coronary angiography
in all patients after thrombolytic therapy is impractical and
expensive and would likely cause increased bleeding. Nev-
ertheless, there are some patients whose clinical course leads
to a strong suspicion that thrombolysis has failed. These
patients often have continuing severe chest pain and a
worsening of their clinical or hemodynamic status. In this
circumstance, the option of immediate coronary arteriogra-
phy followed by PTCA has been studied in several nonran-
domized (209–211) and randomized (212–214) trials. In
the largest randomized trial to date, only patients with their
first anterior infarction demonstrated to have an occluded
artery within 8 h of presentation were allocated to PTCA or
conservative therapy (aspirin, heparin and coronary vasodi-
lators) after coronary angiography (212). Although there
was no difference in resting ejection fraction 30 days after
MI, exercise ejection fraction was higher (0.43 6 0.15% vs.
0.38 6 0.13%) and a composite end point of death or severe
heart failure was lower in those treated by rescue angioplasty
(6% vs. 17%). The outcome after rescue PTCA was also
evaluated in the Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Coronary Ar-
teries (GUSTO-1) angiographic substudy (211). Clinical
and angiographic outcomes in 198 patients treated with
rescue PTCA were compared with those of 266 patients
managed conservatively after failed thrombolysis and 1,058
patients with successful thrombolysis, the latter two groups
documented by angiography. Although the assignment of
thrombolytic therapy was randomized, patients were se-
lected for the rescue PTCA attempt by the investigators and
tended to be those patients with clinical predictors of a poor
outcome. Rescue PTCA successfully opened 88.4% of the
closed arteries, with 68% attaining TIMI grade 3 flow.
Although the majority of arteries were opened by rescue
PTCA, left ventricular function and 30-day mortality were
not different from the group who had a closed infarct-
related artery and were managed conservatively. The mor-
tality rate associated with a failed rescue PTCA attempt was
30.4%, but 5 of the 7 patients who died were in cardiogenic
shock before the procedure. These data are similar to the
experience from the TIMI study in which rescue PTCA was
successful in 82% but there was no difference in mortality
rate at 21 days (12% for rescue PTCA vs. 7% for medical
therapy), and the mortality for a failed rescue PTCA
attempt was 33% (210). On the basis of the available data,
the committee cannot recommend the widespread use of
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coronary angiography followed by rescue PTCA in all
patients with suspected failure of thrombolytic therapy but
believes it may benefit some selected patients.
(b) Coronary Angiography With Primary Angioplasty for
Acute MI
It is the intent of this document to provide guidelines
related only to the use of coronary angiography, but coro-
nary angiography is an obligatory part of the primary PTCA
procedure, and the strategy of primary PTCA really involves
coronary angiography followed by triage to the most appro-
priate means of reperfusion. This is an area of considerable
interest not only for evaluation of the efficacy of primary
PTCA, but also of the usefulness of immediate coronary
angiography as a triage tool (215). Therefore, the committee
believes it is necessary to reinforce the recommendations of
the ACC/AHA Acute Myocardial Infarction Committee
(190), emphasizing relevant information upon which the
recommendations were made and some new data that are
now available.
Those who advocate primary PTCA highlight several
possible advantages of initial triage angiography to direct a
revascularization strategy. First, although PTCA is used for
revascularization after initial coronary angiography in '90%
of those studied, a small subset ('5%) is identified with
severe three-vessel or left main coronary disease, or ana-
tomic features unfavorable for PTCA in whom surgical
revascularization may be more appropriate (216). Second,
immediate angiography identifies an additional 5% of pa-
tients in whom the infarct-related artery has spontaneously
opened with a ,70% residual narrowing and normal flow
beyond the culprit stenosis. In these patients, conservative
management may be used, and it is argued that the risks of
thrombolytic therapy can be avoided. Third, on occasion,
patients are identified for whom thrombolytic therapy
would be inappropriate or unnecessary, such as patients in
whom the cause of the MI is an aortic dissection or those
with suspected MI and bundle-branch block in whom
immediate angiography shows the absence of a coronary
occlusion. Finally, immediate angiography during the initial
evaluation of MI may be valuable for the identification not
only of high-risk patients, but also of low-risk patients.
Results from the Primary Angioplasty in Myocardial
Infarction-2 (PAMI-2) trial show that a combination of
clinical and catheterization variables can stratify patients
with MI treated successfully by primary PTCA into high-
and low-risk subgroups (217,218). In PAMI-2, low-risk
patients were not hospitalized in an intensive care unit,
received no further noninvasive testing and were discharged
on day 3 after MI. In addition to a shorter length of stay and
lower hospital costs compared with traditional care, there
was no difference in mortality or nonfatal complications at
six months. Mortality in the other half of patients, judged to
be at high risk, was '10 times greater (3.8%) than in
low-risk patients (0.4%), and these high-risk patients had a
greater incidence of in-hospital reinfarction and recurrent
ischemic events.
Although the initial results of primary PTCA for the
treatment of acute MI were encouraging (216,219–222),
the treatment advantage for primary PTCA compared with
thrombolytic therapy has been smaller in recent trials. In the
GUSTO IIb trial, 1,138 patients were randomly assigned to
treatment by either primary PTCA or accelerated tissue
plasminogen activator (tPA) (223). At 30 days, the primary
end point (a composite of death, reinfarction, or disabling
stroke) was 13.7% in the tPA group compared with 9.6% in
the PTCA group (p 5 0.03). Mortality was 7% in the
thrombolysis group versus 5.7% in the primary PTCA
group (p 5 0.037). The treatment advantage of primary
PTCA was less than that observed in previous studies, and
by six months, there was no difference in the primary end
point between the groups. Moreover, data from the Myo-
cardial Infarction Triage and Intervention (MITI) Project
Registry showed no difference in mortality during hospital-
ization (5.6% vs. 5.5%) or over three years of follow-up
among the 1,050 patients treated by primary PTCA com-
pared with the 2,095 receiving thrombolytic therapy (224).
It is difficult to predict how these two therapies will compare
in the future because newer, more effective thrombolytic
drugs are being developed, there is an expanding role for
glycoprotein IIb/IIIa inhibitors in the treatment of acute
MI, and there are increasing data to suggest that stenting
may provide a better outcome than primary PTCA both
acutely and after six months. A growing number of obser-
vational and randomized trials have evaluated the role of
coronary stent placement compared with balloon angio-
plasty in patients with acute MI (225–231). All but one have
shown, with a variety of stent designs, that acute angio-
graphic results are improved and the incidence of in-
hospital and 30-day ischemic events is significantly reduced.
The rate of target-vessel restenosis is also lower than that
seen with balloon angioplasty alone. A large multinational
trial is currently under way to evaluate the role of glyco-
protein IIb/IIIa antagonists and stenting in acute MI.
However, from the available data comparing thrombolysis
and angioplasty in patients who are candidates for throm-
bolytic drugs, some conclusions can be made. None of these
reports show that patients treated with primary angioplasty
fare worse than those treated with thrombolytic drugs; thus,
a conservative interpretation of the current data would be
that the two therapies are equivalent. It is important to
emphasize that one factor contributing to the excellent
outcome of primary angioplasty is the skill and experience of
the operator. This committee shares the concerns expressed
in the “ACC/AHA Guidelines for the Management of
Patients With Acute Myocardial Infarction” (190) regard-
ing the widespread use of primary PTCA for the treatment
of acute MI. The investigators performing primary PTCA
studies were highly experienced interventional cardiologists,
which resulted in their ability to perform PTCA successfully
within a short time frame (60 to 90 min) after presentation.
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Recent preliminary data suggest that this level of proficiency
may not be duplicated in all settings for all acute MI
patients (232–234). Moreover, there has been a general
assumption that the results of primary PTCA can be
extrapolated to all patients with acute MI, but these studies
only included patients who were in fact eligible for throm-
bolytic therapy and who generally were at fairly low risk.
Despite the fact that primary PTCA is used frequently in
patients excluded from thrombolytic therapy, only a few
small retrospective studies have examined this important
issue (222,235,236). When used in this setting, primary
PTCA has a success rate approximating that seen in patients
who are thrombolytic candidates. Furthermore, mortality at
six months, one year and three years is satisfactory, and the
occurrence of other adverse cardiac events during follow-up
is not excessive. A randomized trial examining this issue
may never be conducted. Knowing the potential benefits of
reperfusion, it would be difficult to justify randomizing
patients with contraindications to thrombolytics to only
supportive therapy when the option of angioplasty exists.
Until there are data to the contrary, the use of primary
PTCA in patients with contraindications to thrombolytic
therapy seems warranted.
The use of primary PTCA in patients with acute MI who
present with or rapidly develop cardiogenic shock has been
studied in several observational and nonrandomized series.
Immediate coronary angiography followed by PTCA in this
setting results in a better survival rate than with traditional
care, averaging 55% among studies (237–243). However,
the benefit of primary PTCA is strongly related to estab-
lishing an open artery. In the study by Lee et al. (238),
survival was 77% if the artery was opened successfully
compared with 18% if the procedure failed to open the
artery. In another study, 30-month actuarial survival was
54% after a successful PTCA but only 29% after an
unsuccessful procedure (239). Other factors, such as the
increased use of intra-aortic balloon pumps or other left
ventricular assist devices, may contribute to the benefit of
primary PTCA in this situation (238,242). Immediate
coronary angiography followed by emergency coronary by-
pass surgery has also been used in patients with cardiogenic
shock after acute MI. In recent series, operative mortality
rates vary from 12% (241) to 42% (244) in such patients,
and data from the nonrandomized SHOCK Registry sug-
gests that emergency bypass surgery has a lower mortality
rate (19%) than emergency PTCA (60%) (245). A more
complete set of guidelines and indications for bypass surgery
has recently been published by another ACC/AHA Task
Force Committee (189). At the 48th Scientific Sessions of
the ACC (1999), Hochman presented the preliminary
report of the SHOCK Trial, wherein 152 patients with
cardiogenic shock secondary to acute MI were randomized
to an emergency revascularization (ERV) strategy, and 150
others to an initial medical stabilization (IMS) strategy,
with delayed revascularization as needed clinically. At 30
days, mortality for the two groups was not significantly
different, but at six months, mortality was significantly lower
in the ERV group (53.7% vs. 65.7%; p 5 0.04). The
prespecified subgroup analysis of patients less than 75 years
showed a significant 16% reduction in mortality (41% ERV
group vs. 57% IMS group, p , 0.01). Of the entire ERV
group, approximately 60% had PTCA and 40% had CABG;
the respective 30 day mortality rates were 45% and 42%. It
is important to note that patients with cardiogenic shock
were excluded from many of the major thrombolytic trials.
Recent retrospective analyses by the Fibrinolytic Therapy
Trialists’ Collaborative Group suggest, however, that
thrombolytic therapy may provide a greater benefit than
initially appreciated in this subgroup of patients (246).
Nevertheless, at the present time, most clinicians have
adopted an aggressive invasive approach to the management
of patients with cardiogenic shock.
In summary, this committee accepts the use of primary
PTCA and stenting as an alternative to thrombolysis but is
seriously concerned about the widespread use of mechanical
interventions in acute MI by operators without adequate
training or experience. Furthermore, although precedent
exists in the literature (247,248), the extension of primary
PTCA to hospitals without immediate surgical backup is
premature. Indiscriminately applied, this could result in
unacceptable delays in achieving reperfusion in some patients
and less than optimal outcomes if performed by operators with
inadequate experience. Strict performance criteria are necessary
for programs offering primary PTCA so that delays in revas-
cularization do not occur and acceptable outcomes are estab-
lished and documented. Otherwise, the focus of treatment
should be the early use of thrombolytic therapy.
Recommendations for Coronary Angiography During
the Initial Management of Acute MI (MI Suspected
and ST-Segment Elevation or Bundle-Branch Block
Present)
Coronary Angiography Coupled With the Intent to
Perform Primary PTCA
Class I
1. As an alternative to thrombolytic therapy in pa-
tients who can undergo angioplasty of the infarct
related artery within 12 hours of the onset of
symptoms or beyond 12 hours if ischemic symptoms
persist, if performed in a timely fashion* by individ-
uals skilled in the procedure† and supported by expe-
rienced personnel in an appropriate laboratory envi-
ronment.‡ (Level of Evidence: A)
2. In patients who are within 36 hours of an acute ST
elevation/Q-wave or new LBBB MI who develop
cardiogenic shock, are less than 75 years of age and
*Performance standard: within 90 min. †Individuals who perform .75 PTCA
procedures per year. ‡Centers that perform .200 PTCA procedures per year and
have cardiac surgical capability.
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revascularization can be performed within 18 hours
of the onset of shock.
Class IIa
1. As a reperfusion strategy in patients who are can-
didates for reperfusion but who have a contraindi-
cation to fibrinolytic therapy, if angioplasty can be
performed as outlined above in class I. (Level of
Evidence: C)
Class III
1. In patients who are beyond 12 h from onset of
symptoms and who have no evidence of myocardial
ischemia. (Level of Evidence: A)
2. In patients who are eligible for thrombolytic ther-
apy and are undergoing primary angioplasty by an
unskilled operator in a laboratory that does not
have surgical capability. (Level of Evidence: B)
Recommendations for Early Coronary Angiography in
the Patient With Suspected MI (ST-Segment
Elevation or Bundle-Branch Block Present) Who Has
Not Undergone Primary PTCA
Class I
None.
Class IIa
Cardiogenic shock or persistent hemodynamic insta-
bility. (Level of Evidence: B)
Class IIb
1. Evolving large or anterior infarction after throm-
bolytic treatment when it is believed that reperfu-
sion has not occurred and rescue PTCA is planned.
(Level of Evidence: B)
2. Marginal hemodynamic status but not actual car-
diogenic shock when standard management (eg,
optimizing filling pressures) does not result in
improvement. (Level of Evidence: C)
Class III
1. In patients who have received thrombolytic therapy
and have no symptoms of ischemia. (Level of Evi-
dence: A)
2. Routine use of angiography and subsequent PTCA
within 24 hours of the administration of thrombo-
lytic agents. (Level of Evidence: A)
(2) Patients Presenting With Suspected MI but Without
ST-Segment Elevation
Approximately 50% of patients with MI do not present
with ST-segment elevation, but rather have nondiagnostic
ECG changes (249,250). It is believed that most non–Q-
wave MIs are caused by disruption of an atherosclerotic
plaque with transient occlusion of the coronary artery
(133,251–253). This may occur with or without transient
ST-segment elevation (254). Although total coronary oc-
clusion is frequently found in patients with Q-wave MI, it
is much less common in those with non–Q-wave MI
(193,194,251,255). Angiography within 24 h of symptom
onset in non–Q-wave MI documents coronary occlusion in
only 26% to 39% of patients. Paradoxically, when performed
between three and seven days after the event, the incidence
of occlusion increases to 42%. Many early studies suggested
that patients with non–Q-wave MI had a relatively low
in-hospital mortality (256), but it is now known that
recurrent ischemia or MI and death occur at a worrisome
frequency in this population (256–260).
Although most thrombolytic trials focus on patients with
ST elevation (261–263), some data exist within these trials
relevant to patients without ST-segment elevation. In the
first GISSI trial, there was no benefit of thrombolytic
therapy with streptokinase in patients without ST-segment
elevation, and, in fact, mortality rates were slightly higher
(261). Similar observations were made in the ISIS-II trial
(Second International Study of Infarct Survival) (262) and
in two randomized trials of tPA in patients with unstable
angina or MI without diagnostic ST changes (151,264). In
these latter studies, tPA had no benefit compared with
aspirin and heparin alone. In the TIMI IIIB trial, which
included patients with both non–Q-wave MI and unstable
angina, the results of treatment with PTCA were not
improved by routine pretreatment with intravenous tPA
(152). Because thrombolytic therapy appears to have no
benefit in non–Q-wave MI, some clinicians have advocated
a very aggressive approach to management, including im-
mediate coronary angiography in all patients without ST-
segment elevation, but with a high probability of MI.
Typically, these are patients with risk factors for CAD who
have prolonged and/or recurrent (stuttering) ischemic pain,
some ECG abnormalities and the echocardiographic dem-
onstration of a wall motion abnormality. Treatment deci-
sions are then based on the results of coronary angiography,
with some patients referred for percutaneous or surgical
revascularization and those with normal angiography dis-
charged as soon as possible for outpatient evaluation to
determine the cause of their symptoms. Although PTCA
for non–Q-wave MI can be performed safely with a high
success rate and can improve function in the infarct zone
(151,265,266), the efficacy and cost-effectiveness of this very
aggressive approach has not been tested. Moreover, some
data suggest that a period of heparin anticoagulation before
intervention in patients with unstable coronary syndromes
results in a lower rate of procedure-related complications
(267,268). Rather than immediate coronary angiography in
non–Q-wave MI, more moderate management strategies
have been evaluated in studies like TIMI IIIb (151) and the
Veterans Affairs Non–Q-Wave Infarction Strategies in
Hospital (VANQWISH) trial (269). These are discussed
later in these guidelines; thus, the recommendations below
refer only to coronary angiography in the early management
of patients with suspected MI.
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Recommendations for Early Coronary Angiography in
Acute MI (MI Suspected but No ST-Segment
Elevation)
Class I
1. Persistent or recurrent (stuttering) episodes of
symptomatic ischemia, spontaneous or induced,
with or without associated ECG changes. (Level of
Evidence: A)
2. The presence of shock, severe pulmonary conges-
tion, or continuing hypotension. (Level of Evidence: B)
Class II
None.
Class III
None.
d. Hospital-Management Phase of Acute MI
The hospital-management phase of acute MI can encom-
pass several clinical situations. Some patients with acute MI
present too late in their course to be candidates for reper-
fusion therapy, and in others, the occurrence of infarction
may not be appreciated at the time of presentation. These
groups skip the acute-treatment phase of MI and enter the
hospital-management phase directly. During the hospital-
management phase, the actions of the clinician are driven by
the consequences of the infarction, such as congestive heart
failure, hemodynamic instability, recurrent ischemia or ar-
rhythmias. Although it is still convenient to divide patients into
those with Q-wave and non–Q-wave infarctions, some indi-
cations for coronary angiography are common to all patients
with MI regardless of how they have been treated initially and
whether or not Q waves ultimately develop.
(1) Concepts Common to All Patients With MI
The development of spontaneous myocardial ischemia or
ischemia with minimal activity during the hospital-
management phase is a significant event. Both short and
long-term mortality are higher among patients with recur-
rent ischemia (270–276). For any given degree of left
ventricular dysfunction and any burden of CAD, survival is
related to the frequency, severity and magnitude of myocar-
dial ischemia (277). Survival is diminished in patients with
frequent recurrent episodes of myocardial ischemia at rest or
at very low workloads compared with those who have the
same degree of left ventricular dysfunction and coronary
disease but who exhibit no ischemia at high workloads.
Because revascularization procedures relieve myocardial isch-
emia, coronary angiography is indicated in patients who are
potential candidates for revascularization under the assump-
tion that mortality will be decreased. Data supporting the
use of coronary angiography and then revascularization in
patients who develop spontaneous or inducible ischemia
comes from the DANish trial in Acute Myocardial Infarc-
tion (DANAMI) (278). In the DANAMI trial, 1,008
patients with acute MI treated with thrombolytic therapy
who had subsequent ischemia were randomized to coronary
angiography and revascularization versus medical manage-
ment. At a median follow-up of 2.4 years, mortality was 3.6%
in the invasive arm versus 4.4% in the conservative arm (p 5
NS). However, patients in the invasive arm had a lower
incidence of subsequent MI (5.6% vs. 10.5%; p 5 0.004) and
a lower incidence of admissions for unstable angina (17.9% vs.
29.5%; p , 0.00001) compared with the conservative arm.
There are several mechanical complications of acute MI
that require prompt and aggressive evaluation, including
coronary arteriography. These complications potentially can
occur with any infarction but are much more likely to occur
in patients with Q-wave MI. Mitral regurgitation due to
papillary muscle rupture or dysfunction develops in '5% of
patients within the first week after infarction (279). In those
with complete rupture, medical treatment alone has a 75%
mortality rate within the first 24 h (280). The size of the
infarction in patients who die after developing mitral
regurgitation is often small, which suggests that early
surgical intervention can be beneficial, although surgical
mortality is high (27% to 55%) (279,281,282). Acute
ventricular septal defect is less common, occurring in 0.5%
of patients within two to three days from the onset of the
infarction (283). However, there is some indication that it
may occur more frequently and earlier after thrombolytic
therapy (284). There is debate over the proper management
of this severe complication of infarction. Some recommend
emergency coronary angiography followed by surgical repair
for all but the moribund (285,286). Others recommend this
aggressive approach only for those patients with pulmonary
edema or cardiogenic shock ('90% of patients with this
defect) and a delayed approach for the minority whose
hemodynamic status is stable or easily controlled with drugs
(287). Despite cardiogenic shock, 45% of patients will
survive closure of a ventricular septal defect acutely, and 70%
will survive if surgery can be delayed until later in their
course (287). Rupture of the left ventricular free wall is often
fatal, but a subacute form exists that is associated with
leakage of a small amount of blood into the pericardial space
without overwhelming tamponade, sometimes subsequently
forming a left ventricular pseudoaneurysm (288–290). Cor-
onary angiography is indicated before surgical repair of this
condition as well as for the rare patient who requires early
resection of a left ventricular aneurysm because of refractory
congestive heart failure, uncontrollable arrhythmias or sys-
temic embolization despite anticoagulation.
Patients who develop significant congestive heart failure
or who have evidence of left ventricular dysfunction during
the hospital-management phase are an important subgroup.
Numerous studies have demonstrated that prognosis after
acute MI is largely dependent on residual left ventricular
function, as determined by global ejection fraction (291).
The probability of surviving one to four years after MI has
a curvilinear relationship to ejection fraction soon after the
event. In the prethrombolytic era, one-year mortality was
,5% for those with an ejection fraction .0.40 but declined
sharply at ejection fraction levels ,0.40 and approached
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50% in patients with an ejection fraction #0.20 (292). In
more recent trials, one-year mortality is lower than that
stated above but still increases inversely with decreasing
ejection fraction (293,294). Evidence from randomized
trials comparing bypass surgery with medical therapy shows
improved survival with surgery in patients with depressed
left ventricular function who have three-vessel disease or
two-vessel disease with involvement of the LAD coronary
artery (295–297). Although these studies were performed in
patients with chronic stable angina, the results are fre-
quently extrapolated to patients with recent MI. Random-
ized trials specifically addressing revascularization versus
medical therapy early after infarction in the patient with
depressed left ventricular function and multivessel disease
have not been done. However, the importance of left
ventricular function and coronary anatomy is underscored in
a database study of 1,214 medically treated patients with
CAD (298). The incidence of new cardiac events, both fatal
and nonfatal, increased with the number of stenotic vessels
and decreasing left ventricular function. In patients with
multivessel disease, the likelihood that the next event would
be fatal was markedly increased in the subset of patients
with depressed left ventricular function. For example, only
23% of patients with normal left ventricular function suf-
fered a new event during the five-year follow-up period,
whereas 64% of patients with impaired left ventricular
function had a new event. In those with good left ventricular
function, 44% of the new events were fatal compared with
86% in patients with impaired left ventricular function.
Therefore, although not specifically evaluated or proven in a
large randomized study, it seems reasonable to evaluate
patients with depressed left ventricular function after a
recent MI by coronary angiography.
At the extreme of patients with left ventricular dysfunc-
tion are those who develop cardiogenic shock after MI.
Data from the Worcester Heart Study (299) accumulated
over a 13-year period show that '7.5% of patients with
acute MI present with or develop cardiogenic shock after
MI and, without any interventions, have a mortality rate
between 74% and 82%. Even among those who survive their
initial hospitalization, mortality remains high. The use of
coronary angiography as a precursor to revascularization in
patients with shock was discussed previously in the section
on the early treatment of acute MI.
(2) Patients With Q-Wave Infarction Treated With
Thrombolytics
Several large prospective and randomized studies have
examined the routine use of coronary angiography followed
by PTCA at various times after thrombolytic therapy. The
use of both coronary angiography and PTCA immediately
(within 2 h) after thrombolytic therapy was examined in the
TIMI IIA trial, the TAMI trial, and the European Coop-
erative Study Group (198–200) and was discussed previ-
ously. Routine immediate coronary angiography followed by
PTCA was not found to be beneficial in any of these
studies. Subsequent investigations examined routine use of
coronary angiography and PTCA in all patients at later time
intervals. PTCA later after MI was thought to possibly be
safer because there would be more time for a stable
hemostatic environment to develop at the site of the lesion
and less chance of bleeding complications at catheter-
insertion sites. This strategy was examined in two large
prospective trials. In the TIMI IIB trial (300), patients who
received tPA were randomized to receive coronary angiog-
raphy and PTCA within 18 to 48 h of thrombolysis or
conservative management. After six weeks, there was no
difference in mortality, nonfatal recurrent MI, or left ven-
tricular ejection fraction between the groups. Follow-up
reports from this study show no difference in survival,
anginal class or the frequency of bypass surgery between the
two groups after one and three years (127,301). In the
Should We Intervene Following Thrombolysis (SWIFT)
Study (302), 800 patients treated with anistreplase were
randomly assigned to coronary angiography and PTCA
within two to seven days or conservative management with
invasive treatment only for spontaneous or provokable
ischemia. There was no difference in left ventricular func-
tion, incidence of recurrent MI, in-hospital survival or
one-year survival between the two treatment groups. Thus,
the automatic use of coronary angiography and PTCA in all
patients with MI within days after thrombolytic therapy is
not justified. Other smaller trials have examined the routine
use of coronary angiography and PTCA at even longer
intervals after thrombolysis. Maturation of the clot and
remodeling of the infarct-related stenosis continues after the
event and thus could possibly lower the risks and increase
the benefits of a later intervention. Coronary angiography
with PTCA of suitable lesions, including occluded arteries,
was performed .72 h after tPA and compared with
conservative management and revascularization only for
recurrent ischemia in a randomized study of 201 patients
(303). After 10 months, there was no difference in left
ventricular function, recurrent infarction or death between
the groups. In another study, 87 asymptomatic patients were
randomized to coronary angiography and PTCA versus
conservative management 4 to 14 days after thrombolytic
therapy (304). Patients with postinfarction angina or exercise-
induced ischemia were excluded. There was no difference in
mortality between the two groups, but those treated with
PTCA did have less angina after one year of follow-up.
However, neither of these trials was of sufficient power to
detect small differences among the groups.
(3) Patients Treated With Primary Angioplasty
Similar to patients receiving thrombolytic drugs, patients
treated by primary angioplasty can experience recurrent
ischemia and reinfarction, although the incidence is lower
(9% to 15%) compared with patients receiving thrombolytic
therapy (28% to 38%) (216,220,305). This may be due to
reocclusion of the infarct-related artery or ischemia from
another artery. Repeat coronary angiography may be neces-
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sary in these circumstances as a precursor to a second
revascularization procedure.
(4) The “Open Artery Hypothesis”
The benefits of early reperfusion therapy, whether by
thrombolytic drugs or PTCA, have been attributed to
salvage of severely ischemic myocardium, thereby limiting
infarct size and preserving left ventricular function. How-
ever, there is increasing evidence that achieving patency in
the infarct-related artery even later may have a favorable
influence on outcome by mechanisms other than myocardial
salvage (306–308). Late restoration of patency appears to
reduce infarct expansion (309), reduce the severity of ven-
tricular remodeling (310,311) and attenuate the risk for the
development of ventricular arrhythmias (312,313). These
effects could all contribute to improvements in survival
without the acute salvage of myocardium (314–316). The
usefulness of opening persistently occluded infarct-related
arteries 7 to 48 h after symptom onset was assessed in the
randomized TAMI-6 study (317). Six months after infarc-
tion, coronary angiography showed a high incidence of
infarct-artery patency in those who did not have PTCA as
well as a high incidence of reocclusion in those who did, so
that infarct-related artery patency was similar among the
two groups. There were no differences in left ventricular
ejection fraction, or the incidence of recurrent MI, hospi-
talizations or mortality between the two groups at follow-
up. Although the argument to open occluded infarct-related
arteries is persuasive, at least for large arteries subtending
large areas of myocardium, there are few data from random-
ized trials to support its widespread use. However, large
studies are being planned to evaluate this treatment strategy.
(5) Patients With Non–Q-Wave Infarction
Before the impact of thrombolytic and other therapies on
survival in Q-wave MI, short-term mortality from non–Q-
wave MI (10%) was about half that of Q-wave MI (19.9%)
(256). However, long-term mortality in patients with non–
Q-wave infarction was equal to or slightly greater than that
of Q-wave MI, and the incidence of reinfarction was
'3-fold higher (15.7% vs. 5.7%). Recurrent angina also
occurs more frequently after non–Q-wave MI than Q-wave
MI, affecting between 35% and 50% of patients (256). In
this setting, if angina is associated with ST-segment
changes, patients are at extremely high risk (274). On the
basis of these outcome data, many clinicians have adopted
an aggressive approach to the management of patients with
non–Q-wave MI, including coronary angiography in all
patients. Advocates of this approach argue that it allows a
definitive anatomic diagnosis, improved assessment of prog-
nosis and the formation of a therapeutic plan early during
hospitalization (318,319). Alternatively, a more conservative
approach is to perform coronary angiography and revascu-
larization only in those patients with spontaneous or induc-
ible ischemia during provocative testing.
The TIMI IIIB study is the largest randomized, con-
trolled trial of early intervention (angiography and PTCA
within 18 to 48 h of presentation) versus conservative
strategy (invasive testing and PTCA only for recurrent
ischemia) in patients with either unstable angina or MI and
nondiagnostic ECG changes (151). All patients were
treated with beta-blockers, calcium channel blockers, ni-
trates, heparin and aspirin. Patients were randomized in a
2 3 2 factorial design to thrombolytic therapy with tPA or
placebo and an early invasive strategy or conservative man-
agement. The study showed that thrombolytic therapy was
not beneficial and possibly even detrimental. The incidence
of fatal and nonfatal MI after randomization was higher
(7.4% vs. 4.9%) in the tPA group, and there were more
intracranial hemorrhages. There was no significant differ-
ence in the composite end point of death, MI, or failed
symptom-limited exercise-tolerance test at six weeks be-
tween those in the invasive group (16.2%) and those in the
conservative group (18.1%). However, those in the invasive
group did have a slightly shorter (0.7 days) length of stay, a
lower need for second hospitalizations (7.8% versus 14.1%),
and a reduced use of antianginal medications. No economic
analyses were performed as part of TIMI IIIB, and therefore
it is not known whether the cost of routine coronary
angiography and intervention was offset by the reduced need
for further hospitalization and antianginal medications. In
TIMI IIIB, however, 64% of the patients in the conservative
arm had coronary angiography within 42 days of their
infarction; there were no subgroup analyses of only patients
with non–Q-wave MI.
Other data exist, including a small retrospective study
limited to patients with anterior non–Q-wave MI. Early
angiography with revascularization by PTCA or surgery
resulted in a significant decrease in recurrent MI (7.2% vs.
29%) and improved survival after three years of follow-up
compared with patients treated conventionally (320). Al-
though many clinicians have adopted an aggressive ap-
proach with coronary angiography and revascularization in
patients with non–Q-wave MI, a more conservative ap-
proach is supported by data from the VANQWISH trial
(269). In that trial, 920 patients (97% male) with non–Q-
wave MI were randomized to an early invasive strategy with
coronary angiography and revascularization, if appropriate,
versus a conservative strategy with noninvasive testing and
invasive management only for spontaneous or inducible
ischemia. Although the cumulative rate of death or recur-
rent MI did not differ between the two study groups during
the duration of follow-up (12 to 44 months), the rates of
death and nonfatal MI were higher at hospital discharge
after 30 days and during the first year in the invasive group.
These data argue against the aggressive approach of early
angiography for all patients with non–Q-wave MI and
suggest that a conservative strategy with medical therapy,
noninvasive testing, and only ischemia-driven invasive ther-
apy is both safe and effective.
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Recommendations for Coronary Angiography During
the Hospital-Management Phase (Patients With Q-
Wave and Non–Q-Wave Infarction)
Class I
1. Spontaneous myocardial ischemia or myocardial
ischemia provoked by minimal exertion, during
recovery from infarction. (Level of Evidence: C)
2. Before definitive therapy of a mechanical compli-
cation of infarction such as acute mitral regurgita-
tion, ventricular septal defect, pseudoaneurysm or
left ventricular aneurysm. (Level of Evidence: C)
3. Persistent hemodynamic instability. (Level of Evi-
dence: B)
Class IIa
1. When MI is suspected to have occurred by a
mechanism other than thrombotic occlusion at an
atherosclerotic plaque (e.g., coronary embolism,
arteritis, trauma, certain metabolic or hematologic
diseases or coronary spasm). (Level of Evidence: C)
2. Survivors of acute MI with left ventricular EF
<0.40, congestive heart failure, prior revasculariza-
tion or malignant ventricular arrhythmias. (Level of
Evidence: C)
3. Clinical heart failure during the acute episode, but
subsequent demonstration of preserved left ventric-
ular function (left ventricular EF >0.40). (Level of
Evidence: C)
Class IIb
1. Coronary angiography to find a persistently oc-
cluded infarct-related artery in an attempt to revas-
cularize that artery (open artery hypothesis). (Level
of Evidence: C)
2. Coronary angiography performed without other
risk stratification to identify the presence of left
main or three-vessel disease. (Level of Evidence: C)
3. All patients after a non–Q-wave MI. (Level of
Evidence: C)
4. Recurrent ventricular tachycardia and/or ventricu-
lar fibrillation, despite antiarrhythmic therapy,
without evidence of ongoing myocardial ischemia.
(Level of Evidence: C)
Class III
Patients who are not candidates for or who refuse
coronary revascularization. (Level of Evidence: C)
e. Risk Stratification Phase in Preparation for Discharge
From the Hospital After MI
The purpose of risk stratification is to assemble informa-
tion that will help predict prognosis and the need for further
therapies to improve prognosis (321). This process occurs
throughout the entire encounter with the patient and is not
strictly limited to the days before discharge. For example,
rales, tachycardia, hypotension or congestion on the chest
radiograph early in a patient’s course are all important
predictors of increased risk and likely indicate depressed left
ventricular performance (322). Many prior studies have
shown that left ventricular ejection fraction is highly pre-
dictive of survival (323,324). In the prethrombolytic era,
mortality one year after infarction was 2% to 5% when left
ventricular ejection fraction was .0.40, 10% to 15% when it
was between 0.20 and 0.39, and up to 50% when it was
,0.20. One-year mortality is significantly lower now than it
was in the past but is still related to left ventricular
performance (293,294). The cause of the improvement in
outcome is multifactorial and includes the use of thrombo-
lytic agents, beta-blockers and angiotensin converting en-
zyme inhibitors and perhaps includes more aggressive inva-
sive investigation and interventional treatment. Numerous
factors have been related to prognosis after acute MI; these
are summarized in Table 7 (321–326). Of the deaths that
occur within the first year after infarction, 50% happen
within the first three weeks and 75% within the first three
months (327). Therefore, patients at increased risk must be
identified relatively early if they are to be considered for
coronary angiography and possible revascularization.
Cardiac catheterization and coronary arteriography can
identify major determinants of mortality after MI, such as
left ventricular ejection fraction and the presence of mul-
tivessel CAD (325,328–332). Because of the skewed inci-
dence of cardiac events and mortality early within the first
year after infarction, some have proposed that coronary
angiography be performed in all survivors even though it
involves a small risk and is expensive (318). However, there
are ample other data that suggest that evaluation by nonin-
vasive methods such as standard exercise testing (Table 8),
two-dimensional echocardiography, radionuclide ventricu-
Table 7. Factors Associated With Risk After Acute
Myocardial Infarction
Age .70 yr
Congestive heart failure or LVEF ,0.40
Extent of CAD
Large infarct size, anterior infarction, or non–Q-wave
myocardial infarction
New bundle branch block of any type, Mobitz 2, or transient
third-degree heart block
Recurrent angina, reinfarction, or infarct extension
Frequent VPBs, ventricular tachycardia, or ventricular fibrillation
occurring after acute phase or inducible monomorphic
ventricular tachycardia during electrophysiological testing
Supraventricular arrhythmias except sinus bradycardia
Abnormal signal-averaged electrocardiogram
Provokable ischemia during exercise testing or inability to
exercise
Diabetes, hypertension
Female sex
LVEF indicates left ventricular ejection fraction; CAD, coronary artery disease; and
VPB, ventricular premature beat.
Modified with permission from Hessen SE, Brest AN. Risk profiling the patient
after acute myocardial infarction. In: Pepine CJ, ed. Acute Myocardial Infarction.
Philadelphia, Pa: FA Davis; 1989:284.
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lography, thallium scintigraphy or these imaging techniques
coupled with dynamic or pharmacologic stress can identify
most high-risk patients who may benefit from revascular-
ization (321,322,328,329,333–339). Moreover, coronary
angiography demonstrates the anatomy and morphology of
a stenosis at a discrete point in time. Progression of CAD is
quite variable, but it is a major factor affecting prognosis
(340,341). Although some angiographic predictors of future
infarction have been identified (342,343), other studies have
shown that 66% to 78% of infarctions are related to an artery
with a #50% stenosis on a previous angiogram (344,345).
Such lesions would not likely be the target of revascularization
attempts.
Various strategies for the use of coronary angiography
after MI have been discussed in the literature (291,318,321,
337,346), but careful research in this area has been sparse.
Ross et al. (347) developed a scheme in patients younger
than 75 years of age that would avoid early coronary
angiography in those at low risk (#3%) for one-year
mortality and recommends angiography in those at in-
creased risk (average one-year mortality 16%). Indications
for coronary angiography in this scheme included the
following: severe resting ischemia at any time beyond the
first 24 h after infarction (one-year mortality 18%); hospital
survivors with a history of previous MI and clinical or
radiographic signs of left ventricular failure in the hospital
(one-year mortality 25%); an ischemic exercise response or
poor workload achieved (one-year mortality 11%); and a
resting left ventricular ejection fraction between 0.20 and
0.44 alone when exercise testing is not performed (one-year
mortality 12%). With this approach, '55% of patients who
survive to the fifth day after infarction would undergo
coronary angiography. By comparison, data from the Na-
tional Registry of Myocardial Infarction during 1990
through 1993 and the GUSTO trial show that '72% of
patients treated by American participants undergo coronary
angiography during their initial hospitalization after MI
(47,259). This rate is considerably higher than the rate of
55% proposed by Ross et al. and the rate of 33% for
coronary angiography used in the selective approach of the
TIMI II trial (300). Although the frequent use of invasive
evaluations and therapy in the United States is subject to
debate, a recent subgroup analysis from the GUSTO trial
shows that patients treated in the United States had a better
quality of life, less angina and lower mortality during the first
year after infarction than did their Canadian counterparts, of
whom only 25% underwent coronary angiography (47). How-
ever, this approach has not been verified in other studies and is
costly (44,45,346).
The most recent scheme for evaluation and risk stratifi-
cation of patients early after MI was presented in the 1996
“ACC/AHA Guidelines for the Management of Patients
With Acute Myocardial Infarction” (190). This approach is
recommended by the committee and is outlined in Figure 4.
Recommendations for Coronary Angiography During
the Risk-Stratification Phase (Patients With All Types
of MI)
Class I
Ischemia at low levels of exercise with ECG changes
(>1-mm ST-segment depression or other predictors of
adverse outcome) (Table 8) and/or imaging abnormal-
ities. (Level of Evidence: B)
Class IIa
1. Clinically significant CHF during the hospital
course. (Level of Evidence: C)
2. Inability to perform an exercise test with left
ventricular EF <0.45. (Level of Evidence: C)
Class IIb
1. Ischemia occurring at high levels of exercise. (Level
of Evidence: C)
2. Non–Q-wave MI in a patient who is an appropriate
candidate for a revascularization procedure. (Level
of Evidence: C)
3. Need to return to an unusually active form of
employment. (Level of Evidence: C)
4. Remote history of MI without evidence of conges-
tive heart failure during the current event and
without evidence of inducible ischemia. (Level of
Evidence: C)
5. Recurrent ventricular tachycardia, fibrillation, or
both, despite antiarrhythmic therapy, without on-
going myocardial ischemia. (Level of Evidence: C)
Class III
Patients who are not candidates for or who refuse
coronary revascularization. (Level of Evidence: C)
6. Perioperative Coronary Angiography for Patients
Undergoing Noncardiac Surgery
Each year, more than 25 million patients undergo non-
cardiac surgery. Of these patients, it is estimated that nearly
3 million have CAD, .4 million are older than 65 years of
age, and '50,000 will suffer a perioperative MI (348). As
many as half of the annual 40,000 deaths associated with
noncardiac surgery are secondary to coronary disease (348),
and nearly one million patients undergoing noncardiac
surgery will have a serious cardiac complication. The annual
cost of this perioperative morbidity exceeds $10 billion
Table 8. Exercise Test Predictors of Adverse Outcome in
Postinfarction Patients (81)
Ischemic ST-segment depression $1 mm, particularly if
accompanied by symptoms, or at a low level of exercise, or in
the presence of controlled heart failure
Functional capacity ,5 METs
Inadequate blood pressure response (peak systolic blood pressure
,110 mm Hg or ,30 mm Hg increase from resting level)
METs indicates metabolic equivalents.
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(348). Most of these adverse outcomes are directly related to
myocardial ischemia or infarction.
The perioperative evaluation of patients undergoing non-
cardiac surgery has recently been detailed in an ACC/AHA
task force report (349). This document outlines a compre-
hensive approach to perioperative risk assessment that
stresses the patient’s prior clinical indicators of coronary
heart disease, functional status, type of noncardiac surgery
and the role of selected preoperative stress testing in patients
believed to be at intermediate or high risk for major
perioperative coronary events.
A number of studies have suggested that detection of
ischemia-related abnormalities before noncardiac surgery
identifies a subgroup of patients at high risk for periopera-
tive coronary events. In the past, this led some to argue for
routine coronary angiography for all patients undergoing
peripheral vascular surgery (350,351). Others, however,
suggested that such patients should be subjected to multi-
factorial clinical risk assessment (352) before consideration
of coronary angiography. Between these two extremes lies
the practice of combining clinical and noninvasive test
information to stratify these patients (349,353,354). In
addition, the anticipated cardiovascular stress of the partic-
ular type of surgery is an important determinant of the most
appropriate perioperative strategy.
By and large, the indications for coronary angiography for
patients being considered for noncardiac surgery should be
virtually identical to those already outlined in this docu-
ment. However, the presentation for noncardiac surgery, its
potential urgency, the level of cardiovascular stress that is
anticipated, and the general condition of the patient all play
critical roles in determining the most logical sequence of
events for any given patient. The following indications for
coronary angiography in perioperative evaluation before and
after noncardiac surgery reflect these different attributes of
any given patient. In addition, the types of clinical markers
that portend particularly high risk and those noncardiac
procedures that are associated with greater cardiovascular
stresses are listed beneath the table of indications for easy
reference.
Recommendations for Coronary Angiography in
Perioperative Evaluation Before (or After) Noncardiac
Surgery
Class I: Patients with suspected or known CAD
1. Evidence for high risk of adverse outcome based on
noninvasive test results (Table 5). (Level of Evi-
dence: C)
2. Angina unresponsive to adequate medical therapy.
(Level of Evidence: C)
3. Unstable angina, particularly when facing
intermediate-* or high-risk* noncardiac surgery.
(Level of Evidence: C)
Figure 4. Clinical indications of high risk at predischarge. Strategies for risk stratification soon after myocardial infarction. If patients are
at high risk for ischemic events, on the basis of clinical criteria, they should undergo invasive evaluation to determine if they are candidates
for coronary revascularization procedures (strategy I). For patients initially deemed to be at low risk at time of discharge after MI, two
strategies for performing exercise testing can be used. One is a symptom-limited test at 14 to 21 days (strategy II). If the patient is taking
digoxin or if baseline ECG precludes accurate interpretation of ST-segment changes (e.g., baseline left bundle-branch block or left
ventricular hypertrophy), then an initial exercise imaging study can be performed. Results of exercise testing should be stratified to determine the
need for additional invasive or exercise perfusion studies. A third strategy is to perform a submaximal exercise test five to seven days after MI or
just before hospital discharge. The exercise test results could be stratified using the guidelines in strategy I. If exercise test studies are negative,
a second symptom-limited exercise test could be repeated at three to six weeks for patients undergoing vigorous activity during leisure or at work.
From Figure 10 of the ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction (190).
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4. Equivocal noninvasive test result in high-clinical-
risk† patient undergoing high-risk* surgery. (Level
of Evidence: C)
Class IIa
1. Multiple-intermediate-clinical risk markers† and
planned vascular surgery. (Level of Evidence: B)
2. Ischemia on noninvasive testing but without high-
risk criteria (Table 5). (Level of Evidence: B)
3. Equivocal noninvasive test result in intermediate-
clinical-risk† patient undergoing high-risk* non-
cardiac surgery. (Level of Evidence: C)
4. Urgent noncardiac surgery while convalescing from
acute MI. (Level of Evidence: C)
Class IIb
1. Perioperative MI. (Level of Evidence: B)
2. Medically stabilized class III or IV angina and
planned low-risk or minor* surgery. (Level of Evi-
dence: C)
Class III
1. Low-risk* noncardiac surgery, with known CAD
and no high-risk results on noninvasive testing.
(Level of Evidence: B)
2. Asymptomatic after coronary revascularization with
excellent exercise capacity (>7 METs). (Level of
Evidence: C)
3. Mild stable angina with good left ventricular func-
tion and no high-risk noninvasive test results.
(Level of Evidence: B)
4. Noncandidate for coronary revascularization owing
to concomitant medical illness, severe left ventric-
ular dysfunction (e.g., left ventricular EF <0.20), or
refusal to consider revascularization. (Level of Ev-
idence: C)
5. Candidate for liver, lung or renal transplant >40
years old as part of evaluation for transplantation,
unless noninvasive testing reveals high risk for
adverse outcome. (Level of Evidence: C)
B. Valvular Heart Disease
In all forms of valvular heart disease, the presence of
significant coronary disease worsens prognosis (355–358).
For instance, Iung and colleagues (356) found a nine-year
actuarial survival rate of 79% after aortic valve replacement
in patients without coronary disease versus a 66% survival rate
in patients who underwent both aortic valve replacement and
coronary bypass grafting (p , 0.01). Most studies suggest that
in patients with both CAD and aortic valve disease, coronary
bypass reduces the early and late mortality of aortic valve
replacement compared with patients who only undergo aortic
valve replacement, although statistical significance was often
not achieved (359–362). Because it is widely accepted that
reoperation has an increased risk, most practitioners are com-
pelled to assess coronary anatomy before surgery and to bypass
significant obstructions during surgery with the hope of avoid-
ing late reoperation. The presence of valvular heart disease
makes the noninvasive assessment of ischemia less predictive
than in the general population, because valve disease often
limits exercise capacity and increases hemodynamic instability
and for some lesions may be accompanied by left ventricular
hypertrophy, which can lead to false-positive testing. Although
there are no large clinical trials to prove its value, angiography
seems to have an important role in the preoperative evaluation
of patients with valvular heart disease.
Patients with aortic stenosis pose the most difficult
problem in the decision of whether or not to perform
preoperative angiography. Approximately 35% of patients
with aortic stenosis have coronary disease (363–365). This
high incidence exists because both diseases occur with
advancing age and because they share other risk factors in
common. In these patients, the complaint of angina pectoris
is a poor guide to the presence or absence of coronary
disease. Coronary disease is present in '25% of all patients
with aortic stenosis who do not complain of chest pain
(365,366). Conversely, of the 40% of patients with aortic
stenosis who do complain of angina, the presence of
coronary disease varies from 40% to 80% (363–366). Until
recently, coronary angiography was considered to be the
only method available to establish the presence or absence of
coronary disease because exercise scintigraphy or exercise
echocardiography, the other potential modalities for detect-
ing coronary disease, were considered hazardous in patients
with aortic stenosis. However, as a substitute for exercise,
pharmacologic interventions to alter coronary blood flow
have now been used safely in conjunction with thallium or
sestamibi imaging to search for coronary disease in patients
with aortic stenosis. Depending on the definition of a
thallium defect, both sensitivity and specificity for this
procedure in detecting coronary disease in the face of aortic
stenosis are as high as 80% (367–370).
Currently, all patients with aortic stenosis who complain
of chest discomfort should undergo coronary angiography
before surgery. This is the only reliable way to define the
presence or absence of CAD and to determine whether
simple aortic valve replacement or valve replacement plus
coronary bypass is necessary. In patients without angina, it
seems prudent to perform coronary angiography for those
who are at increased risk for the presence of CAD because
of their age or other risk factors.
*Cardiac risk according to type of noncardiac surgery. High risk: emergent major
operations, aortic and major vascular, peripheral vascular, anticipated prolonged
surgical procedure associated with large fluid shifts and blood loss; intermediate risk:
carotid endarterectomy, major head and neck, intraperitoneal and intrathoracic, ortho-
pedic, prostate; and low risk: endoscopic procedures, superficial procedures, cataract,
breast. †Cardiac risk according to clinical predictors of perioperative death, MI or
congestive heart failure. High clinical risk: unstable angina, recent MI and evidence of
important residual ischemic risk, decompensated congestive heart failure, high degree of
atrioventricular block, symptomatic ventricular arrhythmias with known structural heart
disease, severe symptomatic valvular heart disease, patient with multiple intermediate risk
markers such as prior MI, congestive heart failure, and diabetes; intermediate clinical risk:
CCS class I or II angina, prior MI by history or ECG, compensated or prior congestive
heart failure, diabetes mellitus.
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In patients with significant aortic regurgitation, coronary
disease is found in '25% of affected subjects. Angina is less
common in aortic regurgitation than in aortic stenosis,
occurring in '25% of cases (365,371). As with aortic
stenosis, there is a discordance between the presence or
absence of coronary disease and angina. In patients without
angina, the presence of coronary disease ranges from 7% to
15%. It seems prudent to perform coronary angiography for
patients with aortic insufficiency without angina as well as
for those with aortic stenosis if they are at increased risk
because of age or other coronary risk factors.
Coronary angiography should be performed in most
patients before mitral valve surgery for mitral regurgitation
because it is the only valve lesion that commonly has
coronary disease as its cause. Young patients in whom other
origins of mitral regurgitation can clearly be discerned
echocardiographically may not need coronary angiography
before valve surgery.
Although most patients with mitral stenosis are women,
the disease usually presents in people during midlife or later
in the U.S. Because many patients with mitral stenosis have
unrecognized coronary disease, coronary angiography is
usually advised before surgery or balloon mitral valvotomy.
Evidence suggests that coronary angiography might detect
the presence of left atrial thrombus. The finding of neovas-
cularity between the coronary arteries and the left atrium
during injection of the left coronary artery has a sensitivity
of 75% and a specificity of 90% for diagnosing left atrial
thrombus (372,373). However, there are insufficient data to
recommend coronary angiography solely for the purpose of
discovering a left atrial thrombus, nor has this method been
compared with transesophageal echocardiography, which is
frequently used for this purpose.
The role of coronary angiography in the preoperative
evaluation of the patient undergoing valve surgery continues
to evolve. All patients with chest pain or noninvasive
evidence of coronary disease should undergo this procedure.
Although it seems that a negative thallium study may
obviate the need for angiography, the number of studies
examining this question is limited. Thus, it seems prudent
to perform coronary angiography for those patients who are
at increased risk for the presence of coronary disease because
of their age or other risk factors.
Infective endocarditis, whether acute or subacute, may
produce valvular insufficiency that requires valve replace-
ment. In acute aortic insufficiency, the presence of heart
failure may constitute a surgical emergency that requires
immediate valve replacement. In such patients, the risk of
delaying surgery to perform coronary angiography must be
weighed against its benefit. Often, these patients are rela-
tively young and have no risks for coronary disease. In such
patients, coronary angiography is not indicated. However,
in some patients, endocarditis may result in $1 coronary
embolus, resulting in a clinical picture of acute MI together
with endocarditis. If valve replacement is being undertaken
for this type of patient, it is desirable to evaluate the
coronary anatomy to determine whether $1 proximal ob-
structive lesion is present that may warrant concomitant
bypass grafting. Although cardiac catheterization is gen-
erally safe in patients with endocarditis (374), care should
be taken to avoid contacting the aortic valve during
coronary angiography to decrease the risk of vegetation
dislodgement.
Recommendations for Use of Coronary Angiography in
Patients With Valvular Heart Disease
Class I
1. Before valve surgery or balloon valvotomy in an
adult with chest discomfort, ischemia by noninva-
sive imaging, or both. (Level of Evidence: B)
2. Before valve surgery in an adult free of chest pain
but with multiple risk factors for coronary disease.
(Level of Evidence: C)
3. Infective endocarditis with evidence of coronary
embolization. (Level of Evidence: C)
Class IIa
None.
Class IIb
During left-heart catheterization performed for hemo-
dynamic evaluation before aortic or mitral valve sur-
gery in patients without preexisting evidence of coro-
nary disease, multiple CAD risk factors or advanced
age. (Level of Evidence: C)
Class III
1. Before cardiac surgery for infective endocarditis
when there are no risk factors for coronary disease
and no evidence of coronary embolization. (Level of
Evidence: C)
2. In asymptomatic patients when cardiac surgery is
not being considered. (Level of Evidence: C)
3. Before cardiac surgery when preoperative hemody-
namic assessment by catheterization is unnecessary,
and there is neither preexisting evidence for coro-
nary disease, nor risk factors for CAD. (Level of
Evidence: C)
C. Congenital Heart Disease
Although there are no large trials to support its use,
coronary angiography is performed in congenital heart
disease for two broad categorical indications. The first
indication is to assess the hemodynamic impact of congen-
ital coronary lesions (375). The second is to assess the
presence of coronary anomalies, which by themselves may
be innocent but whose presence, if unrecognized, may lead
to coronary injury during the correction of other congenital
heart lesions. Congenital anomalies with hemodynamic
significance include congenital coronary artery stenosis or
atresia, coronary artery fistula (376), anomalous left coro-
nary artery arising from the pulmonary artery (377), and
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anomalous left coronary artery arising from the right coro-
nary artery or right sinus of Valsalva and passing between
the aorta and right ventricular outflow tract (378). Patients
with congenital coronary stenoses may present with angina
or unexplained sudden death in childhood, whereas patients
whose left coronary passes between the pulmonary artery
and aorta often have the same symptoms later in life.
Patients with a coronary arteriovenous fistula often
present with a continuous murmur or may have unex-
plained angina or congestive heart failure. Anomalous
origin of the left coronary artery from the pulmonary
artery should be suspected when there is unexplained MI
or heart failure in early childhood. Other coronary
anomalies of position or origin may cause no physiologic
abnormality by themselves. Some, such as origin of the
circumflex artery from the right sinus of Valsalva, are not
associated with other congenital anomalies and present
only as incidental findings and are significant only be-
cause they complicate the performance and interpretation
of coronary angiograms.
Some coronary anomalies are important because their
anomalous position may lead to their injury at the time of
surgical correction of an associated structural abnormality.
In this category, the most frequently occurring example is
anomalous origin of the LAD coronary artery from the right
coronary artery passing across the anterior right ventricle in
patients with tetralogy of Fallot (379). Important coronary
anomalies are also common in transposition of the great
arteries (380).
Finally, although most congenital heart disease is discov-
ered early in life before patients are at risk for atherosclerotic
coronary disease, in some cases surgical correction is per-
formed at older ages, when the risk of coronary disease
increases. Although there are almost no data addressing this
issue, it seems prudent to perform coronary arteriography in
patients being considered for repair of congenital heart
disease if angina, ischemia by noninvasive testing or multi-
ple coronary risk factors are present.
Recommendations for Use of Coronary Angiography in
Patients With Congenital Heart Disease
Class I
1. Before surgical correction of congenital heart dis-
ease when chest discomfort or noninvasive evidence
is suggestive of associated CAD. (Level of Evidence: C)
2. Before surgical correction of suspected congenital
coronary anomalies such as congenital coronary
artery stenosis, coronary arteriovenous fistula and
anomalous origin of left coronary artery. (Level of
Evidence: C)
3. Forms of congenital heart disease frequently asso-
ciated with coronary artery anomalies that may
complicate surgical management. (Level of Evi-
dence: C)
4. Unexplained cardiac arrest in a young patient.
(Level of Evidence: B)
Class IIa
Before corrective open heart surgery for congenital
heart disease in an adult whose risk profile increases
the likelihood of coexisting coronary disease. (Level of
Evidence: C)
Class IIb
During left-heart catheterization for hemodynamic
assessment of congenital heart disease in an adult in
whom the risk of coronary disease is not high. (Level of
Evidence: C)
Class III
In the routine evaluation of congenital heart disease in
asymptomatic patients for whom heart surgery is not
planned. (Level of Evidence: C)
D. Congestive Heart Failure
1. Systolic Dysfunction
Although it was once believed that myocardial ischemia
was either short-lived and resulted in little or no muscle
dysfunction or resulted in infarction with permanent dam-
age, it is now clear that a middle state may exist in which
chronic ischemic nonfunctioning myocardium is present, to
which function may return after myocardial revasculariza-
tion (381,382). This intermediate state has been termed
“myocardial hibernation.” Although most cases of myocar-
dial dysfunction resulting from CAD are probably irrevers-
ible when due to infarction and subsequent deleterious
ventricular remodeling (ischemic cardiomyopathy) (383),
some patients with hibernating myocardium have been
shown to experience a doubling of resting ejection fraction
with resolution of congestive heart failure after coronary
revascularization (384,385). However, in most cases of
hibernation, a more modest improvement in ejection frac-
tion of '5% occurs after revascularization (386). In view of
this phenomenon, the possibility of reversible myocardial
systolic dysfunction should always be considered, especially
before consideration for a cardiac transplantation. Usually,
segmental wall motion abnormalities in ischemic cardiomy-
opathy coupled with perfusion defects during myocardial
scintigraphy allow the diagnosis of ischemia as a probable
cause of myocardial dysfunction before angiography. Like-
wise, the presence of a thin-walled dilated cardiomyopathy
with homogeneously poor wall motion and normal myocar-
dial scintigraphy strongly suggests that nonischemic cardio-
myopathy is present (387). However, the two conditions
may overlap such that some patients with idiopathic dilated
cardiomyopathy may have regional wall motion abnormal-
ities, whereas some patients with ischemic cardiomyopathy
may have global left ventricular dysfunction. Currently,
thallium scintigraphy is the most widely used test of viability
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(387). Thallium, a potassium analog, requires an intact
(viable) sarcolemma for myocardial uptake. Sestamibi scin-
tigraphy, which detects intact mitochondria as its measure
of viability, and PET scanning, which relies on intact
glucose metabolism as a marker of viability, are alternatives
to thallium imaging. By way of example, the circumstance in
which echocardiography demonstrates an akinetic anterior
wall while scintigraphy demonstrates anterior thallium up-
take suggests anterior wall viability with hibernating myo-
cardium in that region. In such cases, coronary angiography
should be performed to identify a potential revascularization
target in the LAD artery.
It is worth noting that most centers do perform coronary
angiography in the workup for cardiac transplantation.
2. Diastolic Dysfunction
Isolated diastolic dysfunction is the cause of heart failure
in 10% to 30% of affected patients. This disorder is common
in older patients with hypertension and often is suspected
because of echocardiographically detected concentric left
ventricular hypertrophy, normal systolic function and ab-
normal transmitral flow velocity patterns (388). However, in
some patients with normal systolic function, the abrupt
onset of pulmonary edema raises the suspicion that transient
ischemia was the cause of decompensation, because
elderly patients with hypertension have, by definition, at
least two risk factors for coronary disease. In these
patients, who are often too ill to undergo stress testing,
coronary angiography may be necessary to establish or
rule out the diagnosis of ischemically related diastolic
dysfunction and heart failure.
Recommendations for Use of Coronary Angiography in
Patients With Congestive Heart Failure
Class I
1. Congestive heart failure due to systolic dysfunction
with angina or with regional wall motion abnormal-
ities and/or scintigraphic evidence of reversible
myocardial ischemia when revascularization is be-
ing considered. (Level of Evidence: B)
2. Before cardiac transplantation. (Level of Evidence: C)
3. Congestive heart failure secondary to postinfarction
ventricular aneurysm or other mechanical compli-
cations of MI. (Level of Evidence: C)
Class IIa
1. Systolic dysfunction with unexplained cause despite
noninvasive testing. (Level of Evidence: C)
2. Normal systolic function, but episodic heart failure
raises suspicion of ischemically mediated left ven-
tricular dysfunction. (Level of Evidence: C)
Class III
Congestive heart failure with previous coronary angio-
grams showing normal coronary arteries, with no new
evidence to suggest ischemic heart disease. (Level of
Evidence: C)
E. Other Conditions
1. Aortic Dissection
The need for coronary angiography before surgical treat-
ment for aortic dissection remains controversial because
there are no large trials to support its use. In young patients
with dissection due to Marfan syndrome or in dissection in
peripartum females, coronary angiography is unnecessary
unless there is suspicion that the dissection has affected one
or both coronary ostia. In older patients, in whom dissection
is usually related to hypertension, coronary angiography is
often necessary, especially if patients are suspected of having
coronary disease because of a history of angina or objective
evidence of myocardial ischemia. In patients who have no
history of coronary disease, the indications for coronary
angiography are much less certain. Because of the high
incidence of coronary disease in older patients with dissec-
tion, some studies have advocated routine coronary angiog-
raphy (389), whereas others have found increased mortality
when angiography is performed (390).
2. Arteritis
Some patients with inflammatory processes affecting the
aorta, such as Takayasu arteritis, may have coronary artery
involvement requiring coronary artery revascularization. In
such patients, coronary angiography is required before the
surgical procedure. Kawasaki disease can result in coronary
artery aneurysm and coronary artery stenosis producing
myocardial ischemia or silent occlusion and may require
coronary angiographic assessment (391,392).
3. Hypertrophic Cardiomyopathy
Significant CAD due to atherosclerosis is found in '25%
of patients aged .45 years with hypertrophic cardiomyop-
athy (393). Because symptoms due to CAD and hypertro-
phic cardiomyopathy are similar, patients with ischemic
symptoms not well controlled with medical therapy may
require coronary angiography to resolve the cause of chest
pain. Coronary angiography also is indicated in patients
with chest discomfort and hypertrophic cardiomyopathy in
whom a surgical procedure is planned to correct outflow
tract obstruction.
4. Chest Trauma
Patients who have an acute MI shortly after blunt or
penetrating chest trauma may have atherosclerotic CAD,
but coronary artery obstruction or damage has been reported
in the absence of coronary atherosclerosis (394). Further-
more, myocardial contusion may simulate acute MI. Infre-
quently, coronary angiography is indicated in the manage-
ment of such patients.
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5. Miscellaneous Conditions
Preoperative coronary angiography may be indicated in
patients undergoing cardiac operations such as pericardiec-
tomy or removal of chronic pulmonary emboli if they have
$1 risk factor for coronary disease, especially advanced age.
Because of the concern about transplanting a donor heart
affected by coronary disease, many advocate coronary an-
giography before transplantation, at least for those donors
with a significant likelihood of CAD.
Recommendations for Use of Coronary Angiography in
Other Conditions
Class I
1. Diseases affecting the aorta when knowledge of the
presence or extent of coronary artery involvement is
necessary for management (e.g., aortic dissection or
aneurysm with known coronary disease). (Level of
Evidence: B)
2. Hypertrophic cardiomyopathy with angina despite
medical therapy when knowledge of coronary anat-
omy might affect therapy. (Level of Evidence: C)
3. Hypertrophic cardiomyopathy with angina when
heart surgery is planned. (Level of Evidence: B)
Class IIa
1. High risk for coronary disease when other cardiac
surgical procedures are planned (e.g., pericardiec-
tomy or removal of chronic pulmonary emboli).
(Level of Evidence: C)
2. Prospective immediate cardiac transplant donors
whose risk profile increases the likelihood of coro-
nary disease. (Level of Evidence: B)
3. Asymptomatic patients with Kawasaki disease who
have coronary artery aneurysms on echocardiogra-
phy. (Level of Evidence: B)
4. Before surgery for aortic aneurysm/dissection in
patients without known coronary disease.
5. Recent blunt chest trauma and suspicion of acute
MI, without evidence of preexisting CAD. (Level of
Evidence: C)
APPENDIX A
Anatomic angiographic definitions. Proper communica-
tion of the results of coronary arteriography requires some
standardization of nomenclature regarding measurement
and description of the coronary arterial tree. Clinical inves-
tigators of the CASS, TIMI, and BARI trials have pre-
sented standardized systems. These guidelines endorse the
system developed by the BARI investigators and published
by Alderman and Stadius in Coronary Artery Disease (395).
This system provides for nomenclature of the most fre-
quently encountered coronary arterial segments as shown in
Figure 5 and as described in Table 9.
Coronary artery dominance refers to the origin of blood
flow to the inferolateral wall of the left ventricle. Right
dominance denotes right coronary origin of flow (segments
1 through 9), left dominance to left coronary artery origin of
flow (segments 18 and 19 and 23 through 27), and mixed
dominance to an intermediate pattern.
Coronary artery lesions can be described by their location,
severity and classification. Location description uses the
scheme shown in Figure 5, with the proximal shoulder of
the lesion defining the location. Stenosis severity may be
estimated visually, but is more accurately estimated by
Figure 5. The coronary artery map used by the BARI investigators. The map is derived from that used in CASS with the addition of
branch segments for the diagonal, marginal and ramus vessels. Reprinted with permission from Alderman et al. (395). See Table 9 for
corresponding map location.
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electric or digital means, with percent stenosis defined as the
ratio of reference luminal diameter divided by the reference
diameter vessel measurement.
Severe stenoses (.85%) defy quantitative methods and
should be so stated. Vessel occlusion (100% stenosis) is
defined as termination of the original luminal channel and
TIMI flow 0 through it.
In addition to the above characteristics of coronary
lesions, a scaled qualitative measurement of flow through
the stenosis has been proposed by Sheehan for the TIMI
investigators. Table 10 describes TIMI flow grades for
native coronary vessels, collateral vessels, and coronary
bypass graft conduits (396).
APPENDIX B
Special Considerations Regarding Coronary Angiography
1. Accuracy
Cineangiographic images of coronary arteries have been
the principal clinical tool for determining the severity of
coronary luminal stenosis. Modern angiographic equipment
has a resolution of four to five line pairs per millimeter with
a six-inch field of view, the usual image magnification for
coronary angiography (397). Validation studies that use
known phantoms show a high correlation between actual
size and that measured by quantitative coronary angiogra-
phy (QCA) (r 5 0.95) (398–401). The resolution of these
phantom studies indicates the precision of coronary angiog-
raphy to be 0.02 to 0.04 mm. Factors that limit resolution in
the clinical setting include grainy films from “quantum
mottling” and motion artifact that, in a clinical setting, limit
resolution to 0.2 mm, far less than that realized from static
images of known phantoms. Other factors, such as angula-
tion, overlap of vessels and image tube resolution can also
influence accuracy in the clinical setting. Nevertheless, the
accuracy of coronary angiography does allow for anatomic
detail that is not obtainable by current noninvasive or other
invasive technology. Only intravascular ultrasound, which is
discussed in Appendix C, has an image resolution greater
than that of coronary angiography. However, intravascular
ultrasound cannot visualize the entire coronary tree nor
define the anatomic course of the coronary vessels. It is also
limited by shadowing from heavy calcification and by its
inability to image very small vessels or very severe stenosis.
2. Reproducibility
In clinical practice, the degree of coronary artery obstruc-
tion is commonly expressed as the percent diameter stenosis.
This is done by comparing the diameter of the site of
greatest narrowing (minimal lumen diameter) to an adjacent
Table 10. Distal Flow of Native Vessel, Collaterals, and Grafts
Contrast Flow
TIMI
Grade
Native
Vessel
Flow
Collateral
Flow
Graft
Flow
Prompt anterograde
flow and rapid
clearing
3 3 Excellent 3
Slowed distal filling
but full
opacification of
distal vessel
2 2 Good 2
Small amount of flow
but incomplete
opacification of
distal vessel
1 1 Poor 1
No contrast flow 0 0 No visible flow 0
TIMI indicates Thrombolysis in Myocardial Infarction.
Table 9. Bypass Angioplasty Revascularization Investigation
(BARI) Coronary Artery Segments and Corresponding Map
Location
Segment Map Location
1 Proximal right coronary artery conduit segment
2 Mid-right coronary artery conduit segment
3 Distal right coronary artery conduit segment
4 Right posterior descending artery segment
5 Right posterior atrioventricular segment
6 First right posterolateral segment
7 Second right posterolateral segment
8 Third right posterolateral segment
9 Posterior descending septal perforators segment
10 Acute marginal segment(s)
11 Left main coronary artery segment
12 Proximal LAD artery segment
13 Mid-LAD artery segment
14 Distal LAD artery segment
15 First diagonal branch segment
15a Lateral first diagonal branch segment
16 Second diagonal branch segment
16a Lateral second diagonal branch segment
17 LAD septal perforator segments
18 Proximal circumflex artery segment
19 Mid-circumflex artery segment
19a Distal circumflex artery segment
20 First obtuse marginal branch segment
20a Lateral first obtuse marginal branch segment
21 Second obtuse marginal branch segment
21a Lateral second obtuse marginal branch segment
22 Third obtuse marginal branch segment
22a Lateral third obtuse marginal branch segment
23 Circumflex artery AV groove continuation segment
24 First left posterolateral branch segment
25 Second left posterolateral branch segment
26 Third posterolateral descending artery segment
27 Left posterolateral descending artery segment
28 Ramus intermedius segment
28a Lateral ramus intermedius segment
29 Third diagonal branch segment
29a Lateral third diagonal branch segment
AV indicates atrioventricular; and LAD, left anterior descending.
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segment assumed to be free of disease. In clinical practice,
the most common method used to estimate the percent
diameter narrowing is subjective visual assessment. Because
vasomotor tone can alter the reference diameter, nitroglyc-
erin is frequently administered before angiography to im-
prove the reproducibility of the measurement. Several stud-
ies have shown that measurement of the degree and extent
of luminal narrowing correlates with symptoms as well as
with assessments of coronary flow reserve (CFR) and
abnormalities on treadmill exercise testing, perfusion imag-
ing with 201Tl or sestamibi, stress echocardiography and fast
computerized tomography (402–406). In addition, the per-
cent diameter reduction and the number of stenoses of
$50% to 70% correlate with long-term outcome (407–
414). When other clinical variables predictive of mortality,
such as age or left ventricular function, are considered, the
number and extent of luminal coronary diameter narrowings
on coronary angiography remain important independent
predictors of outcome (8,409,413,415).
Despite the relationship between visual assessments of
coronary disease and outcome, it is well recognized that
visual assessments have significant interobserver and in-
traobserver variability ranging from 7.5% to 50% (416–
424). Originally described in the late 1970s, QCA with a
computer-based system can reduce the wide variability in
readings of the angiogram (399–401,425–433). Although
both videodensitometric and edge-detection techniques
have been used, the latter is more commonly used. Valida-
tion studies in which static images were used have shown
that reproducibility is greatly improved. However, results
vary among different QCA systems, ranging from 0.07 mm
to 0.31 mm (398). An additional advantage of this type of
assessment is the ability to measure the degree of luminal
narrowing in absolute terms as the minimal lumen diameter
(432,434–436). This measurement is not influenced by the
adjacent segment, which may also be significantly diseased
and can lead to inaccuracies in determination of the percent
stenosis (437). Studies have shown that the minimal lumen
diameter is a reliable measurement that can be used to
follow the progression or regression of disease by angiogra-
phy (434–436). It has also been used extensively to define
the presence of restenosis and is the standard for restenosis
trials that have used coronary angiography as the primary
end point (434,435). In addition, it correlates well with
noninvasive assessments of myocardial ischemia. In one
recent study, QCA-determined percent stenosis of .50%
had a positive predictive value of 79% and a negative
predictive value of 80% for a positive dobutamine echo,
whereas a minimal lumen diameter of ,1.0 mm had a
positive predictive value of 81% and a negative predictive
value of 90% (438). Similar relationships have been found
with other noninvasive tests of myocardial ischemia.
Although QCA systems are becoming more readily
available, they have not yet been used routinely in clinical
practice (428,439,440). Recent studies have shown that
handheld or digital calipers are a suitable alternative for
QCA, and many laboratories have adopted this quantitative
methodology to reduce interobserver and intraobserver vari-
ability. The variability of digital calipers (5.9% to 9%) is
lower than that of visual assessments (7.5% to 50%);
however, computer-generated QCA measurements have the
lowest interobserver and intraobserver variabilities (3.5% to
7.3%) (441–443). QCA measurements also are superior to
visual readings when the angiographic measurements are
repeated weeks to months later, resulting in the lowest
medium and long-term variability (5% to 14%) (399,400).
Use of QCA, although more reproducible, is limited by the
use of one or two selected cine frames for analysis (433,444).
Coronary lesions are frequently eccentric, and overlapping
and nontangential views can result in poor definition.
Projections that position the vessel over other structures,
such as the spine, can also lead to significant difficulty in
quantitative assessment (444–447). The frame selection is
also important, because any single frame can misrepresent
the true extent of a coronary narrowing (433,444). The
value of cineangiography is that motion can improve the
assessment of the stenosis and allow for the visual integra-
tion of many frames. Several recent studies suggest that
despite a greater interobserver variability, visual assessments
with caliper measurements are more predictive of long-term
outcome than QCA after angioplasty (448,449).
The maintenance of high-quality angiographic readings
that have low interobserver and intraobserver variabilities
requires a formal quality-assurance/quality-control program
(450). Some of the responsibilities of the cardiac catheter-
ization laboratory director are to ensure that the cineangio-
graphic quality of the laboratory is high, that optimal views
of the coronary vessels are obtained in each case, and that
angiographic interpretation by the participating physicians
is as uniform and as reproducible as possible. Standardiza-
tion of methodology, periodic cine review and the use of
some form of lesion quantification, such as handheld cali-
pers, are strongly recommended.
3. Digital Imaging of Coronary Angiography
Recent advances in computer storage technology have
made feasible digital acquisition, processing and archival
storage of angiographic images obtained during cardiac
catheterization. Widespread conversion from cineangio-
graphic film to digital archiving and storage is anticipated
during the next decade. Analog storage technologies such as
super VHS videotape and analog optical disks have inade-
quate resolution to faithfully record coronary angiography.
Digital storage methods are generally adequate but until
recently have lacked standardization, which precluded easy
exchange of digital angiograms between centers with differ-
ent equipment. The development of the Digital Imaging
and Communication standard (DICOM) for cardiac an-
giography ensures compatibility between equipment from
participating vendors.
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In the interventional era, the advantages of digital an-
giography are important. The image quality provided by
digital angiography is better than any common videotape
format. Improvements in computer speed and processing
capability enable rapid replay of coronary injection se-
quences, as well as evaluation of the results of each inter-
vention and identification of complications such as intralu-
minal thrombus and dissection. In many laboratories, the
availability of high-quality images during catheterization
permits diagnostic and therapeutic catheterization to consist
of a single procedure, a capability with significant implica-
tions for the cost of interventional procedures. Industry
sources now estimate that .75% of existing laboratories are
equipped with digital imaging capability.
In some cases, the conversion to filmless catheterization
has resulted in inadequate archiving. For example, storage of
digital angiographic studies on analog super VHS videocas-
sette tape results in significant image degradation, offering
at best only '50% the resolution of the original digital
image. Angiograms stored on analog videocassette tape are
often inadequate for clinical decision making. Another
format, analog optical disks, has been commonly used to
replace cine film. Image quality is better than videotape, and
equivalency to film has been reported. Other proposed
systems use data compression to enable storage of complete
studies on limited-capacity media. However, high levels of
data compression may produce measurable image degrada-
tion with an uncertain clinical impact.
a. The DICOM Standard
The ACC Cardiac Catheterization Committee is coor-
dinating efforts to develop and promote a standard for
archival storage and exchange of digital cardiac angiogra-
phy. The committee has joined in this common cause with
an industry organization, the National Electrical Manufac-
turers Association (NEMA), and representatives of the
American College of Radiology (ACR). The ACR and
NEMA have recently released an interim standard known as
Digital Imaging Communication in Medicine (DICOM
version 3.0).
The initial efforts of the standards committee have
focused on adoption of a file format and physical medium
for interchange of digital angiographic studies. To transfer
images between medical centers, the sender would generate
a DICOM-compatible file for review by the receiver.
Recently, this working group has chosen a recordable form
of the common CD-ROM, termed CD-R, as the official
exchange medium. Nearly all equipment vendors have
announced support for this format.
Recommendations
Class I
None.
Class IIa
Replacement of cine film by a digital storage modality
that meets the DICOM standards to ensure exchang-
ability of angiographic studies. (Level of Evidence: C)
Class III
Replacement of cineangiographic film by videotape or
other existing analog storage media that do not meet
DICOM standards. (Level of Evidence: C)
4. Limitations
Although coronary angiography is considered the refer-
ence standard for anatomic assessment of coronary obstruc-
tions, there are limitations to the technique. When luminal
narrowings are present on coronary angiography (in the
absence of spasm), pathological analyses almost always
demonstrate severe atherosclerotic obstruction. Even minor
angiographic abnormalities are associated with a poorer
long-term outcome than are completely normal–appearing
angiograms. Coronary angiography has a high predictive
value for the presence of CAD when abnormalities are
present. However, the converse is not true. A normal
coronary angiogram does not exclude atherosclerosis, and in
fact, most pathological studies suggest that angiography
grossly underestimates the extent and severity of atheroscle-
rosis (451–455). Several factors contribute to this discrep-
ancy.
First, angiography depicts coronary anatomy from a
planar two-dimensional silhouette of the contrast-filled
vessel lumen. However, coronary lesions are often geomet-
rically complex, with an eccentric luminal shape such that
one angle of view may misrepresent the extent of narrowing
(452). Two orthogonal angiograms should demonstrate
more correctly the severity of most lesions, but adequate
orthogonal views are frequently unobtainable because the
stenosis may be obscured by overlapping side branches,
disease at bifurcation sites, radiographic foreshortening or
tortuosity. This can be especially difficult in the left main
coronary artery, where identifying a significant stenosis is of
utmost clinical importance (420).
Second, an adaptive phenomenon, coronary “remodel-
ing,” contributes to the inability of coronary angiography to
identify mild atherosclerosis (456). Remodeling was initially
observed on histology as the outward displacement of the
external vessel wall in vascular segments with significant
atherosclerosis. In the early phases of atherosclerosis, this
vessel enlargement “compensates” for luminal encroach-
ment, thereby concealing the atheroma from the angiogram.
When the atherosclerotic plaque becomes severe, luminal
encroachment becomes evident. Although such mild lesions
do not restrict blood flow, clinical studies have demon-
strated that these minimal or even unseen angiographic
lesions represent an important predisposing cause of acute
coronary syndromes, including MI (344).
Third, assessment of luminal diameter narrowing is compli-
cated by the frequent absence of a normal reference segment
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(437). Angiography visualizes only the lumen of the vessel and
cannot determine if the wall of the reference segment has
atherosclerosis (451–455). In the presence of diffuse reference-
segment disease, percent stenosis will predictably underesti-
mate the true amount of diameter narrowing.
Finally, in the setting of percutaneous intervention, the
assumptions underlying simple projection imaging of the
lumen are further impaired. Necropsy studies and intravas-
cular ultrasound demonstrate that most mechanical coro-
nary interventions exaggerate the extent of luminal eccen-
tricity by fracturing or dissecting the atheroma within the
lesion (457–461). The angiographic appearance of the
postintervention vessel often consists of an enlarged, al-
though frequently “hazy” lumen (458). In this setting, the
lumen size on angiography may overestimate the vessel
cross-sectional area and misrepresent the actual gain in
lumen size.
Experimental and clinical studies have shown that when
percent stenosis is .50%, the ability to increase blood flow
in response to metabolic demands is impaired (462). This
augmentation of coronary blood flow to demand is termed
the coronary flow reserve. Determination of CFR requires
measurement of blood flow at rest and after induction of
reactive hyperemia, usually by administration of a coronary
vasodilator. Several methods for measurement of CFR in
patients have been developed, including intracoronary Dopp-
ler flow probes, digital angiography and quantitative PET
(463–466). Although each of these approaches correlates
with the angiographic severity of coronary lesions and their
physiological effects, significant discrepancies exist among
the techniques. Animal and human studies show that a
normal CFR should exceed '5:1 (hyperemic to basal flow
ratio). Flow reserve remains normal until stenosis severity
approaches a 75% luminal area reduction or 50% diameter
narrowing. For stenoses between 75% and 95% diameter
narrowing, CFR falls progressively to reach values ap-
proaching unity. Because important stenoses occur in vessels
2 to 5 mm in diameter, the difference in minimal lumen
diameter by angiography between a moderate and severe
stenosis may comprise only a few tenths of a millimeter.
Accordingly, the dissociation between angiographic and
physiologic estimates is not surprising given the resolution
limitations of angiography, the confounding effects of pro-
jection angles, the irregularity of luminal shape and the
effect of diffuse disease (467). Several other factors weaken
the correlation between angiographic measures of lesion
severity and CFR, including ventricular hypertrophy, the
metabolic state of the myocardium, and microvascular
impairment (468–470). Thus, the epicardial stenosis seen
by angiography is only one factor responsible for a reduction
in flow reserve in patients with clinical symptoms. Accord-
ingly, a stenosis incapable of producing angina in one
patient can result in severe functional limitation in another.
Coronary collaterals can provide significant additional
blood flow to territories served by stenotic vessels (471). In
general, collaterals are not evident unless resting ischemia is
present, such as that which occurs with a stenosis .90%. In
many patients, collateral flow merely restores normal resting
blood flow but does not provide adequate flow when
metabolic demand increases. The presence of collaterals,
however, is associated with preservation of myocardial
function after MI, reduced myocardial ischemia on nonin-
vasive stress testing, and reduced ischemia during angio-
plasty (472,473). Paradoxically, a greater ischemic response
on noninvasive functional testing with adenosine than with
exercise has been reported in the presence of collaterals,
presumably due to an increase in the coronary steal phe-
nomenon (474). Collateral blood flow can only be semi-
quantified by angiography (475), and precise assessment of
perfusion by angiography is poor. This inability to ade-
quately measure collateral flow is one of the factors that
prevent accurate assessment of the functional significance of
coronary stenoses by angiography alone (470).
These limitations have resulted in the development of
new adjunctive imaging methods and physiologic measure-
ments to help improve the assessment of CAD, as discussed
later (476). Although these new adjunctive techniques have
not replaced coronary angiography, they have provided
additional valuable information that has allowed further
determination of the severity and extent and physiologic
significance of luminal obstructions. Coronary angiography,
despite its limitations, remains the principal clinical tool in
assessment of CAD and will likely remain so in the near
future.
5. Contrast Agents
For an understanding of the pharmacologic properties
and adverse effects of contrast agents, the reader is referred
to the 1993 review of the subject by the ACC Cardiovas-
cular Imaging Committee (477) and the 1996 review by
Hirshfeld (478).
a. Selection of a Contrast Agent for Coronary Angiography
Except for a less potent anticoagulant effect, nonionic
agents are better tolerated and have fewer side effects than
ionic agents (477). Several randomized trials have compared
their use during cardiac angiography. Barrett et al. (479)
compared a nonionic low-osmolar contrast agent with an
ionic high-osmolar contrast agent. Although adverse events
were reduced, severe reactions were confined to patients
with underlying severe cardiac disease. These authors sup-
ported the use of nonionic low-osmolar agents in these
high-risk patients. Steinberg et al. (480) compared high-
versus low-osmolar agents in 505 patients and found a
significant difference in moderate but not severe reactions.
They concluded that routine use of low-osmolar agents in
all patients was not justified. In a single-center, randomized,
blinded study of 2,166 patients undergoing coronary an-
giography, diatrizoic acid (Hypaque 76) was compared with
iohexol (Omnipaque) (25). The overall incidence of severe
contrast-related adverse reactions was lower with iohexol
versus diatrizoic acid (2.6% vs. 4.6%; p 5 0.02). The study
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also demonstrated the important fact that in very high-risk
patients, a two-fold lower incidence of adverse reactions
occurred with nonionic agents. In patients not at high risk,
however, no significant benefit was demonstrated.
The reduction in adverse events seen with the use of
nonionic contrast media in diagnostic angiography may not
be the same for patients undergoing interventional proce-
dures because of their less potent anticoagulant effect
compared with that of ionic agents. In a randomized trial of
211 patients with acute MI or unstable angina undergoing
angioplasty, patients receiving ionic contrast media had
fewer acute complications, fewer symptoms of angina and
less need for subsequent bypass surgery during follow-up.
Whether these differences would still be evident with the
widespread use of new antiplatelet therapy, including plate-
let glycoprotein IIb/IIIa receptor inhibitors, remains to be
demonstrated.
The primary reason not to routinely use nonionic agents
is cost, because the price difference between nonionic and
ionic agents in the U.S. is 12- to 25-fold. It has been
estimated that uniform use of nonionic contrast agents
would cost $1.1 billion in the U.S. alone (481). As reported
above, patients at high risk for adverse outcomes benefit the
most from the use of nonionic contrast agents. The differ-
ence in the incidence of any major contrast reaction is
proportional to the New York Heart Association clinical
function class, rising from 0.5% for class I patients to 3.6%
for class IV patients (482). Given these observations, it has
been suggested that nonionic agents should be reserved for
patients who are at high risk for adverse reactions and that
ionic agents should be used for all other patients (478).
Factors that have been associated with high risk of adverse
reactions to contrast media include prior adverse reaction to
contrast agents, age .65 years, New York Heart Associa-
tion functional class IV (or hemodynamic evidence of
congestive heart failure), impaired renal function (creatinine
.2.0 mg/dL), acute coronary syndromes (unstable angina
or acute MI) and severe valvular disease (aortic valve area
,0.7 cm2 or mitral valve area ,1.25 cm2) (478). It is
recommended that the individual practitioner appropriately
assess the cost and benefit relationship when selecting
contrast agents in any individual patient and that a strategy
of reserving nonionic agents for patients who are at high risk
of adverse reactions is prudent and cost-effective.
6. Pharmacologic Assessment of Coronary Spasm
a. Coronary Artery Spasm
Epicardial coronary arteries exhibit vasoactivity similar to
that of many systemic arteries of a similar caliber. The
presence of atherosclerotic plaque is associated with endo-
thelial dysfunction, which can increase or decrease segmen-
tal responses to endogenous and exogenous vasoactive sub-
stances. Thus, patients with coronary atherosclerosis may
have spontaneous increases in coronary vasomotor tone,
resulting in myocardial ischemia. These regional coronary
vasospastic events can cause ischemia associated with a
variety of ST and T-wave changes. Tobacco and cocaine
abuse are important risk factors for the provocation of
vasospasm. Provocative testing with either methylergono-
vine or acetylcholine often demonstrates the presence of
coronary spasm. Although vasomotion can result in as much
as a 20% change in lumen diameter, coronary spasm is
considered to be present when a reduction in lumen caliber
of .50% occurs during a provocative test and reversal is
achieved with intracoronary nitroglycerin.
Prinzmetal variant angina is a clinical syndrome occurring
in a small percentage of patients without angiographic
evidence of significant stenosis or normal angiograms in
whom ischemia is caused by severe spasm of an epicardial
coronary artery. Variant angina, as described by Prinzmetal
in 1959 (483), is an unusual syndrome characterized by
ischemic myocardial pain that usually occurs at rest, with
accompanying ECG ST-segment elevation. Basal coronary
artery vasoreactivity and tone are increased in variant an-
gina. Studies using 123I metaiodobenzylguanidine (123I
MIBG) SPECT demonstrate regional myocardial sympa-
thetic dysinnervation in patients with variant angina (484).
Tobacco and cocaine may cause episodes of variant angina,
the latter because it blocks presynaptic uptake of norepi-
nephrine and dopamine, thereby facilitating alpha-
adrenergically mediated vasospasm. Cardiac arrhythmias,
including ventricular tachycardia and fibrillation, heart
block, acute infarction and sudden death, may occur in
association with variant angina. Studies using 123I BMIPP,
a branched fatty acid, have demonstrated myocardial injury
in association with some episodes of variant angina (485).
b. Provocative Testing for Spasm
Of the tests available to demonstrate coronary spasm,
provocation by ergonovine maleate, methylergonovine mal-
eate, acetylcholine or hyperventilation are the most useful.
Ergonovine maleate for injection is no longer available, and
the availability of methylergonovine is limited. The intra-
venous administration of incremental doses of methyler-
gonovine starting at 0.05 mg to a maximum of 0.40 mg is
both sensitive and specific, and there is an inverse relation-
ship between the dose required to provoke spasm in the
laboratory and the frequency of spontaneous episodes expe-
rienced by the patient. To ensure a valid test, nitrates and
calcium antagonists must be withdrawn for $48 h before
testing. Women are more sensitive than men to methyler-
gonovine (486).
The intracoronary route of administration of methyler-
gonovine for provocation of spasm is safe, sensitive and
specific. This route is preferable in hypertensive patients and
affords the opportunity to evaluate the left and right
coronary circulations separately. Small dosing increments of
5 to 10 mg are used, with a total dose not to exceed 50 mg
(487).
Absolute contraindications to methylergonovine include
pregnancy, severe hypertension, severe left ventricular dys-
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function, moderate to severe aortic stenosis and high-grade
left main coronary stenosis. Relative contraindications in-
clude uncontrolled or unstable angina, uncontrolled ventric-
ular arrhythmia, recent MI and advanced coronary disease.
Alternatively, intracoronary acetylcholine can be used as a
provocative test for spasm, and its effectiveness is compara-
ble to methylergonovine. Acetylcholine is infused over
1 min into a coronary artery in incremental doses of 10, 25,
50 and 100 mg. Doses should be separated by 5-min
intervals. The same procedural safeguards must be used with
acetylcholine and methylergonovine (486).
In patients with $1 episode of variant angina per day, the
hyperventilation provocative test is nearly as effective as
methylergonovine in causing vasospasm (488). In patients
with less frequent attacks, hyperventilation is less sensitive.
The test requires a patient to hyperventilate vigorously at 30
respirations per minute for 5 min. With this degree of
hyperventilation, arterial pH will increase to '7.60 and
pCO2 will decrease to '20 mm Hg. Variant angina, if
provoked, will occur during hyperventilation and will sub-
side more rapidly than after methylergonovine infusion. The
cold presser test can also provoke coronary spasm but is less
reliable than pharmacologic techniques.
In patients with ST-segment elevation during episodes of
chest pain and a normal coronary angiogram, provocative
tests are usually not necessary, because ample clinical evi-
dence is present to confirm the diagnosis of coronary spasm.
Recommendations for Pharmacologic Assessment of
Coronary Disease 48 H After Withdrawal of Coronary
Vasodilators
Class I
None.
Class IIa
Recurrent episodes of apparent ischemic cardiac pain
at rest in a patient found to have a normal or mildly
abnormal coronary angiogram and in whom there have
been no clinical observations substantiating the diag-
nosis of variant angina, i.e., ST-segment elevation
during pain. (Level of Evidence: C)
Class IIb
1. Recurrent episodes of ischemic cardiac pain at rest
with associated transient ST-segment elevation in a
patient subsequently found to have a normal or
mildly abnormal coronary angiogram in whom
medical therapy has been unsuccessful in control-
ling symptoms of ischemia. (Level of Evidence: C)
2. After recovery from sudden cardiac death in a
patient subsequently found to have a normal or
mildly abnormal coronary angiogram and no other
detectable significant cardiac disease. (Level of Ev-
idence: C)
Class III
1. Any absolute contraindication to pharmacologic
challenge, including possible pregnancy, severe hy-
pertension, severe left ventricular dysfunction,
moderate to severe aortic stenosis or high-grade left
main coronary stenosis. (Level of Evidence: C)
2. Patients with any relative contraindication to phar-
macologic testing, including uncontrolled or unsta-
ble angina, uncontrolled ventricular arrhythmia,
recent MI or severe three-vessel coronary disease.
(Level of Evidence: C)
APPENDIX C
Alternative Imaging Modalities
1. Coronary Intravascular Ultrasound
The recent development of intravascular ultrasound rep-
resents an emerging alternative to angiography for direct
visualization of coronary anatomy during diagnostic and
interventional catheterization (118,489–491). Unlike an-
giography, which depicts a silhouette of the coronary lumen,
intravascular ultrasound portrays the vessel from a tomo-
graphic, cross-sectional perspective. This orientation en-
ables direct measurements of lumen dimensions, including
minimum and maximum diameter and cross-sectional area.
Measurements obtained by ultrasound are considered more
accurate than angiographic dimensions. In addition to
luminal measurements, the ability of coronary ultrasound to
image the soft tissues within the arterial wall enables
characterization of atheroma size, plaque distribution and
lesion composition during diagnostic or therapeutic cathe-
terization. Accordingly, ultrasound can detect the presence
or absence of structural abnormalities of the vessel wall after
mechanical interventions, including dissections, tissue flaps,
and irregular surface features.
Intravascular Ultrasound Devices
Intracoronary ultrasound equipment consists of two ma-
jor components, a catheter incorporating a miniaturized
transducer and a console containing the necessary electron-
ics to reconstruct an ultrasound image. Modern catheters
typically range in size from 2.9F to 3.5F, a corresponding
diameter of 0.96 to 1.17 mm. Two dissimilar technical
approaches to transducer design have emerged: mechani-
cally rotated imaging devices and a 64-element electronic
array device. Most systems use a monorail design to facili-
tate rapid catheter exchanges.
Artifacts and Limitations
Mechanical transducers may exhibit cyclical oscillations
in rotational speed, with nonuniform rotational distortion
(NURD), which arises from mechanical drag on the cath-
eter driveshaft producing visible distortion. The NURD is
most evident when the driveshaft is bent into a small radius
of curvature by a tortuous vessel and is recognized as
1797JACC Vol. 33, No. 6, 1999 Scanlon and Faxon
May 1999:1756–824 ACC/AHA Coronary Angiography Guidelines
circumferential “stretching” of a portion of the image with
compression of the contralateral vessel wall. An additional
artifact, transducer ring-down, appears in virtually all med-
ical ultrasound devices. This artifact arises from acoustic
oscillations in the piezoelectric transducer material, result-
ing in high-amplitude signals that obscure near-field imag-
ing. All intravascular imaging systems are vulnerable to
geometric distortion produced by oblique imaging. Thus,
when the ultrasound beam interrogates a plane not orthog-
onal to the vessel walls, an artery with a circular lumen
appears elliptical in shape. Repeat ultrasound studies can be
unreliable owing to imprecision in placement of the imaging
transducer in exactly the same location on reimaging.
Safety of Coronary Ultrasound
Although intravascular ultrasound requires intracoronary
instrumentation, initial studies conducted during diagnostic
catheterization demonstrated few serious untoward effects.
Transient coronary spasm occurs in '5% of patients but
usually responds rapidly to administration of intracoronary
nitroglycerin (492). The imaging transducer can transiently
occlude the coronary when advanced into a tight stenosis or
a small distal vessel, but patients generally do not experience
chest pain if the catheter is promptly withdrawn. In inter-
ventional practice, operators have safely used coronary
ultrasound after most types of procedures, including balloon
angioplasty, atherectomy, rotablation and stent deployment.
Despite the relative safety of coronary ultrasound, any
intracoronary instrumentation carries the potential risk of
intimal injury or acute vessel dissection. Although many
centers use intravascular ultrasound during diagnostic cath-
eterization, most laboratories limit credentialing for intra-
vascular imaging procedures to personnel with interven-
tional training. In the unlikely event of intimal disruption,
this safety measure ensures that the necessary personnel and
equipment are immediately available to initiate appropriate
interventional corrective action.
Quantitative Luminal Measurements
Diagnostic and interventional practitioners routinely use
luminal measurements to evaluate the severity of stenoses,
determine the size of the “normal” reference segment and
assess gain in lumen size achieved by revascularization.
Comparisons of vessel dimensions by angiography and
intravascular ultrasound generally reveal a limited correla-
tion, particularly for vessels with an eccentric luminal shape
(490,492–494), presumably owing to the inability of an-
giography to accurately portray the complex, irregular cross-
sectional profiles of atherosclerotic vessels.
Angiographically Unrecognized Disease
Intravascular ultrasound commonly detects atheroscle-
rotic abnormalities at angiographically normal coronary sites
(493–495). The long-term implications of these findings
remain uncertain. However, Little and others (344) have
demonstrated that plaques with minimal to moderate an-
giographic narrowing are the most likely to rupture and
cause acute MI. Accordingly, the presence of angiographi-
cally occult coronary disease may have important prognostic
significance. Studies are currently under way to determine
the predictive value of intravascular ultrasound in determin-
ing the prognosis in patients with coronary disease.
Lesions of Uncertain Severity
Despite thorough radiographic examination with multi-
ple projections, angiographers commonly encounter lesions
that elude accurate characterization. Lesions of uncertain
severity often include ostial lesions and moderate stenoses
(angiographic severity ranging from 40% to 70%) in patients
whose symptomatic status is difficult to evaluate. For these
ambiguous lesions, ultrasound provides tomographic mea-
surements, enabling quantification of the stenosis indepen-
dent of the radiographic projection (476,492–494). Bifur-
cation lesions are particularly difficult to assess by
angiography because overlapping side branches often ob-
scure the lesion.
Cardiac Allograft Disease
Identification of atherosclerotic lesions in cardiac allo-
graft recipients represents a particularly challenging task
(495,496). These patients may have diffuse vessel involve-
ment that for reasons already enumerated conceals the
atherosclerosis from angiography. Many large transplant
centers now routinely perform intravascular ultrasound as an
annual catheterization in all cardiac transplant recipients.
Recent studies have revealed two pathways to transplant-
associated atherosclerosis, with some patients receiving
atherosclerotic plaques from the donor heart, whereas others
develop immune-mediated vasculopathy (496).
Intravascular Ultrasound and Restenosis
The relatively poor correlation between angiographic and
ultrasonic dimensions after angioplasty raises the issue of
whether poor long-term results represent recurrence of disease
or an inadequate initial procedure. Several multicenter clinical
trials have shown that certain findings on ultrasound, such as
minimal lumen diameter and plaque buildup, can predict
restenosis after intervention (497,498). Ultrasound has also
been shown to determine if “vascular remodeling” has occurred
in de novo lesions or after PTCA (499).
Wall Morphology After Angioplasty
Pre- and post-PTCA imaging reveals that plaque fissur-
ing occurs in 40% to 80% of patients, stretching of the vessel
wall occurs in at least 20% of patients, and apparent
“compression” of the atheromatous material occurs in at
least 10% (500,501). More recent studies using automatic
pullback devices (which withdraw the ultrasound catheter at
a constant rate) have shown that “compression” may repre-
sent redistribution of plaque along the long axis of the
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vessel. The prognostic significance of different mechanisms
of luminal enlargement is under investigation.
Guidance of Directional Atherectomy
Intravascular ultrasound has been used to guide direc-
tional coronary atherectomy. By determining the location
and composition of the target atheroma, ultrasound poten-
tially improves preprocedural planning and may aid intra-
procedural decision making by assisting in device orienta-
tion and extent of cuts (459,502).
Guidance of Rotational Atherectomy
Rotational ablation uses a high-speed, diamond-coated
burr to debulk atheromata within coronary stenoses. This
approach has been proved effective for removing superficial
calcium from stenotic vessels. There is a poor correlation
between ultrasound and fluoroscopy in assessment of the
presence and amount of calcification (503,504). Accordingly,
the demonstration of a heavily calcified vessel by ultrasound
permits the operator to use rotational ablation in settings in
which it may be particularly efficacious (505). Ultrasound is
often used to size the vessel and determine the largest burr that
can be safely used. Observational ultrasound studies to date
have confirmed that ablation of plaque constitutes the primary
mechanism of rotational atherectomy, particularly the more
fibrotic or calcified components of the lesion.
Coronary Stent Deployment
Intravascular ultrasound has significantly influenced un-
derstanding of the mechanism underlying stent deployment
and is now widely used in guiding clinical procedures. A
large, nonrandomized ultrasound study of angiographically
guided stent deployment revealed an average residual ste-
nosis of 51% when ultrasound was used to compare mini-
mum stent diameter with reference-segment diameter
(506). Additional balloon inflations resulted in a final
ultrasound that showed an average residual stenosis of 34%
with a negative final angiographic percent stenosis (27.0%).
Ultrasound was used to guide deployment; this study
reported a subacute thrombosis rate of only 0.3% with
antiplatelet agents alone.
Optimal goals for ultrasound-guided stent deployment are
yet to be determined. Most authorities recommend that
operators attempt to achieve a minimum percentage of
reference-vessel diameter within the stent, usually $70%. In
addition, most protocols require nearly complete apposition,
with separation of any strut from the vessel wall not .0.3 mm.
In stenting as a bailout for coronary dissection, intravas-
cular ultrasound can prove helpful in determining the
longitudinal extent of dissection before placement of a stent
for vessel salvage.
Future Directions of Intravascular Ultrasound
During the next several years, technological advances in
intravascular imaging are anticipated, including further
reductions in the size of imaging catheters to guidewire
dimensions (,0.025 in. [0.06 cm]). Higher-frequency
transducers (e.g., 35 MHz) are now available and should
improve resolution further. Combination devices are also
undergoing refinement, permitting online guidance dur-
ing revascularization procedures. An angioplasty balloon
with an ultrasound transducer has been approved by the
Food and Drug Administration, and a transducer com-
bined with an atherectomy device is under development
(507). As a consequence of refinements in equipment and
knowledge derived from clinical investigations, it is
anticipated that intravascular ultrasound will play an
increased role in the diagnosis and therapy of coronary
disease in the near future.
Recommendations for Coronary
Intravascular Ultrasound
Class I
None.
Class IIa
1. Evaluation of lesion severity at a location difficult
to image by angiography in a patient with a positive
functional study and a suspected flow-limiting ste-
nosis. (Level of Evidence: C)
2. Assessment of a suboptimal angiographic result
after coronary intervention. (Level of Evidence: C)
3. Diagnosis and management of coronary disease
after cardiac transplantation. (Level of Evidence: C)
4. Assessment of the adequacy of deployment of the
Palmaz-Schatz coronary stent, including the extent
of stent apposition and determination of the mini-
mum luminal diameter within the stent. (Level of
Evidence: B)
Class IIb
1. Determination of plaque location and circumferen-
tial distribution for guidance of directional coro-
nary atherectomy. (Level of Evidence: C)
2. Further evaluation of patients with characteristic
anginal symptoms and a positive functional study
with no focal stenoses or mild CAD on angiogra-
phy. (Level of Evidence: C)
3. Determination of the mechanism of stent restenosis
(inadequate expansion versus neointimal prolifera-
tion) and to enable selection of appropriate therapy
(plaque ablation versus repeat balloon expansion).
(Level of Evidence: C)
4. Preinterventional assessment of lesional character-
istics as a means to select an optimal revasculariza-
tion device. (Level of Evidence: C)
Class III
1. When angiographic diagnosis is clear and no inter-
ventional treatment is planned.
2. Intracoronary Doppler Ultrasound
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2. Intracoronary Doppler Ultrasound
Intracoronary Doppler Velocimetry
The development of small intracoronary devices incorpo-
rating a Doppler flow transducer has made feasible the
physiological assessment of coronary blood flow in vivo
during diagnostic or therapeutic catheterization. Doppler
flow probes are commonly used to evaluate ambiguous
lesions and to determine the success of coronary interven-
tions at restoring normal flow reserve.
Principles of Doppler Flow Measurement
Blood flow velocity is calculated by the Doppler equation.
Analysis of the Doppler coronary blood flow signal typically
relies on one of two common techniques. The zero-
crossings method is simple and accurate in areas of laminar
flow but is imprecise in nonlaminar flow such as that which
occurs distal to stenosis and in the measurement of peak
velocities (508). The second method of signal processing
uses spectral analysis with the fast Fourier transformation
(FFT). In vitro, animal and human models have consistently
shown that FFT analysis is more accurate and correlates
more closely with implanted electromagnetic flowmeter
measurements in animals (509,510), and thus, the FFT has
become the method of choice for intracoronary use.
Intracoronary Doppler Equipment and Techniques
The most commonly used device employs a miniaturized
Doppler-equipped guidewire with a 12-MHz piezoelectric
transducer integrated into the tip. The major advantages of
this system include the small profile (0.018-in. [0.045 cm]
or 0.014-in. [0.035 cm] diameter), favorable handling char-
acteristics, and a negligible effect on luminal cross-sectional
area, allowing the operator to advance the device into distal
coronary segments and beyond stenoses. In addition, the
guidewire device accommodates typical over-the-wire or
monorail balloon angioplasty systems, thus enabling diagnostic
and therapeutic procedures without exchange of the wire.
On this device, the transducer uses a pulsed waveform
Doppler that samples 5.2 mm beyond the guidewire tip at
an angle of 14° on either side of the centerline of flow using
FFT signal processing and an adjustable pulse-repetition
frequency ranging from 16 to 94 kHz. This system has been
validated in in vitro and in vivo models by comparison with
electromagnetic quantitative voltmetry (511). These studies
have shown that blood flow velocity measurements by the
Doppler guidewire exhibit a close correlation to measured
flow (r2 5 0.85 to 0.99).
Safety
This device has proved safe in a large number of proce-
dures, and the risks of its use are similar to those of other
intracoronary instrumentation (512).
Limitations of Doppler Flow
The Doppler guidewire device, like all similar catheters, is
highly dependent on positioning within the coronary, and
care and experience are necessary to obtain reliable mea-
surements. Various artifacts related to wall motion and
signals from adjacent venous structures can often be elimi-
nated by repositioning the device to a more central location
or by adjusting the J curve of the tip.
The measured velocity (V) is highly dependent on the
angle of incidence (F). Alignment of the transducer to the
direction of blood flow (F 5 0°) is a requisite for accurate
velocity measurement. The greater the angle, the smaller its
cosine and the less accurate is the measurement of flow
(508). The tight spatial coupling of transducer position to
the sampled volume, which limits sampling of the blood
volume, may not accurately reflect the velocity of the whole
bloodstream at the interrogated location (513). This prob-
lem is particularly important in zones of turbulent flow
(such as areas distal to severe stenoses) or lumen segments
with odd geometric configuration, where different strata of
the bloodstream may move at different velocities.
The blood flow velocity measured in coronary arteries is
used as a surrogate for the actual volumetric flow. The two
parameters are related by the formula:
Q 5 k 3 A 3 V
where Q is the volume of flow in mL/s, V is the velocity in
cm/s, A is the cross-sectional area of the blood vessel in cm2,
and k is the constant that adjusts for mean velocity. In a
conduit with a relatively constant cross-sectional area, the
velocity is directly related to the volumetric flow. Con-
versely, under conditions of constant blood flow, velocity is
inversely related to vessel cross-sectional area. However, it
must be remembered that velocity may not represent a good
surrogate for flow if the cross-sectional area changes or the
Doppler probe moves slightly and lies in an adjacent
coronary segment with a different cross-sectional area.
Coronary Flow: Normal and Abnormal
Flow patterns differ substantially among different coro-
nary segments. The proximity of most of the left coronary
artery to the transmitted pressure from the left ventricle has
a major effect on flow characteristics, whereas the right
coronary artery is subject to much smaller variations. Under
normal conditions, flow in the left coronary artery and its
branches occurs primarily in diastole, whereas the right
coronary artery exhibits a more homogenous distribution of
flow throughout the cardiac cycle. Pulsatile flow is presumed
secondary to the “reservoir” that is compressed during the
systolic phase of the cardiac cycle, which subsequently is
refilled during the following diastole (514).
The pulsatile pattern of flow represents one method for
Doppler assessment of a coronary stenosis, because a hemo-
dynamically important narrowing significantly depresses the
diastolic component (515,516). Under these circumstances,
most of the flow occurs in systole, although average peak
velocity may remain relatively preserved. The redistribution
of flow is a marker for the hemodynamic significance of the
lesion, although this approach is limited to vessels with a
systolic-to-diastolic flow distribution characteristic of the
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left coronary. Preliminary data suggests that the relative
contribution of collateral flow to the perfusion of an
ischemic territory may be assessed by Doppler flow mea-
surements (517). The venous flow pattern in the heart has
mostly a systolic component, while saphenous vein grafts
and arterial conduits behave according to the pattern of flow
in the native artery to which they are grafted.
In the human coronary artery, average peak velocity varies
between 9 and 70 cm/s. In an individual patient, this value
is similar among the three coronary vessels (516). The value
of peak flow in the assessment of coronary flow is limited,
because a number of confounding variables (such as cardiac
output, vessel cross-sectional area and abnormal myocar-
dium) affect the average peak velocity. Despite branching,
experimental data demonstrate that the coronary arterial
tree maintains relatively constant flow velocities (518). This
phenomenon can be used to characterize hemodynamically
significant lesions as a reduction in the velocity (and
volume) of flow in the distal portion of the stenotic artery.
This translates into an abnormally high ratio of proximal to
distal average peak velocities (516,519).
Assessment of Intermediate Coronary Lesions
In clinical practice, intermediate lesions, typically with a
30% to 70% diameter reduction, are difficult to assess by
angiography alone. The intracoronary Doppler guidewire
has been used to evaluate such lesions by providing physi-
ological measurements of stenosis severity. Measurement of
proximal and distal diastolic-to-systolic velocity ratios
(DSVRs) can be obtained and a proximal-to-distal (P/D)
ratio of average peak velocities calculated (463,520).
In evaluating a stenosis, the final assessed parameter is
CFR. Doppler assessment of CFR requires measurement of
the ratio of hyperemic to basal flow after the pharmacolog-
ical stimulation (usually by adenosine) of maximal blood
flow (521). The absence of an appropriate increase in
velocity during hyperemia constitutes abnormal flow re-
serve. However, other factors, for example, left ventricular
hypertrophy or myocardial scar, are associated with abnor-
mal CFR (521,522). Despite these limitations, the CFR
parameter often provides valuable information.
In clinical practice, a DSVR ,1.8 for the left coronary
artery, a P/D ratio .1.7, and a CFR ,2.0 are indicators of
hemodynamically significant lesions. The validity of these
observations has been shown in studies comparing Doppler
with SPECT 201Tl imaging, which report an overall predictive
accuracy of 94% (523,524). Donohue et al. (525) compared
angiographic findings with translesional pressure gradients and
Doppler wire measurements. There was a highly statistically
significant difference in the distal average peak velocity, DSVR,
and CFR values in patients with lesional gradients
.20 mm Hg compared with those with lesser gradients.
Intracoronary Doppler measurements can also identify
patients who do not need revascularization. Mozes et al.
(53) used Doppler-derived measurements to defer interven-
tion in 42 patients with intermediate lesions who subse-
quently showed an excellent event-free survival at 10 6 6
months of follow-up. Similar results were reported by
Lesser et al. (526). Although additional work is required
before this technique can be more widely adopted, these
data support the hypothesis that patients can be stratified in
the catheterization laboratory with the information derived
from intracoronary Doppler measurements.
Flow Alterations After Angioplasty
Doppler flow measurements are sometimes used to assess
the results of percutaneous revascularization. Angiographi-
cally successful coronary revascularization is usually associ-
ated with restoration of normal Doppler flow characteristics,
including normalization of the P/D ratio and a return of
diastolic predominance. In some patients, the CFR normal-
izes immediately after angioplasty, but flow reserve must be
interpreted cautiously, because angioplasty may increase
absolute flow velocity secondary to transient, postischemic
(postballoon) hyperemia (519,527).
The continuity equation can be used to estimate the
residual lumen narrowing:
APVL 3 AL 5 APVD 3 AD
where APV is average peak velocity, AL is area within the
lesion, and AD is area distal to the lesion.
The calculated diameter reflects the actual channel
through which blood flows rather than the anatomic dimen-
sions. Nevertheless, this value can be useful in evaluating the
functional stenosis after intervention, particularly in seg-
ments poorly visualized angiographically (such as bends and
superimposed vessels) (528,529). Onodera et al. (530) re-
ported that postintervention Doppler flow characteristics
correlate with the relative risk of restenosis. These investi-
gators observed a higher proximal and distal average peak
velocity in arteries that subsequently developed restenosis,
independent of angiographic stenosis severity immediately
after intervention.
Recommendations for Intracoronary Doppler
Ultrasound
Class I
None.
Class IIa
Assessment of the physiological effects of intermediate
coronary stenoses (30% to 70% luminal narrowing) in
patients with anginal symptoms. Doppler velocimetry
may also be useful as an alternative to performing a
noninvasive functional study to determine whether an
intervention is warranted for intermediate lesions (or
when the functional study is ambiguous). (Level of
Evidence: C)
Class IIb
1. Evaluation of the success of percutaneous coronary
revascularization in restoring flow reserve and to
predict the risk of restenosis. (Level of Evidence: C)
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2. After cardiac transplantation, diagnosis of impaired
CFR in patients with anginal symptoms but no
apparent angiographic culprit lesion. (Level of Ev-
idence: C)
3. Assessment of the severity of coronary flow abnor-
malities in patients with anginal symptoms and a
positive noninvasive functional study but no appar-
ent angiographic lesion. (Level of Evidence: C)
Class III
Routine assessment of the severity of angiographic
disease in patients with a positive noninvasive func-
tional study. (Level of Evidence: C)
3. Coronary Angioscopy
Coronary angioscopy uses visible light conducted through
fiberoptic filaments to provide direct visual assessment of
the surface characteristics and intraluminal morphology in
vivo. The images appear in color on a television monitor,
which enables examination of the hue of the target lesion
and associated plaques. Although difficult to use, angioscopy
allows the differentiation of platelet-rich from fibrin-rich
thrombus, and it may provide evidence of atheroma rupture,
intraplaque hemorrhage, and coronary dissection. Accordingly,
this diagnostic imaging modality yields information on the
pathogenesis of acute coronary syndromes (531–536).
Angioscopy Equipment and Technique
All angioscopes require a blood-free field for clear visu-
alization of the arterial wall. This is obtained by inflating a
proximal balloon to temporarily occlude blood flow, fol-
lowed by continuous saline irrigation, which requires a
second catheter lumen. Two additional lumens are required
for the optical fibers, one for visualization and another to
serve as a light source. Videotape recording allows for more
detailed offline analysis. A commonly used device is a
120-cm-long 4.5 monorail catheter with an imaging bundle
containing 3,000 fibers that permits a viewing arc of '55°
and a depth-of-field of 0.5 mm. A video camera displays the
images in real time on a color monitor, while videotape
recording allows for more detailed offline analysis.
Angioscopy of Unstable Coronary Syndromes
Small-scale studies of fiberoptic angioscopy demonstrate
differences in the intraluminal appearance of stable versus
unstable coronary lesions (537). An intraoperative study of
32 patients showed distinctive intimal abnormalities in all
10 patients with unstable angina: four patients had “complex
plaque” and seven had overt intraluminal thrombus. Neither
complex plaques nor thrombi were observed by angioscopy
in any patient with stable coronary disease. These findings
were later confirmed by percutaneous angioscopy (538). In
16 patients with unstable angina, 50% had thrombus and
14% had overt dissection. Neither thrombus nor dissection
was seen in any of the four patients with stable angina.
In addition to identifying the presence of thrombus,
angioscopy can differentiate platelet-rich from fibrin-rich
thrombi. Mizuno et al. (539) performed angioscopy in 15
patients with unstable angina and 16 patients with acute
MI. Angioscopy identified intraluminal thrombus in 29 of
31 patients. However, the typical thrombus in patients with
unstable angina was grayish-white in color, suggesting the
predominance of platelets, whereas in patients with acute
MI, angioscopy identified a preponderance of red thrombi,
suggesting an erythrocyte and fibrin-rich clot. Angioscopy
can distinguish other surface features of coronary athero-
mata. Stable plaques are recognized by their elevated con-
tour, smooth configuration, and yellowish-white color. In a
study of 199 patients, those with predominantly yellow
plaques were found to have higher LDL cholesterol and
apolipoprotein B levels (540).
Angioscopy During Interventions
Assessment of lesions before or after coronary interven-
tion represents the most commonly reported application of
coronary angioscopy (533,534,536,538,541,542). Angios-
copy after balloon angioplasty demonstrates that dissections
and thrombus are present in almost all cases. However, no
prospective data exist that demonstrate a different outcome
for patients on the basis of angioscopic findings. The
preprocedural identification of thrombus may also prove
useful in selecting candidates for coronary stenting and for
the use of any of the new antiplatelet agents. Although the
value of angioscopy in identifying thrombus is well estab-
lished, no data exist to suggest that angioscopy can reduce
stent-related complications.
Limitations of Coronary Angioscopy
Despite recent technical advances, angioscopy is still
limited to the proximal and mid portions of relatively
straight, large epicardial coronary arteries. Furthermore, the
rapid development of ischemia during balloon inflation
limits the time of examination. For successful imaging,
lesions need to be located $20 mm distal to the balloon site,
which makes it impossible to visualize ostial or very proxi-
mal lesions. Angioscopy shows only the surface character-
istics of plaques and cannot discern the underlying atheroma
morphology. Accordingly, it remains unproved whether
visualization of surface anatomy alone warrants the time,
expense and risk of angioscopy. In addition, occlusion of
coronary flow may produce important imaging artifacts.
A recently published study of the European Working
Group on Coronary Angioscopy (543) demonstrated that
the identification of red thrombus and dissection has
relatively close interobserver agreement. However, other
angioscopic diagnoses have wide interobserver variability.
Recommendations for Coronary Angioscopy
Class I
None.
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Class II
None.
Class III
Coronary angioscopy should be considered a research
tool for which there are no established clinical indica-
tions.
4. Fractional Flow Reserve
The measurement of pressure gradients across coronary
stenoses was the earliest method used to assess the adequacy
of coronary angioplasty. However, because of the size of the
catheter and changes in technology, angiographic and now
ultrasonic assessments are more commonly used. Recently,
small catheters and guidewires have been developed to more
accurately measure pressure gradients across stenoses before
and after interventional procedures. Pijls and colleagues
demonstrated that just as with CFR measurements by
Doppler ultrasound, fractional flow reserve is useful in
assessing the severity of a coronary stenosis (544–549). The
ratio of the mean pressure distal to a coronary stenosis to
that proximal to the stenosis, usually measured through the
guiding catheter after maximal vasodilation induced by
adenosine or papaverine, can assess the severity of the
stenosis. When this ratio falls below 75%, there is an 88%
sensitivity and an 84% specificity for an abnormal exercise
test. Similar correlations have been made with PET and
CFR measured by Doppler ultrasound. The technique is
easier to use than Doppler ultrasound. Although it is still in
development and validation, it appears likely to be a useful
tool in the future to assess coronary stenoses.
APPENDIX D
APPENDIX E
Elements of a Coronary Angiographic Report
This appendix lists certain items that may be useful if
included in the coronary angiographic report. Practice will
vary from laboratory to laboratory. Although this list is not
inclusive, it should provide for adequate transmission of
useful clinical information as well as for other purposes of
medical record keeping.
Commercial coronary angiography laboratory systems
provide for a semiautomated report to be generated
promptly after the procedure. These also may include a
graphic presentation of the coronary arterial anatomy.
This is often a useful summary presentation of the
examination.
I. Patient demographic information to include
Age
Gender
Height
Weight
Body surface area
Medical record number
Referring physician
Laboratory number
II. Operators and laboratory assistants
III. Indications for angiography
IV. Technical procedures to include
Informed consent
Anesthetic technique
Vascular approach and location
Catheter selection
Anatomic site of cannulations achieved
Injection technique
Contrast agent used
Volume of contrast agent used
Views recorded
Filming or recording modalities used
Baseline hemodynamics and alterations, if any
Radiographic views recorded
Preprocedure or intraprocedure medications
administered
V. Hemodynamic data
Pressures
Cardiac outputs, if measured
VI. Angiographic interpretation
General considerations
Adequacy of examination
General anatomic presentation
Coronary artery arterial analysis by segment
The map depicted in Appendix A allows for
examination of 29 named segments. Each can be
judged for size, location and extent of arterial
lesions.
Canadian Cardiovascular Society Classification of Angina Pectoris
Class Description of Stage
Class I Ordinary physical activity does not cause angina,
such as walking or climbing stairs. Angina occurs
with strenuous, rapid, or prolonged exertion at
work or recreation.
Class II Slight limitation of ordinary activity. Angina occurs
on walking or climbing stairs quickly, walking
uphill, walking or climbing stairs after meals, in
the cold, in wind, under emotional stress, or only
during the first few hours after awakening.
Walking .2 blocks on the level and climbing
.1 flight of ordinary stairs at a normal pace
under normal conditions.
Class III Marked limitations of ordinary physical activity.
Angina occurs on walking 1–2 blocks on the
level and climbing 1 flight of stairs in normal
condition and at a normal pace.
Class IV Inability to carry on any physical activity without
discomfort: anginal symptoms may be present at
rest.
From Campeau (87).
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Segments uninvolved by significant lesions
should also be mentioned. The presence of
features such as clot, aneurysm, collaterals and
spasm should also be noted.
Analysis of vascular conduits (coronary bypass
grafts, left internal thoracic grafts) should be
assessed to include patency of the origin, body
and anastomotic site, flow pattern and other
abnormalities.
Analysis of left ventriculogram to include
Adequacy of examination
Rhythm
Diastolic appearance
Systolic appearance
Global function
Focal abnormality
Mitral and aortic valve function
Unusual features
Clots
Masses
Aneurysms
VII. Diagnosis
VIII. Comments (if necessary)
IX. Recommendations (may or may not be included)
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transluminal extraction, for vein graft
atherosclerosis, 1774
Atheroma, 1759
location and composition of, intravascular
ultrasound determination of, 1798
rupture, 1801
size, characterization of, 1797
surface features of, angioscopy differentiation of, 1802
Atheromatous material, compression of, 1798
Atherosclerosis. See also Coronary artery disease; Plaque
allograft, intravascular ultrasound of, 1798
at angiographically normal coronary sites,
intravascular ultrasound detection of, 1798
coronary angiography for, 1764
coronary artery disease from, in hypertrophic
cardiomyopathy, 1790
mild, inability of coronary angiography to identify,
1794
progression of, after revascularization, 1774
saphenous vein graft, 1774
vasomotor tone in, 1796
vein graft, treatment of, 1774
Atresia, congenital, use of coronary angiography in, 1788
B
Balloon, angioplasty, use with ultrasound transducer,
1799
BARI (Bypass Angioplasty Revascularization
Investigation) Study group, 1759
BARI investigators, coronary artery map used by,
1791f, 1792t
BARI registry, 1774
BARI trial, standardization of nomenclature, 1791
Beta-adrenergic blocking agents, 1761
for angina
stable, 1766
unstable, 1772t
for myocardial infarction
non–Q-wave, 1783
survival rates related to, 1784
Bifurcation lesions, intravascular ultrasound detection
of, 1798
Blood flow, 1759. See also Coronary flow reserve
abnormalities, severity of, intracoronary Doppler
ultrasound assessment of, 1801
alterations, after angioplasty, Doppler assessment
of, 1801
assessment of, 1759
constant, 1800
Doppler signal, 1799
normal, restoring of, 1776
obstruction of, 1770
redistribution of, 1800
velocity, in coronary arteries, 1800
Brachial artery, percutaneous or cutdown techniques
from, 1759
Braunwald classification, for angina pectoris patients,
1771
Bruce protocol, influences of, in angina, stable, 1766
Bundle branch block, 1777
in myocardial infarction, 1776
recommendations for coronary angiography
during initial management, 1779
patients presenting in emergency department with,
angiography for, 1776
Bypass Angioplasty Revascularization Investigation.
See BARI
C
CABG. See Surgery, coronary artery bypass
CAD. See Coronary artery disease
Calcification
assessment of, 1798
coronary, angiography for, 1769
Calcium channel blockers
for angina
stable, 1766
unstable, 1772t
in non–Q-wave myocardial infarction, 1783
Caliper, digital, variability of, 1792
Caliper measurements, compared with quantitative
coronary angiography, 1793
Canada
inappropriate angiography performed in, 1763
rates of angiography performed in, 1762
Canadian Cardiovascular Society (CCS), 1759
class III angina, recommendations for coronary
angiography in, 1769
Classification of Angina Pectoris, 1803t
Cardiac arrest. See also Sudden death
out-of-hospital, survivors of, angiography for, 1768
Cardiac catheterization, 1759. See also Angiography
emergency, for unstable angina, 1771, 1772
filmless, conversion to, 1793
interventional, 1797
left-heart, for hemodynamic assessment of
congenital heart disease, 1789
after myocardial infarction, determinants of
mortality by, 1784
predictors of manor complications after, 1760, 1760t
risks related to, 1759, 1759t. See also Risk factors
Cardiac transplantation. See Heart transplantation
Cardiogenic shock. See Shock, cardiogenic
Cardiologist, patients cared for by, frequency of
angiography in, 1763
Cardiomyopathy
dilated, 1789
hypertrophic. See also Hypertrophy
coronary angiography in, 1790
ischemic, 1789
risk of, angiography and, 1760t
CASS (Coronary Artery Surgery Study), 1759
definition of anginal type, 1765
standardization of nomenclature, 1790
Catheter
for fractional flow reserve measurement, 1802
intravascular, insertion of, 1759
intravascular ultrasound, 1797
Catheter-based techniques
abrupt closure after, 1774
risk of reoperation in, 1774
Catheter lumen, for angioscopy, 1801
Catheterization. See Cardiac catheterization
CAVEAT, 1774
CCS. See Canadian Cardiovascular Society
CD-R, 1794
CD-ROM, 1794
Cerebrovascular accident, risk for, 1760t
Charge information, 1763. See also Cost
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Chest pain. See also Angina pectoris
causes of, 1770
ischemic, 1775, 1776
nonspecific, 1765
angiography for, 1769–1770
cardiac causes of, 1769
medical therapy for, 1770
noncardiac causes of, 1769–1770
terms related to, 1769
Circumflex artery, 1788
anatomic variation, 1759
circulation, 1759
Class I conditions, 1760t
congenital heart disease, use of coronary
angiography in, 1788–1789
congestive heart failure, coronary angiography in, 1789
coronary angiography for, 1790
digital imaging of coronary angiography, 1794
as indication for angiography, 1758
known or suspected coronary artery disease,
recommendations for coronary angiography in,
1769
myocardial infarction
coronary angiography coupled with intent to
perform primary PTCA in, 1779
recommendations for coronary angiography
during hospital management phase, 1784
recommendations for coronary angiography
during risk stratification phase, 1785
recommendations for early coronary angiography
in, 1781
noncardiac surgery, recommendations for coronary
angiography in perioperative evaluation before
or after, 1786
nonspecific chest pain, coronary angiography for,
1770
recommendations for coronary angioscopy in, 1802
recommendations for intravascular Doppler
ultrasound, 1801
recommendations for intravascular ultrasound in, 1799
recommendations for pharmacologic assessment of
coronary artery disease 48 H after withdrawal
of vasodilators, 1796
revascularization ischemia, coronary angiography in
patients with, 1775
unstable coronary syndromes, recommendations for
coronary angiography in, 1772–1773
valvular heart disease, coronary angiography in,
1788
Class II conditions, 1760t
as indication for angiography, 1758
myocardial infarction, recommendations for early
coronary angiography in, 1780
recommendations for coronary angioscopy in, 1802
Class IIa conditions
congenital heart disease, use of coronary
angiography in, 1789
congestive heart failure, coronary angiography in,
1789–1790
coronary angiography for, 1790
digital imaging of coronary angiography, 1794
as indication for angiography, 1758
known or suspected coronary artery disease,
recommendations for coronary angiography in,
1768
myocardial infarction
coronary angiography coupled with intent to
perform primary PTCA in, 1779
recommendations for coronary angiography
during hospital management phase, 1784
recommendations for coronary angiography
during risk stratification phase, 1785
noncardiac surgery, recommendations for coronary
angiography in perioperative evaluation before
or after, 1786
nonspecific chest pain, coronary angiography for,
1770
recommendations for intravascular Doppler
ultrasound, 1801
recommendations for intravascular ultrasound in,
1799
recommendations for pharmacologic assessment of
coronary artery disease 48 H after withdrawal
of vasodilators, 1797
revascularization ischemia, coronary angiography in
patients with, 1775
unstable coronary syndromes, recommendations for
coronary angiography in, 1773
valvular heart disease, coronary angiography in, 1788
Class IIb conditions
congenital heart disease
use of coronary angiography in, 1789
as indication for angiography, 1758
known or suspected coronary artery disease,
recommendations for coronary angiography in,
1769
myocardial infarction
coronary angiography coupled with intent to
perform primary PTCA in, 1779
recommendations for coronary angiography
during hospital management phase, 1784
recommendations for coronary angiography
during risk stratification phase, 1785
noncardiac surgery, recommendations for coronary
angiography in perioperative evaluation before
or after, 1786
nonspecific chest pain, coronary angiography for,
1770
recommendations for intravascular Doppler
ultrasound, 1801
recommendations for intravascular ultrasound in, 1799
recommendations for pharmacologic assessment of
coronary artery disease 48 H after withdrawal
of vasodilators, 1796–1797
revascularization ischemia, coronary angiography in
patients with, 1775
Class III conditions, 1760t
congenital heart disease, use of coronary
angiography in, 1789
congestive heart failure, coronary angiography in,
1790
digital imaging of coronary angiography, 1794
as indication for angiography, 1758
myocardial infarction
coronary angiography coupled with intent to
perform primary PTCA in, 1179
recommendations for coronary angiography
during hospital management phase, 1784
recommendations for coronary angiography
during risk stratification phase, 1785
noncardiac surgery, recommendations for coronary
angiography in perioperative evaluation before
or after, 1786
nonspecific chest pain, coronary angiography for, 1770
recommendations for coronary angiography in, 1769
recommendations for coronary angioscopy in, 1802
recommendations for intravascular Doppler
ultrasound, 1801
recommendations for intravascular ultrasound in,
1799
recommendations for pharmacologic assessment of
coronary artery disease 48 H after withdrawal
of vasodilators, 1797
revascularization ischemia, coronary angiography in
patients with, 1775
unstable coronary syndromes, recommendations for
coronary angiography in, 1773
valvular heart disease, coronary angiography in, 1788
Class IV conditions, 1760t
Cocaine abuse, 1770
variant angina from, 1796
Collateral vessels
assessment of, 1759
blood flow, 1795
Doppler assessment of, 1800
presence of, 1795
TIMI flow grades for, 1792
Comorbidities, 1757
Computed tomography. See also Single-photon
emission computed tomography
fast, 1792
Computer storage technology, 1793
Conduits
coronary bypass graft, TIMI flow grades for, 1792
vascular, analysis of, 1803
Conflicts of interest, avoiding of, 1757
Congenital heart defects. See also specific defect
evaluation of, coronary angiography for, 1764
use of coronary angiography in, 1788–1789
recommendations for, 1788–1789
Congestive heart failure. See Heart failure
Continuity equation, for residual lumen narrowing,
1801
Contraindications to coronary angiography, 1760t,
1760–1761
in angina, stress, 1766
Contrast agent
for coronary angiography, 1795
selection of, 1795
injection, 1759
renal insufficiency following, 1761
ionic, 1795
adverse reactions to, 1795
high-osmolar, 1795
nonionic, 1795
adverse reactions to, 1795
costs related to, 1795
low-osmolar, 1795
reaction to, 1761
risk for, 1759t
Contusion, myocardial, coronary angiography in, 1790
Coronary anatomy
in myocardial infarction, angiography of, 1781
visualization of, 1797
Coronary anomalies
congenital heart disease associated with
coronary angiography for, 1789
use of coronary angiography in, 1788
Coronary artery disease (CAD)
angina in, 1765
aortic valve disease with, 1787
assessment of, 1795
in asymptomatic patients, 1765
from atherosclerosis, in hypertrophic
cardiomyopathy, 1790
coronary angiography for
cost-effectiveness, compared with other
procedures, 1764
costs related to, 1763
extent of, definition of, 1759
gastroesophageal reflux and, 1770
identification of, 1784
known or suspected, coronary angiography for
myocardial infarction, 1775–1785. See also
Myocardial infarction
perioperative coronary angiography for patients
undergoing noncardiac surgery, 1785–1787
recurrence of symptoms after revascularization,
1773–1775. See also Revascularization
stable angina, 1765–1770. See also Angina
pectoris, stable
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unstable angina, 1770–1773. See also Angina
pectoris, unstable
left main, 1777
myocardial dysfunction resulting from, 1789
in myocardial infarction, angiography of, 1781
myocardial ischemia secondary to, nonspecific chest
pain from, 1769
noncardiac surgery in patients with, perioperative
coronary angiography for patients undergoing,
1785, 1786
obstructive. See Coronary obstruction
presence of, predictive value of coronary
angiography for, 1794
prognosis of, intravascular ultrasound determination
of, 1798
recommendations for pharmacologic assessment of,
48 H after withdrawal of coronary
vasodilators, 1797
repeat angiography for, 1763
risk factors for, 1780
screening test for, angiography as, 1769
suspected, 1766
symptomatic, 1766
symptoms of, 1764
three-vessel, 1777
treatment decisions, angiography for, 1780
types of, 1765
unstable angina and, management approach, 1771,
1772
Coronary artery dominance, defined, 1791
Coronary artery lesions
composition, characterization of, intravascular
ultrasound for, 1797
description, by location, 1791, 1791f
visualization, inadequate, 1763
Coronary artery patency
in infarct-artery, 1782
late restoration of, 1782
Coronary artery spasm, 1759, 1769, 1795–1796
provocative testing for, 1796
transient, in intravascular ultrasound, 1797
Coronary Artery Surgery Study. See CASS
Coronary artery(ies)
arterial analysis by segment, 1803
blood flow velocity measured in, 1800
major, 1759
Coronary dissection, 1801
Coronary flow reserve (CFR)
after angioplasty, Doppler assessment of, 1801
assessment of, 1792
Doppler, 1800, 1801
fractional flow reserve, 1803
measurement of, 1794, 1802
normal, 1794
stenosis severity and, 1794
Coronary lesions, poor definitions of, 1792
Coronary obstruction
degree of, 1791
presence and extent of, determination of, 1759,
1760
Coronary occlusion
acute, in survivors of out-of-hospital cardiac arrest,
1768
in infarct-related artery, recommendations for
coronary angiography during hospital
management phase in, 1784
total, 1780
Coronary “remodeling,” 1794. See also Ventricular
remodeling
Coronary reocclusion, 1776
PTCA and, 1782
Coronary tree, segments, 1759
Corticosteroids, effect on incidence of anaphylactoid
reactions, 1761
Costs
hospital, for myocardial infarction, effect of
angioplasty on, 1778
related to contrast agents, 1795
related to coronary angiography, 1763
Creatine kinase (CK), level, after catheter-based
revascularization, 1774
Creatine kinase (CK) isoforms, prognosis of unstable
angina and, 1771
Creatine phosphokinase isoforms, 1770
CSS
class I patients, unstable angina in, 1766
class II patients, unstable angina in, 1766
class IV patients, recommendations for coronary
angiography in, 1769
classification of angina, 1766
Cutdown techniques, 1759
D
DANAMI (DANish trial in Acute Myocardial Infarc-
tion), 1780–1781
DANish trial in Acute Myocardial Infarction. See
DANAMI
Data, examination of, 1757
Definitions, related to coronary angiography, 1758,
1759
Demographic information, patient’s, included in
angiography report, 1803
Diabetes
in angina, stable, 1766
renal failure and, 1761
Diagnosis related group. See DRG
Diastolic dysfunction, coronary angiography of, 1789
Diastolic-to-systolic-velocity ratios (DSVR), 1801
Diatrizoic acid (Hypaque 76), adverse reactions to,
1795
DICOM (Digital Imaging and Communication
Standard), 1793
Dicom standard, 1793–1794
Digital angiography, limitations of, 1794
Digital calipers, variability of, 1792
Digital Imaging and Communication Standard. See
DICOM
Digital imaging of coronary angiography, 1793, 1794
DICOM standard, 1793–1794
Discharge. See Hospital discharge
Disclosure statements, providing of, 1757
Dissection, 1759
aortic. See Aortic dissection
Dominance, coronary artery, 1791
Doppler flow probes, intracoronary, limitations, 1794
Doppler ultrasound, intracoronary
assessment of intermediate coronary lesions, 1801
comparison with fractional flow reserve, 1802
coronary flow: normal and abnormal, 1800–1801
equipment and techniques, 1800
flow alterations after angioplasty, 1801
limitations of, 1800
principles of Doppler flow measurement, 1799
recommendations for, 1801–1802
safety, 1800
velocimetry, 1799
DRG (Diagnosis Related Group), diagnosis of
myocardial infarction, 1762
Drug therapy, for myocardial infarction, versus
revascularization, 1781
DSVR. See Diastolic-to-systolic-velocity ratios
Dyslipidemia, in angina, stable, 1766
E
ECG. See Electrocardiography
Echocardiography, 1766. See also Doppler ultrasound;
Ultrasound
in myocardial hibernation, 1789
stress, 1764, 1792
in coronary disease, aortic stenosis and, 1787
Ejection fraction
in hibernating myocardium, 1789
after myocardial infarction
indications for angiography and, 1784
prognosis and, 1781
survival and, 1777, 1783, 1784
Elderly
cardiac catheterization performed in, 1761
hypertension in, aortic dissection related to, 1790
Electrocardiography (ECG)
changes, difficulty in interpreting, 1766
in myocardial infarction, 1775
for unstable angina, 1772t
Emboli, chronic pulmonary, removal of, 1790
Emergency care
angiography, for myocardial infarction, followed by
surgical repair, 1781
bypass surgery, mortality rates, 1779
cardiac catheterization, for unstable angina pectoris,
1771, 1772
PTCA, mortality rates for, 1779
Emergency department
coronary angiography during initial management of
patients in, 1776–1779
recognition and management of myocardial infarc-
tion in
angiography for, 1776
Emergency setting, complications of angiography in,
1760
Employment, return to, 1785
Endocarditis, infective, valve surgery and, preoperative
angiography in, 1787–1788
Endoluminal vascular anatomy, defining of, 1759
Endothelial dysfunction, plaque associated with, 1796
Enzyme elevation, periprocedural, after
revascularization, 1774
Enzyme markers, of myocardial necrosis, 1775
Epicardial coronary arteries, vasoactivity, 1795–1796
See also Coronary artery spasm
Epicardial stenosis, 1794
Equipment
angiographic, resolution of, 1791
coronary angioscopy, 1801–1802
Ergonovine maleate, for provocative testing for
coronary spasm, 1796
Esophageal disorders
motility, 1770
medical therapy for, 1770
nonspecific chest pain from, 1769–1770
European Cooperative Study Group, 1781–1782
European Working Group on Coronary Angioscopy,
1802
Evidence, weighing of, 1758–1759
Evidence A, level of, 1758
Evidence B, level of, 1758
Evidence C, level of, 1758
Exercise testing. See Stress testing
Exertional syndrome, 1770
F
Fast Fourier transform (FFT), in Doppler flow
measurement, 1800
Femoral artery, percutaneous or cutdown techniques
from, 1759
FFT. See Fast Fourier transform
Fiberoptic angioscopy, 1802
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Fibrillation. See Ventricular fibrillation
Fibrinolysis, 1770. See also thrombolytic therapy
Fibrinolytic Therapy Trialists’ Collaborative Group,
1779
Film, cineangiographic, 1793
Fistula, coronary artery, use of coronary angiography
in, 1788
Flow probes, Doppler, 1800
Flowmeter, electromagnetic, 1800
Fluoroscopy, assessment of calcifications by, 1798
Fractional flow reserve, 1803
Frame selection, 1792
Furosemide, 1761
G
Gastroesophageal reflux, chest discomfort from, 1770
Gender issues
cardiac catheterization and, 1761
postoperative angina and, 1774
Generalist, patients cared for by, frequency of
angiography in, 1763
Geometric distortion, 1797
Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary
Arteries study. See GUSTO study; GUSTO
trial
Glycoprotein IIb/IIIa inhibitors
effect on risk of periprocedural enzyme elevation,
1774
for myocardial infarction, 1778
for unstable angina, 1771
Graft. See also Internal mammary artery graft;
Saphenous vein graft
coronary bypass, conduits, TIMI flow grades for,
1791
Graft disease, intravascular ultrasound of, 1798
Graft occlusion, symptoms, 1774
Grainy film, 1791
Guidelines, writing of, 1757
Guidewire
Doppler, 1799, 1800
for fractional flow reserve measurement, 1803
GUSTO (Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded
Coronary Arteries) study, 1762, 1784, 1795
GUSTO-I (Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded
Coronary Arteries) substudy, 1777
GUSTO-IIb trial, 1778
H
Heart failure, 1760t, 1789
complications after coronary angiography and, 1761
contrast agents used for, 1795
diastolic dysfunction, 1790
evaluation of, coronary angiography for, 1764
after myocardial infarction, 1781
outcome and, 1785
systolic dysfunction, 1789
Heart transplantation
angiography and ultrasound in, 1768
coronary angiography before, 1790
evaluation after, recommendations for coronary
angiography in, 1768–1770
use of intracoronary Doppler ultrasound in, 1801
Hemodynamic assessment of congenital heart disease,
left-heart catheterization for, 1789
Hemodynamic complications, risk for, 1760t
Hemodynamic data, included in angiography report,
1803
Hemodynamic instability, 1780
Heparin
intravenous, for unstable angina, 1772t
low-molecular weight, for unstable angina, 1772
for myocardial infarction
after angiography, 1777
non–Q-wave myocardial infarction, 1783
for unstable coronary syndromes, 1780
Hibernation. See Myocardial hibernation
High-risk patients, contrast agents for, 1795
Histamine blockers, 1761
Holter monitoring, 1765
Hospital care, charges for, catheterization laboratory
and ancillary charges and, 1763
Hospital discharge, after myocardial infarction
angiography and, 1776
risk stratification in preparation for, 1783–1784
Hospital-management phase of myocardial infarction,
coronary angiography during, 1776, 1780–
1783
recommendations for, 1783–1785
Hospital stay
effect of angiography on, 1764
for myocardial infarction, effect of angioplasty on,
1778
in unstable angina, effect of urgent angiography on,
1771
Hospitalization, for non–Q-wave myocardial infarc-
tion, 1783
Hypaque 76. See Diatrizoic acid
Hyperemia, 1801
Hypertension, 1760t
in angina, stable, 1766
aortic dissection related to, 1790
diastolic dysfunction in, 1790
Hypertrophy, 1790. See also Cardiomyopathy,
hypertrophic
Hyperventilation, for provocative testing for coronary
spasm, 1797
I
Image
angiographic, archival storage of, 1793
radiographic, recording of, 1759
ultrasound, circumferential stretching of, 1797
Image quality
from digital angiography, 1793
inadequate, 1763
Image resolution, 1791. See also Resolution
Imaging modalities, alternative. See Alternative
imaging modalities
Inpatient complications, 1760t
Inpatient procedures, 1761
Intermediate coronary lesions, assessment of, by
intracoronary Doppler ultrasound, 1800–1801
Internal mammary artery graft, 1759
International differences in use of coronary
angiography, 1762
Interobserver variability, 1792
Interventional angiography, 1783
Intimal abnormalities, angioscopy of, 1802
Intra-aortic balloon pumps, 1778
Intraobserver variability, 1792
Iohexol (Omnipaque), adverse reactions to, 1795
Ionic contrast agents. See Contrast agents, ionic
Ischemia, 1775. See also Myocardial ischemia; Silent
ischemia
assessment of, in valvular heart disease, 1787
defined, 1765
demonstrable, recommendations for coronary
angiography in, 1769
after myocardial infarction, coronary angiography
for, 1785
postrevascularization, recommendations for coronary
angiography in patients with, 1775
recurrent, 1780, 1782
related abnormalities, detection, before noncardiac
surgery, 1786
treatment of, 1767
Ischemic coronary syndromes, unstable, 1770. See also
Angina pectoris, unstable
Ischemic discomfort, in acute coronary syndromes,
1776, 1776f
ISIS II (Second International Study of Infarct
Survival) trial, 1780
Israel, inappropriate angiography in, 1762–1763
J
J curve, 1800
K
Kaiser Permanente hospitals, 1762
Kawasaki disease, coronary angiography in, 1790
L
Laboratory, angiography, commercial, 1803
Laboratory volume
complications related to, 1760
effect on costs, 1763
Laser, excimer, for vein graft atherosclerosis, 1774
Left anterior descending coronary artery (LAD),
circulation, 1759
Left coronary artery
anomalous origin of, use of coronary angiography
in, 1788
DSVR for, 1801
Left-heart catheterization, inpatient, 1761
Life expectancy, for myocardial infarction, effect of
coronary angiography on, 1764
Life years, quality adjusted (QALY), 1764
Lifestyle risks, performance of coronary angiography
and, 1768
Limitations
of coronary angiography, 1759, 1794–1795
of coronary angioscopy, 1802
of intracoronary Doppler ultrasound, 1800
of intravascular ultrasound, 1797
of quantitative coronary angiography, 1792
Literature review, 1757
Liver transplantation, candidates for, angiographic
evaluation of, 1786
recommendations for, 1769
Lumen
catheter, for angioscopy, 1802
diameter
coronary lesions reducing, 1759
minimal, 1791, 1792
dimensions, measurement of, by intravascular
ultrasound, 1797
hazy, in postintervention vessels, 1794
measurement, intravascular ultrasound for, 1797
narrowing, 1794
assessment of, limitation of angiography in, 1794
measurement of, 1792
residual, 1801
obstruction of, defining of, 1759
shape of, 1794
stenosis, severity of, 1791
Lung transplantation, candidates for, angiographic
evaluation of, 1786
recommendations for, 1769
M
Managed care, frequency of cardiac catheterization
and, 1761
Mannitol, 1761
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Marfan syndrome, aortic dissection from, coronary
angiography in, 1790
Medicare
cardiac catheterization and, 1761
payment for physician fees, 1763
Medicare patients, with myocardial infarction,
frequency of cardiac catheterizations in, 1762
123I Metaiodobenzylguanidine (123I MIBG), 1796
Methylergonovine maleate
contraindications to, 1796
detection of coronary spasm with, 1796
for provocative testing for coronary spasm, 1796
MI. See Myocardial infarction
MIBG. See 123I Metaiodobenzylguanidine
Minimal luminal diameter, 1791
use of, 1792
MITI (Myocardial Infarction Triage and Intervention)
Project, 1762, 1778
Mitral regurgitation, after myocardial infarction, 1781
Mitral valve disease, 1760t
Mitral valve prolapse, nonspecific chest pain related to,
1769
Mitral valve surgery, coronary angiography before,
1787
Modifiers, patient-specific, 1757
Morbidity
perioperative, in noncardiac surgery, 1786
related to coronary angiography, predictors of,
1760, 1760t
Morphologic characteristics, 1770
Mortality rates, 1760t, 1762
abrupt closure after catheter-based
revascularization-related, 1774
after catheter-based revascularization, 1774
coronary angiography and, 1762
predictors of, 1759t, 1760, 1760t
for coronary artery bypass surgery, 1774
for emergency PTCA, 1779
in ischemia following myocardial infarction, type of
treatment and, 1781
for myocardial infarction
ejection fraction and, 1784
mitral regurgitation and, 1781
non–Q-wave myocardial infarction, 1782
for Q-wave myocardial infarction, 1782
noncardiac surgery-associated, causes of, 1785–1786
in patients with unstable angina, 1772t
predictor of, 1766
for PTCA, 1777, 1778
recurrent ischemia-related, 1780
thrombolysis versus primary PTCA, 1778
unstable angina-related, 1771
Mottling, quantum, 1791
Myocardial bridging, 1759
Myocardial contusion, coronary angiography in, 1790
Myocardial hibernation, myocardial ischemia, 1789
Myocardial infarction (MI)
acute treatment phase of, 1780
angiography for, 1775, 1780
appropriateness of, 1762
cost-effectiveness of, 1764
coupled with intent to perform primary PTCA,
1779
immediately after thrombolytic therapy, 1776–
1777
indications for, 1784
during initial management in emergency
department, 1776
in patient who has not undergone PTCA, 1779–
1780
with primary angioplasty, 1777–1779
studies on, 1784
time period for, 1775–1776
asymptomatic, 1764
after catheter-based revascularization, 1774
chest pain from, 1765
after chest trauma, 1790
complications of, 1776
concepts common to all patients, 1789–1781
consequences of, 1780
definitions, 1775–1776
DRG diagnosis of, 1762
frequency of cardiac catheterizations and, 1762
hospital-management phase, 1780
mechanical complications of, 1781
nonfatal
in patients with unstable angina, 1771
predictor of, 1766
risk for, in unstable angina, 1772t
non–Q-wave, 1770, 1776f
angiography for, 1780
management of, 1782–1783
periprocedural enzyme elevation after
revascularization in, 1774
unstable angina and, 1771
“open artery hypothesis,” 1783
patients treated with primary angioplasty, 1782
prior, patients with, recommendations for coronary
angiography in, 1769
Q-wave, 1776f, 1780
angioplasty during hospital management phase,
1783
treatment of, 1775
recurrent, 1762
repeat angiography in, 1763
risk for, 1759t
angiography and, 1760, 1760t
risk stratification phase in preparation from
discharge from hospital after, 1783–1785
Myocardial Infarction Triage and Intervention Project.
See MITI
Myocardial ischemia
atypical angina and, 1769
causes of, 1769
chest pain syndromes in, terms for, 1769
development of, 1780
medical therapy for, 1770
myocardial hibernation, 1789
in postoperative patients, after coronary artery
bypass surgery, 1774
recommendations for coronary angiography during
hospital management phase, 1783
recurrence, after revascularization, 1774
Myocardial jeopardy score, 1759
Myocardial necrosis
enzyme markers of, 1775
after revascularization, periprocedural enzyme
elevation in, 1774
serum markers of, 1775
Myocarditis, 1769
Myocardium, metabolic state of, 1794
N
National Electrical Manufactures Association
(NEMA), 1794
National Registry of Myocardial Infarction, 1784
Native coronary vessels, TIMI flow grades for, 1791
“Need-to-know” circumstances, 1766
NEMA. See National Electrical Manufactures
Association
New York
angiography performed in, 1763
frequency of cardiac catheterization sin, 1762
New York Heart Association, 1760t
Nitrates, for angina
stable, 1766
unstable, 1772t
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in angina pectoris, stable, 1766, 1767f
in coronary disease, aortic stenosis and, 1787
costs related to, compared with coronary
angiography, 1764
ECG, for angina, stable, outcome of, 1766, 1767f
ischemic response to, in presence of collaterals,
1795
positive, 1763
predictors of adverse outcome in postinfarction
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